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Summary 
 
Pseudomonas aeruginosa is one of the most problematic versatile Gram-negative 
bacteria in causing opportunistic human infections which are particularly difficult to treat 
because of its intrinsic resistance to antibiotics, as a consequence of many intervening resistance 
mechanisms involving the ability to overproduce the chromosomally encoded 
cephalosporinases, Pae-AmpC, which are periplasmic enzymes, belong to group I class C serine 
β-lactamases and are also responsible of bacterial resistance in many bacteria. In P. aeruginosa, 
ampC expression is regulated mainly by AmpG permeases, AmpD amidases, AmpR, NagZ, and 
two competing AmpR-binding muropeptides [UDP-MurNAc-pentapeptides (ampC suppressor) 
and 1,6-anhydromuropeptides (ampC inducer)]. Low molecular mass penicillin-binding proteins 
[LMM-PBP; e.g. PBP4 (DacB), PBP5 (DacC), PBP7 (PbpG)] are a group of periplasmic 
enzymes that have DD-carboxypeptidase and/or DD-endopeptidase activities which participate 
in cell separation, peptidoglycan (PG) maturation and recycling. Binding of β-lactams (e.g. 
penicillin) with LMM-PBPs causes an increase in anhydromuropeptides and periplasmic AmpC 
overproduction to hydrolyze that external unwelcome inducer. This study aims to highlight and 
to characterize the functions of Pae-AmpC and the role of LMM-PBPs PBP4, PBP5 and PBP7 
in PG composition and bacterial resistance in P. aeruginosa; also, to study the role of these 
LMM-PBPs in Pae-ampC regulation and to see if they are needed for the recovery of rod shape 
of imipenem-induced round cells in P. aeruginosa. To fulfill this study we characterized several 
Pae-AmpC forms (wild type and mutants) in wild type and mutants of E. coli and in P. 
aeruginosa PAO1 strain which were tested for their PG composition by HPLC analysis and for 
bacterial resistance by disc diffusion method. Also, we constructed single and combined 
mutants of dacB, dacC, pbpG and ampC in PAO1 strain which were tested for their PG 
composition, ampC expression by RT-PCR, β-lactams susceptibility and their PBPs pattern by 
Bocillin-FL binding test. We analyzed PG composition and PBPs pattern in imipenem-induced 
round cells and their rod shape recovered cells in PAO1. We found that some Pae-AmpC 
mutants had a very low β-lactamase activity (AmpC-F4:C3 and AmpC-F4:C6); the mature form 
of Pae-AmpC had a high β-lactamase activity and a secondary DD-endopeptidase and DD-
carboxypeptidase activities; only dacB single and combined mutations produced high ampC 
expression and β-lactam resistance; only dacC single and combined mutations produced 
maximum increase of PG pentapeptides. The triple mutant of dacB, dacC and pbpG displayed 
the largest increase in ampC expression and β-lactams resistance. Microscopic examination of 
all the constructed Pae mutants showed that they still retain their rod shape morphology similar 
to their parental PAO1 strain. Also, we found that activities of DacB, DacC and PbpG are not 
essential for recovery of rod shape in imipenem-induced spheres in P. aeruginosa. 
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Resumen  
 
P. aeruginosa es una de las bacterias Gram-negativas versátiles y más problemáticas 
causantes de infecciones oportunistas en humanos y que son particularmente difíciles de curar 
debido a su resistencia intrínseca a los antibióticos, como consecuencia de los muchos 
mecanismos de resistencia intervinientes, y que implica la capacidad de sobreproducir las 
cefalosporinas codificados cromosómicamente, Pae-AmpC. En P. aeruginosa, la expresión de 
ampC se rige principalmente por la permeasa AmpG, la amidasa AmpD, AmpR, NagZ y dos 
muropéptidos competidores fijadores de AmpR [UDP-MurNAc-pentapéptido (supresor de 
ampC) y 1,6-anhidro-muropéptidos (inductor de ampC)]. Las proteínas (de baja masa 
molecular) fijadoras de penicilina [LMM-PBP; por ejemplo PBP4 (DacB), PBP5 (DacC), PBP7 
(PbpG)] son un grupo de enzimas periplásmicas que tienen actividades DD-
carboxipeptidasa/DD-endopeptidasa y que participan en la separación celular, y en la 
maduración y reciclaje del peptidoglicano (PG). La unión de un β-lactámicos (por ejemplo, 
penicilina) a las LMM-PBP provoca un aumento en anhidro-muropéptidos y sobreproducción 
de AmpC en periplasma para hidrolizar este inductor externo no deseado. Este estudio tiene 
como objetivo destacar y caracterizar las funciones de Pae-AmpC y la implicación de PBP4, 
PBP5 y PBP7 en la composición del PG y la resistencia bacteriana en P. aeruginosa y además, 
analizar el papel de estas LMM-PBPs en la regulación de Pae-ampC y determinar si son 
necesarias para la recuperación de la forma bacilar a partir de esferoplastos de P. aeruginosa 
inducidos por imipenem. Para realizar este estudio hemos caracterizado varias formas de Pae-
AmpC en E. coli y P. aeruginosa PAO1 que se ensayaron mediante la determinación de su 
composición del PG por análisis de HPLC y su resistencia bacteriana por el método de difusión 
en disco en agar. Además, hemos construido mutantes individuales y combinados de dacB, 
dacC, pbpG y ampC en la cepa PAO1. Además, se analizó la composición del PG y los patrones 
de PBP en esferoplastos inducidos por imipenem y de sus formas bacilares recuperadas en 
PAO1. Hemos encontrado que algunos mutantes de Pae-AmpC tenían una actividad muy baja 
β-lactamasa (AmpC-F4: C3 y AmpC-F4: C6); que el tipo silvestre de Pae-AmpC (AmpC-F4) 
tenía una alta actividad β-lactamasa y unas actividades secundarias de DD-endopeptidasa y DD-
carboxipeptidasa; que sólo mutaciones individuales en dacB y combinadas producen una alta 
expresión de ampC y resistencia a β-lactámicos; que  sólo mutaciones individuales en dacC y 
combinadas producen un aumento máximo de pentapéptidos en el PG. El triple mutante de 
dacB, dacC y pbpG mostró el mayor aumento en la resistencia a β-lactámicos y en la expresión 
de ampC. El examen microscópico de todos los mutantes construidos en PAO1 mostró que 
todavía conservan sus formas morfologías bacilares similar a su cepa parental PAO1. Las 
actividades de DacB, DacC y PbpG no son esenciales para la recuperación de la forma bacilar 
en los esferoplastos de P. aeruginosa inducidos por imipenem. 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Index 
  
 
 
 
 
 
 
 
 
 
 
 
 
Index 
 
1 | P a g e  
 
Alaa Ropy_Doctoral Thesis 
 
Index 
 
Contents Page 
Acknowledgements i 
Summary (in English) ii 
Resumen (in Spanish) iii 
List of abbreviations 7 
List of figures  9 
List of tables 13 
  
1. Introduction 15 
1.1. Pseudomonas aeruginosa & high challenge  17 
1.2. Penicillin-binding proteins (PBPs) 18 
1.2.1. High molecular mass HMM-PBPs (class A, B) 18 
1.2.2. Low molecular mass LMM-PBPs (class C) 19 
1.3. Peptidoglycan (PG, murein, cell wall)   20 
1.3.1. PG structure & chemical and physical properties  21 
1.3.2. PG biosynthesis and remodeling 22 
1.4. Antibiotics targeting cell wall biosynthesis & bacterial resistance 23 
1.4.1. Inhibitors of Mur family and PG precursors   25 
1.4.2. β-Lactam antibiotics 27 
1.4.3. Bacterial resistance to β-Lactams 28 
1.4.4. β-lactamase inhibitors 29 
1.5. β-Lactamases 29 
1.5.1. Classification of β-lactamases 29 
1.5.2. Group 2 and 3 β-lactamases 30 
1.5.3. AmpC β-lactamases 30 
1.5.4. Mechanism of action 31 
1.5.5. AmpC structure 34 
Index 
 
2 | P a g e  
 
Alaa Ropy_Doctoral Thesis 
 
1.5.6. AmpC regulation in Pseudomonas aeruginosa 34 
  
2. Objectives of this study 39 
  
3. Materials & methods 41 
3.1. Bacterial strains and plasmids 43 
3.2. Primers 47 
3.3. Culture media for cell growth  47 
3.4. DNA manipulation 50 
3.4.1. DNA purification and sequencing  50 
3.4.2. Agarose DNA electrophoresis 50 
3.4.3. PCR amplification 50 
3.4.4. ampC cloning and expression using pET28b plasmid  52 
3.4.5. ampC cloning and expression using pUCP24 plasmid  53 
3.4.6. Bacterial transformation  56 
3.5. Protein manipulation 56 
3.5.1. Estimation of protein concentration 56 
3.5.2. SDS-PAGE electrophoresis 56 
3.5.3. Western blot 57 
3.5.4. β-lactamase activity assay 57 
3.5.5. Bocillin-FL test 58 
3.5.6. MALDI-TOF 58 
3.5.7. Cell fractionation for protein localization  58 
3.6. AmpC purification  59 
3.7. Construction PAO1 mutants  61 
3.8. Estimation of ampC expression by RT-PCR 62 
3.9. Antimicrobial susceptibility testing 63 
3.10. Production of imipenem-induced round cells of PAO1 wild 
type and mutants  
 
65 
3.11. Confocal microscopic analysis 65 
3.12. Peptidoglycan (PG) manipulation 66 
3.12.1. Preparation of PG 66 
3.12.2. HPLC analysis 67 
Index 
 
3 | P a g e  
 
Alaa Ropy_Doctoral Thesis 
 
3.12.3. Effect of Pae-AmpC on the whole PG and individual 
muropeptides in vitro 
 
67 
  
4. Results 69 
4.1. Functional characterization of  Pae-AmpC β-lactamase in E. coli and  
P. aeruginosa PAO1 strains 
71 
4.1.1. Summary 71 
4.1.2. Pae-ampC cloning  72 
4.1.3. Pae-ampC expression 76 
4.1.4. Pae-AmpC purification  and characterization  85 
4.1.5. Pae-AmpC structure and crystallization   85 
4.1.6. Effect of Pae-ampC expression on bacterial resistance 88 
4.1.7. Effect of Pae-ampC expression on PG composition (in vivo) 91 
4.1.8. Effect of the purified Pae-AmpC forms on PG composition and 
individual muropeptides (in vitro) 
 
92 
4.2. Role of LMM-PBPs in ampC regulation, β-lactam resistance and 
peptidoglycan structure in P. aeruginosa 
 
103 
4.2.1. Summary 103 
4.2.2. The constructed PAO1 mutants 103 
4.2.3. Growth rates and microscopic examination of PAO1 mutants  106 
4.2.4. Bocillin-FL test of PAO1 mutants 106 
4.2.5. Effect of LMM-PBPs inactivation on ampC expression and β-
lactam resistance in P. aeruginosa PAO1.   
 
107 
4.2.6. PG composition of the constructed PAO1 mutants 116 
4.3.  Activities of DacB, DacC and PbpG are not essential for recovery of 
rod shape in imipenem-induced spheroplasts in P. aeruginosa. 
 
119 
4.3.1. Summary  119 
4.3.2. Microscopic examination of imipenem-induced spheroplasts of 
PAO1 wild type and mutants. 
 
120 
4.3.3. PG composition of imipenem-induced spheroplasts PAO1 wild 
type and mutants 
 
120 
4.3.4. Bocillin-FL test of imipenem-induced spheroplasts of PAO1 
wild type and PAOΔampC 
 
121 
Index 
 
4 | P a g e  
 
Alaa Ropy_Doctoral Thesis 
 
  
5. Discussion 127 
5.1. Motivation and design of this study 129 
5.2. Functional characterization of Pae-AmpC β-lactamase  130 
5.2.1. Various forms of Pae-AmpC were produced 130 
5.2.2. Interpretation AmpC production using pET28b and pUCP24 
vectors 
 
130 
5.2.3. Mutations, sub-cellular localization and solubility can largely 
affect AmpC β-lactamase activity 
 
131 
5.2.4. The secondary DD-peptidase activity was clear with AmpC-F3 
rather than the other studied AmpC forms   
 
133 
5.2.5. AmpC-F3 crystallization & obstacles on the way!  134 
5.3.  Role of Pseudomonas aeruginosa LMM-PBPs in PG composition, β-
lactam resistance and ampC regulation in P. aeruginosa 
 
135 
5.3.1. Role of P. aeruginosa LMM-PBPs in cell wall physiology 135 
5.3.2. Role of P. aeruginosa LMM-PBPs in AmpC regulation and β-
lactam resistance 
 
136 
5.4. Activities of DacB, DacC and PbpG are not essential for recovery of 
rod shape in imipenem-induced spheroplasts in P. aeruginosa 
 
138 
  
6. Conclusions (in English) 143 
  
Conclusiones (in Spanish) 145 
  
Bibliography 149 
  
Addendum 161 
 
 
 
 
 5 | P a g e  
 
Alaa Ropy_Doctoral Thesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Lists of abbreviations, figures 
and tables 
 6 | P a g e  
 
Alaa Ropy_Doctoral Thesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
List of abbreviations 
 
7 | P a g e  
 
Alaa Ropy_Doctoral Thesis 
 
List of abbreviations 
 
AMC Amoxacillin/clavulanic acid 
AmpD anhMurNAc-L-Ala amidases 
AmpG Permease-muropeptide transporter 
AmpR LysR-type transcriptional regulator 
AN Amikacin  
anhMurNAc  1,6-anhydro-N-acetylmuramic acid 
AnmK AnhMurNAc kinase 
ATM Aztreonam  
C Chloramphenicol  
CPase(s) Carboxypeptidase(s) 
CRO Ceftriaxone 
CTX Cefotaxim 
Eco E. coli 
EPase(s) Endopeptidase(s) 
ESACs Extended-spectrum AmpC cephalosporinases  
ESBLs Extended-Spectrum β-lactamases  
FOX Cefoxitin  
Fru-6-P Fructose-6-phosphate 
GlcNAc N-acetylglucosamine 
GlmM Phosphoglucosamine mutase 
GlmU Bifunctional N-acetylglucosamine-1-phosphate 
Uridyltransferase/glucosamine-1-phosphate acetyltransferase 
TGase(s) Transglycosylase(s) 
HMM-PBPs High molecular mass penicillin-binding proteins 
IMI Imipenem 
LdcA LD-Carboxypeptidase 
lipid I Undecaprenoyl-pyrophosphoryl-MurNAc‒pentapeptide 
lipid II Undecaprenoyl-pyrophosphoryl-GlcNAc-MurNAc-pentapeptide 
LMM-PBPs Low molecular mass penicillin-binding proteins  
LTs Lytic transglycosylases 
MBLs Metallo-β-lactamases 
List of abbreviations 
 
8 | P a g e  
 
Alaa Ropy_Doctoral Thesis 
 
m-DAP& m-A2pm meso-diaminopimelic acid 
Moe A Moenomycins  A 
Mpl Murein tripeptide ligase  
MppA Muropeptides binding protein 
MraY UDP-MurNAc‒pentapeptide phosphotransferase 
MurA UDP-GlcNAc enolpyruvyl transferase 
MurB UDP-MurNAc dehydrogenase 
MurC UDP-MurNAc–L-Ala ligase 
MurD UDP-MurNAc-L-Ala–D-Glu ligase 
MurE UDP-MurNAc-L-Ala-D-Glu–meso-Dap ligase 
MurF UDP-MurNAc-tripeptide–D-alanyl‒D-Alal ligase 
MurG UDP-GlcNAc-undecaprenoyl-pyrophosphoryl‒MurNAc‒ 
pentapeptide transferase 
MurI Glu racemase 
MurNAc N-acetylmuramic acid 
MurP N-acetylmuramic acid transporter 
MurQ MurNAc-6-phosphate etherase 
NagA N-acetylglucosamine-6-phosphate deacetylase 
NagB Glucosamine-6-phosphate deaminase 
NagE PTS phosphotransferase system 
NagZ N-acetylglucosaminidase 
OMPs Outer membrane proteins 
Opp Oligopeptide permease 
Pae Pseudomonas aeruginosa 
PB Penicillin-binding domain 
PBP(s) Penicillin binding protein(s) 
PBS Phosphate-buffered saline  
PG Peptidoglycan 
RBS Ribosome binding site 
TIC Ticarcillin  
TPase Transpeptidase 
UDP-GlcNAc Uridine diphosphate N-acetylglucosamine 
UDP-MurNAc Uridine diphosphate N-acetylmuramic acid 
 
List of figures 
 
9 | P a g e  
 
Alaa Ropy_Doctoral Thesis 
 
List of figures  
 
No. Chapter/ 
Description  
Page 
   
 Introduction (section 1)  
1.1 Common 3-4 crosslinks between glycan strands of PG  22 
1.2 Outline of PG biosynthesis, PG recycling and ampC regulation in 
Gram-negative bacteria 
 
24 
1.3 Sub-cellular targets for antibiotic actions 26 
1.4 Mechanism of antibiotic inhibition of bacterial cell wall 
biosynthesis 
 
26 
1.5 Chemical structures of penicillins and cephems 27 
1.6 Chemical structures of penems, carbapenems, aztreonam, 
sulbactam and tazobactam 
 
28 
1.7 Mechanism of action of β-lactamases and PBPs on β-lactams 33 
   
 Methods (section 3)  
3.1 Outline of Pae-ampC cloning region in pET28b vector 54 
3.2 Outline of Pae-ampC cloning region in pUCP24 vector 55 
3.3 Outline for gene-knockout inactivation of  pbpG and dacC in P. 
aeruginosa by cre-lox method 
 
64 
   
 Results (section 4)  
4.1 Schematic outline of general structures and amino acid sequences 
of the studied Pae-AmpC forms 
 
75 
4.2 Detection of AmpC-F1, AmpC-F1:C3, AmpC-F1:C6 and AmpC-
F2 in cellular fractions (total sonicate, cell extract and cell 
membrane) of Bl21(DE3)   
 
 
78 
4.3 Detection of AmpC-F4, AmpC-F4:C3, AmpC-F4:C6 and AmpC-
F3 in cellular fractions (total sonicate, cell extract and cell 
membrane) of Bl21(DE3) 
 
 
79 
4.4 Detection of AmpC-F4, AmpC-F4:C3, AmpC-F4:C6, AmpC-F2  
List of figures 
 
10 | P a g e  
 
Alaa Ropy_Doctoral Thesis 
 
and AmpC-F3 in cellular fractions (total sonicate, cell extract and 
cell membrane) of DV900(DE3)  
 
80 
4.5 Expression and production of AmpC-F3, AmpC-F3-TEV and 
AmpC-F4-TEV in Bl21(DE3) transformants 
 
81 
4.6 Pae-ampC expression in PAO1 mutants transformed with pUCP-
F3 and pUCP-F4 
 
83 
4.7 Analysis of the purified Pae-AmpC forms by SDS-PAGE and 
western blot 
 
87 
4.8 Muropeptides structures and chromatograms of HPLC analysis of 
PG of E. coli Bl21(DE3) and DV900(DE3) 
 
94 
4.9 Effect of AmpC-F3(b) activity on individual muropeptides M4, 
M5, D44 and D45 at 37 and 42°C (in vitro) 
 
101 
4.10 Effect of AmpC-F3(a) activity on individual muropeptides M4, 
M5, D44 and D45 at 42°C (in vitro) 
 
102 
4.11 Growth curves of the constructed PAO1 mutants 108 
4.12 Microscopic examination of the constructed PAO1 mutants 109 
4.13 Bocillin-FL binding test of cell membranes of PAO1 mutants 
under non-induction conditions    
 
112 
4.14 Bocillin-FL binding test of cell membranes of PAO1 mutants 
previously induced with cefoxitin 
 
113 
4.15 Microscopic examination of spheroplasts of imipenem-induced 
PAO1 wild type, PAOΔampC  and PAOΔdacBΔdacCΔpbpG 
ΔampC mutants 
 
 
124 
4.16 Bocillin-FL binding of Pae spheroplasts membranes of IMI-
induced PAO1 wild type and PAOΔampC mutant 
 
126 
   
 Addendum    
A.1 Colony-PCR amplifications of the different ampC forms 
displaying their DNA fragment sizes 
 
161 
A.2 Confirmation of the constructed pbpG and dacC gene-specific 
mutagenesis vectors 
 
162 
A.3 Verification of the constructed mutants PAOΔpbpG, PAOΔdacB 
ΔpbpG and PAOΔpbpGΔampC by colony PCR and agarose gel 
 
 
List of figures 
 
11 | P a g e  
 
Alaa Ropy_Doctoral Thesis 
 
electrophoresis 163 
A.4 Verification of the constructed mutants PAOΔdacCΔampC, 
PAOΔdacCΔpbpG, PAOΔdacC, PAOΔdacBΔdacC and 
PAOΔdacBΔdacCΔpbpG 
 
 
164 
A.5 Verification of the constructed mutants PAOΔdacBΔampC and 
PAOΔdacBΔpbpGΔampC 
 
165 
A.6  Verification of the constructed mutants PAOΔdacBΔdacCΔampC, 
PAOΔdacCΔpbpGΔampC and PAOΔdacBΔdacCΔpbpGΔampC 
 
166 
A.7 Verification of the constructed mutant PAOΔdacBΔpbpGΔampC 
ΔdacC 
 
167 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 12 | P a g e  
 
Alaa Ropy_Doctoral Thesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
List of tables 
 
13 | P a g e  
 
Alaa Ropy_Doctoral Thesis 
 
List of tables 
 
No. Chapter/ 
Description 
Page 
   
 Introduction (section 1)  
1.1 Various cephalosporin generations 28 
1.2 Functional and structural classification of β-lactamases 32 
   
 Material & Methods (section 3)  
3.1 Bacterial strains and plasmids  44 
3.2 Primers used for PCR amplification and DNA sequencing. 48 
3.3 Primers used for the construction of knockout mutants of ampC, 
dacB, dacC and pbpG in PAO1  
 
49 
3.4 Conditions used for PCR amplification of different ampC forms  51 
   
 Results (section 4)  
4.1 Mutations and changes in the main sequence of the  cloned Pae-
ampC constructs 
 
74 
4.2 β-lactamase activity of different forms of AmpC expressed in 
BL21(DE3) and DV900(DE3) after IPTG induction 
 
82 
4.3 β-lactamase activity of some PAO1 mutants transformed with 
pUCP-F3 and pUCP-F4 
 
84 
4.4 Characterization of the purified Pae-AmpC Forms 86 
4.5 Disc diffusion assay for Pae-AmpC expression in Bl21(DE3)/pET-
ampC 
 
89 
4.6 Disc diffusion assay for complementation of ampC deletion in some 
PAO1 mutants 
 
90 
4.7 HPLC analysis of muropeptides prepared from PG of induced E. 
coli Bl21(DE3)/pET-ampC  
 
96 
4.8 HPLC analysis of muropeptides prepared from PG of induced E. 
coli DV900(DE3)/pET-ampC 
 
97 
4.9 HPLC analysis of muropeptides prepared from PG of  
List of tables 
 
14 | P a g e  
 
Alaa Ropy_Doctoral Thesis 
 
PAO1/pUCP24-ampC 98 
4.10a HPLC PG analysis of E. coli DV900 and CS109 after incubation 
with different forms of Pae-AmpC in vitro 
 
99 
4.10b Selected muropeptides from HPLC analysis of PG of DV900 after 
incubation with different forms of Pae-AmpC in vitro 
 
100 
4.11 Estimated IC50 values for cefoxitin with cell membranes of the wild 
type and some PAO1 mutants using Bocillin-FL test 
 
111 
4.12 MICs and ampC expression under basal and cefoxitin induction 
conditions for all studied mutants 
 
114 
4.13 HPLC analysis of muropeptides prepared from PG of the 
constructed Pae mutants under non-induction conditions 
 
117 
4.14 HPLC analysis of muropeptides prepared from PG of the 
constructed Pae PAO1 mutants treated with FOX 
 
118 
4.15a HPLC analysis of muropeptides prepared from PG of imipenem-
induced Pae spheroplasts   
 
122 
4.15b Selected muropeptides produced from PG of imipenem-induced Pae 
spheroplasts   
 
123 
   
 
 
 
 
 
 
 
 
 
 
 15 | P a g e  
 
Alaa Ropy_Doctoral Thesis 
 
Introduction 
 
1. Introduction 
1.1. Pseudomonas aeruginosa & high challenge  
1.2. Penicillin-binding proteins (PBPs) 
1.2.1. High molecular mass HMM-PBPs (class A, B) 
1.2.2. Low molecular mass LMM-PBPs (class C) 
1.3. Peptidoglycan (PG, murein, cell wall)   
1.3.1. PG structure & chemical and physical properties  
1.3.2. PG biosynthesis and remodeling 
1.4. Antibiotics targeting cell wall biosynthesis & bacterial resistance 
1.4.1. Inhibitors of Mur family and PG precursors    
1.4.2. β-Lactam antibiotics 
1.4.3. Bacterial resistance to β-Lactams 
1.4.4. β-lactamase inhibitors 
1.5. β-Lactamases 
1.5.1. Classification of β-lactamases 
1.5.2. Group 2 and 3 β-lactamases 
1.5.3. AmpC β-lactamases 
1.5.4. Mechanism of action 
1.5.5. AmpC structure 
1.5.6. AmpC regulation in Pseudomonas aeruginosa 
 
 
 
 
 
 
 
 16 | P a g e  
 
Alaa Ropy_Doctoral Thesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
17 | P a g e  
 
Alaa Ropy_Doctoral Thesis 
 
1. Introduction  
 
1.1. Pseudomonas aeruginosa & high challenge  
 
Classification 
Bacteria (Super-kingdom); Proteobacteria (Phylum); Gammaproteobacteria (Class); 
Pseudomonadales (Order); Pseudomonadaceae (Family); Pseudomonas (Genus), aeruginosa 
(Species) (Benson et al, 2009; Sayers et al, 2009).  
 
Genetic complexity and diversity & clinical challenge  
The complete genome of P. aeruginosa PAO1 strain was sequenced and displayed 6.3 
Mbp with 5570 predicted open reading frames (ORFs) which are mostly larger than sequenced 
genomes of 25 bacterial strains showing how complex is P. aeruginosa. This massive number 
of ORFs has only a few gene clusters duplicated and lacks recent gene duplications referring to 
high functional diversity, genetic complexity and evolutionary adaptations of this 
microorganism which can explain its versatility and wide occurrence in soil, water, as well as on 
plant and animal tissues as a pathogen (Stover et al, 2000). PAO1 strain is considered as the 
major reference strain for research P. aeruginosa, where new genomic sequences of other 
Pseudomonas strains are being discovered, annotated and compared with PAO1 reference to 
reveal the function and genetic variations (SNPs) of the new ORFs (Klockgether et al, 2010; 
Winsor et al, 2011). P. aeruginosa is considered as one of the most challenging versatile Gram 
negative bacteria in causing opportunistic human infections which are particularly difficult to 
treat because of its intrinsic resistance to antibiotics, as a consequence of many intervening 
resistance mechanisms; its low outer membrane permeability (OprD porin), active drug efflux 
pumps and mutations leading overproduction of the chromosomally encoded cephalosporinase, 
AmpC. While the incidences of concerning transferable resistance determinants, such as those 
encoding class B carbapenemases are increasing, especially in other pathogens, the current 
global threat of antimicrobial resistance in P. aeruginosa mainly still results from the 
extraordinary capacity of this microorganism to develop resistance to almost any available 
antibiotic by the selection of mutations in chromosomal genes. This enables P. aeruginosa to 
produce multidrug-resistance strains through combinations of the previous resistance 
mechanisms beside accumulation of multiple chromosomal changes overtime. So, treatment of 
P. aeruginosa is a serious therapeutic challenge (Lister et al, 2009; Stover et al, 2000; Strateva 
& Yordanov, 2009). P. aeruginosa secretes several virulence factors (e.g. pili, flagella, 
lipopolysaccharides, quorum sensing, toxins, lipases and proteases), (Lyczak et al, 2000; Stover 
et al, 2000). Also, P. aeruginosa is able to develop biofilm which is surface-attached microbial 
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populations with distinctive construction and phenotypic and biochemical properties different 
from their free-swimming, planktonic counterparts. Bacterial biofilm is characterized by a very 
high antibiotic resistance when compared with planktonic cells (Mah et al, 2003). AmpC 
overproduction is the main mechanism in P. aeruginosa to develop resistance to most of β-
lactams, with the exception of carbapenems and cefepime which require additional mechanisms 
to develop resistance [e.g., AmpC mutations, downregulation of porin production] (Cabot et al, 
2014; Lister et al, 2009). It was reported that P. aeruginosa is the second common pathogen to 
be clinically isolated after E. coli and it was reported that among 56 random isolates of P. 
aeruginosa there were 41.1% non-multidrug resistant (non-MDR) strains, 37.5% extensively 
drug resistant (XDR) strains and 21.4% multidrug resistant (MDR) strains (Gomila et al, 2013); 
such a study highlights how dangerous are the resistant mutants of this microorganism. 
Therefore, finding more effective antibiotics to cure infections with resistant (MDR and XDR) 
P. aeruginosa pathogens is a public necessity.  
 
1.2. Penicillin-binding proteins (PBPs)  
PBPs are a group of enzymes responsible for PG polymerization, crosslinking and 
remodeling in the periplasmic compartment (section 1.3.2; Fig.1.2). They have a common 
penicillin-binding domain although they may have different overall structures and activities. 
According to their molecular masses and structures, PBPs were classified into class A (HMM-
PBPs), class B (HMM-PBPs) and class C (LMM-PBPs) referring to E. coli type which has 
twelve PBPs involving three class A PBPs (PBP1a, PBP1b and PBP1c), two class B PBPs 
(PBP2 and PBP3) and seven class C LMM-PBPs (PBP4, PBP5, PBP6, PBP6b, PBP7, PBP4b 
and AmpH) (Sauvage et al, 2008). Penicillin-binding proteins in E. coli are the best 
characterized, both at molecular and functional level, and the PBPs from most other 
microorganisms are always referred to those one, including Gram-positive that have a different 
peptidoglycan structure (Sauvage et al, 2008).  
 
1.2.1. High molecular mass HMM-PBPs (class A, B)  
HMM-PBPs are multimodular enzymes (>60 kDa) which catalyze PG polymerization 
and/or crosslinking by glycosyltransferase (TGase) and transpeptidase (TPase) activities 
respectively. They mainly act to construct a new PG strands by TGase activity from 
muropeptide subunits carried by lipid II and then to crosslink these new strands into the old PG 
mesh by TPase activity. They have a cytoplasmic tail, a transmembrane anchor and two 
periplasmic domains whose C-terminal one is called penicillin-binding (PB) domain, due to the 
ability to bind β-lactams, and is responsible for TPase activity. HMM-PBPs were further 
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classified into class A and class B depending on the structures and the catalytic activity of the 
N-terminal domain (Sauvage et al, 2008; Vollmer & Bertsche, 2008).  
Class A PBPs (e.g. Eco-PBP1a and Eco-PBP1b) are bifunctional enzymes with TGase 
and TPase activities as their N-terminal domain has TGase activity. Eco-PBP1a and Eco-PBP1b 
are the main bifunctional TGase-TPase enzymes in E. coli (Sauvage et al, 2008). Inactivation of 
both of PBP1a and PBP1b was lethal to E. coli; indicating their vital role in PG synthesis and 
cell life (Denome et al, 1999; Kong et al, 2010; Sauvage et al, 2008). Penicillin-binding proteins 
Pae-PBP1a and Pae-PBP1b of Pseudomonas belong to this class (Sauvage et al, 2008). 
Class B PBPs (e.g. Eco-PBP2 and Eco-PBP3) are monofunctional TPase enzymes. 
They are involved in cell elongation complex (elongase), cell division complex (divisome) and 
cell morphogenesis. Their N-terminal domain may interact with some other proteins involved in 
the cell cycle and in turn affects cell morphogenesis. It was reported that Eco-PBP2 is essential 
for cell elongation and shape maintenance, while Eco-PBP3 is essential for cell division in E. 
coli (Sauvage et al, 2008). Penicillin-binding proteins Pae-PBP2, Pae-PBP3 and Pae-PBP3b of 
Pseudomonas belong to this class (Sauvage et al, 2008). 
1.2.2. Low molecular mass, LMM-PBPs (class C) 
LMM-PBPs include periplasmic proteins (<60 kDa) that are either soluble or associated 
with the cytoplasmic membrane. They are not essential for bacterial viability under laboratory 
conditions (Clarke et al, 2009; Sauvage et al, 2008). Their PB domain has carboxypeptidase 
(CPase) and/or endopeptidase (EPase) activities which enable them to participate in PG 
maturation and recycling and cell separation. LMM-PBPs were sub-divided into 4 sub-groups 
(Type-4, type-5, type-7 and type-AmpH) referring to E. coli type concerning structural and 
functional similarities (Sauvage et al, 2008).  
 
Type-4 class C LMM-PBPs (e.g. Eco-PBP4): E. coli PBP4 with solved crystal 
structure was reported to have both DD-EPase and DD-CPase activities (Clarke et al, 2009; 
Kishida et al, 2006). Type-4 PBPs are very loosely associated with the cytoplasmic membrane 
and may be involved in cell morphology, daughter cell separation and biofilm formation. 
(Sauvage et al, 2008). Inactivation of PBP4 in P. aeruginosa was reported to cause AmpC 
overproduction triggering high β-lactam resistance (Moya et al, 2009). Penicillin-binding 
protein Pae-DacB of Pseudomonas belongs to this class (Sauvage et al, 2008). 
Type-5 class C LMM-PBPs [e.g. Eco-PBP5, Eco-PB6 and Eco-PBP6b (DacD)]: 
Type-5 LMM-PBPs have DD-CPase activity, being Eco-PBP5 the prototype and it is the most 
abundant LMM-PBP with major DD-CPase. Type-5 LMM-PBPs are associated with the 
cytoplasmic membrane by amphipathic helix and play an important role in determining the cell 
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diameter and the correct septum formation (Chowdhury & Ghosh, 2011; Chowdhury et al, 
2010; Ghosh et al, 2008; Sauvage et al, 2008). It was suggested that Eco-PBP5 (but not Eco-
PBP6 and Eco-DacD) may have a role in intrinsic β-lactam resistance (Sarkar et al, 2011). 
Recently, it has been described that the soluble form of PBP5 from PA01 (Pae-sPBP5) 
displayed in vitro bifunctional DD-CPase and expanded-spectrum β-lactamase activities even 
for carbapenems which is unusual when compared with the monofunctional DD-CPase Eco-
PBP5 in E. coli. This behavior was explained by the flexibility and enlargement of the active 
site to share the same catalytic apparatus and similar mechanisms. This may be helpful for 
understanding the evolution of β-lactamase activity from the PBP enzymes (Smith et al, 2013). 
Penicillin-binding protein Pae-DacC of Pseudomonas belongs to this class (Sauvage et al, 
2008). 
Type-7 class C LMM-PBPs (e.g. Eco-PBP7): PBP7 enzymes are loosely associated to 
the cytoplasmic membrane and have DD-EPase activity. It was found that E. coli double mutant 
ΔPBP5-ΔPBP7 had more abnormality than the single mutant ΔPBP5; however the single mutant 
ΔPBP7 showed no morphological change (Sauvage et al, 2008). It was suggested that PBP4 and 
PBP7 affect cell shape in concert with PBP 5 (Meberg et al, 2004). Penicillin-binding protein 
Pae-PpbG of Pseudomonas belongs to this class (Sauvage et al, 2008). 
Type-AmpH class C LMM-PBPs (e.g. Eco-AmpH): It was described that AmpH from 
E. coli showed a bifunctional behavior of EPase and CPase activities (Gonzalez-Leiza et al, 
2011). Type-AmpH PBPs have a close structural similarity to class C-β-lactamase. It was 
suggested that AmpH and AmpC may participate in the normal PG synthesis, remodeling or 
recycling (Pratt, 2008; Sauvage et al, 2008). No penicillin-binding proteins of this class are 
identified in Pseudomonas (Sauvage et al, 2008).  
 
1.3. Peptidoglycan (PG, murein, cell wall)  
PG and murein are synonyms for the periplasmic sacculus surrounding the cytoplasmic 
membrane as mesh-like envelope. Furthermore, PG is the main structural component of the 
bacterial cell wall and mainly acts to maintain the bacterial cell shape and integrity (bacilli, 
cocci …) protecting the cell from its turgor and acts as a support for some other envelope 
components like proteins and teichoic acid. Therefore, PG is vital to the bacterial cell life and 
any major changes in its composition can affect the bacterial cell shape. Moreover, PG 
deformation or degradation can lead to cell lysis (Vollmer & Bertsche, 2008; Vollmer et al, 
2008a; Vollmer & Holtje, 2004; Vollmer & Seligman, 2010).   
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1.3.1. PG structure& chemical and physical properties 
PG is a heterogeneous elastic biopolymer of muropeptides which are linked together by 
β-1,4-bonds to form a long glycan strands cross-linked by bridges between its peptide stems. 
Each muropeptide subunit is composed of disaccharide derivatives of N-acetylglucosamine 
(GlcNAc) and N-acetylmuramic acid (MurNAc) in addition to a peptide stem of di-, tri-, tetra- 
or pentapeptides. Moreover, the glycan chains of muropeptides are crosslinked together 
frequently by 3-4 crosslinks which can be either direct as in most Gram-negative bacteria (e.g. 
E. coli) or through an inter-peptide bridge within most Gram-positive bacteria (e.g. 
Staphylococcus aureus) (fig. 1.1). The peptide stem in PG of E. coli and most Gram-negative 
bacteria is composed of amino acids L-Ala, D-Glu, Dap, D-Ala and D-Ala which occupy 
positions of numbers 1, 2, 3, 4 and 5, respectively, where amino acid number 1 (L-Ala) is linked 
to the D-lactyl group of MurNAc. The same was reported for PG peptide stem in most of Gram-
positive bacteria except for positions number 2 and 3 which are occupied by D-Gln and L-Lys, 
respectively. (Vollmer & Bertsche, 2008; Vollmer et al, 2008a; Vollmer & Holtje, 2004; 
Vollmer & Seligman, 2010). D-amino acids in peptide stems provide PG with resistance against 
auto-degradation by cellular proteases because D-amino acids are not common in natural 
proteins and peptides (Cava et al, 2011). PG composition can change from one strain to another 
and even within the same strain because it is sensitive to changes in growth conditions (e.g. 
growth media, temperature and growth phase). These changes may involve variations in the 
length of the glycan strands, types and degree of cross-linkage, amino acids of the peptide stem 
and PG layers which are almost one layer in Gram-negative bacteria while several PG layers 
occur frequently in Gram-positive bacteria. PG of E. coli was used for long time for HPLC 
analysis to understand its chemical structure beyond its purification and digestion with 
muramidase which cleaves β-1,4-glycosidic bonds between MurNAc and GlcNAc residues 
liberating the constituting muropeptide subunits which can be separated and analyzed by HPLC 
(Glauner, 1988; Glauner et al, 1988). Knowing PG chemical composition provides important 
data concerning cell wall structure which in turns may explain variations in cell shapes (Cava et 
al, 2013). Atomic Force Microscopy and TEM tomography were used to track the mechanics 
and spatial architecture of PG from different bacteria (Cava et al, 2013; Vollmer & Seligman, 
2010; Yao et al, 1999). Additionally, it was concluded that the glycan strands in Gram-negative 
bacteria (e.g. E. coli and P. aeruginosa) run almost in parallel to the cell membrane in the 
direction of the short axis of the cell, while the PG peptide-stems are oriented mostly in the 
direction of the long axis. Also, It was found that the PG is thinner and shorter with less 
crosslinks and larger pores in Pseudomonas aeruginosa than in E. coli (Vollmer & Seligman, 
2010).  
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Figure 1.1. Common 3-4 crosslinks 
between glycan strands of PG 
(Vollmer et al, 2008a).  
(a) Direct 3-4 crosslinks in E. coli 
between D-Ala and m-A2pm. (b)  3–4 
cross-link with a penta-glycine bridge 
between D-Ala and L-Lys in 
Staphylococcus aureus.   
M: N-acetylmuramic acid, G: N-
acetylglucosamine. Numbers refer to positions of amino acids in peptide stems where the 1st 
amino acid, L-Ala, is linked to N-acetylmuramic acid.  
 
 
1.3.2. PG biosynthesis and remodeling  
Biosynthesis of PG takes place in three cellular compartments (cytoplasm, cytoplasmic 
membrane and periplasm) beginning in the cytoplasm where UDP-MurNAc-pentapeptide (fig. 
1.2; 2) is constructed from Fructose-6-P (fig. 1.2; 1), free tri-, tetra- or pentapeptides (fig. 1.2; 
7a-c), GlcNAc-6-P, MurNAc-6-P and anhMurNAc (fig. 1.2; 10) by consecutive activities of 
AnmK, MurQ, NagA, GlmS, GlmM, GlmU, MurA-F and Mpl. The next step occurs at the 
cytoplasmic membrane in the cytoplasmic side where PG precursor carriers (Lipid I and II) are 
formed by the action of MraY and MurG on UDP-MurNAc-pentapeptide, undecaprenoyl 
phosphate carrier and UDP-GlcNAc. Then, lipid II (disaccharide pentapeptide carrier) is turned 
out by flippase activity from cytoplasm into the periplasmic side where muropeptide subunits 
are liberated from lipid II and incorporated into newly formed PG chains by glycosyltransferase 
action of TGase HMM-PBPs (fig. 1.2; 3) and then newly formed PG strands are crosslinked 
with the old PG network by transpeptidase activity of TPase HMM-PBPs (fig. 1.2; 4). 
Meanwhile, PG pentapeptide stems (fig. 1.2; 3c, 4c) are trimmed into tetrapeptide stems by the 
action of DD-CPases. Also, undecaprenoyl phosphate carriers are recycled for new lipid II 
synthesis (Fisher & Mobashery, 2014; Johnson et al, 2013; Typas et al, 2012). Normally, many 
bacterial cells remodel about half of their PG per generation which aids in insertion of newly PG 
strands in PG mesh and cell elongation and division. PG turnover starts in the periplasm by the 
action of PG hydrolases (fig. 1.2; steps 1-5) where endopeptidases (EPases LMM-PBPs) 
hydrolyze the peptide crosslinks between peptide stems of PG strands; DD-carboxypeptidases 
(DD-CPases LMM-PBPs) convert pentapeptide stems into tetrapeptides by elimination of the 
terminal D-Ala (fig. 1.2; 5b; step 1); Lytic transglycosylases (LTs) hydrolyze 1,4-β-glycosidic 
bonds within glycan strands releasing anhydromuropeptides GlcNAc-anhMurNAc-peptides [tri-
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, tetra- or pentapeptides; (fig. 1.2; 6a-c; step 2)]. Moreover, periplasmic amidases AmiA-D in E. 
coli or AmpDh2 and AmpDh3 in P. aeruginosa cleave the peptide stem releasing free tri-, tetra- 
and pentapeptides from the muropeptide subunits in PG strands (fig. 1.2; 7a-c). After that, free 
GlcNAc, MurNAc and peptides are passed into cytoplasm by NagE, MurP and Opp and 
converted into GlcNAc-6-P, MurNAc-6-P and tripeptides, respectively, to be recycled into PG 
biosynthesis. Also, GlcNAc-anhMurNAc (fig. 1.2; 9) and GlcNAc-anhMurNAc-peptide (tri-, 
tetra- or penta-peptide; fig. 1.2; 6a-c) are transported into cytoplasm by AmpG permeases (Fig. 
1.2; step 3). In cytoplasm, muropeptides (fig. 1.2; 6a-c; step 4) and free disaccharide derivatives 
(fig. 1.2; 9) are further cleaved by NagZ into anhMurNAc-peptide (tri-, tetra- or pentapeptides; 
fig. 1.2; 8a-c) and the constituting sugars (GlcNAc and anhMurNAc), respectively. Also, LdcA 
(LD-CPase) enzymes trim all tetrapeptides (free and sugar-linked) into their corresponding 
tripeptides (fig. 1.2; 6a, 7a, 8a). Meanwhile, cytoplasmic AmpD amidases eliminate peptide 
stems from sugar residues releasing free peptides (fig. 1.2; 7a-c; step 5). At the end, free 
peptides and sugar subunits are recycled in synthesis of lipid II and it seems to be a closed circle 
of PG biosynthesis and recycling. On the other hand, it was reported that the liberated 
anhydromuropeptides (ampC inducing peptides) accumulate in the cytoplasm and enter in a 
competition with UDP-MurNAc-pentapeptides (ampC repressing peptides) in binding to AmpR 
(fig. 1.2; step 6) which is a transcription factor for both of ampR and ampC β-lactamase in many 
Gram-negative bacteria (e.g. P. aeruginosa but not E. coli) causing AmpC overproduction and 
in turn β-lactam resistance (Fisher & Mobashery, 2014; Johnson et al, 2013; Reith & Mayer, 
2011; Vollmer et al, 2008b).  
 
1.4. Antibiotics targeting cell wall biosynthesis & bacterial resistance 
In general, antibiotics are a group of natural (e.g. penicillin, erythromycin and 
vancomycin) and synthetic (e.g. linezolid, sulphomethoxazole, cephalosporins and 
trimethoprim) compounds that have variant inhibitory effects to vital physiological pathways 
leading to inhibition of bacterial growth (bacteriostatic effect) or cell death (bactericidal effect). 
As shown in figure 1.3, the main targets for antibiotic inhibition are DNA replication, folate 
metabolism, biosynthesis of bacterial proteins and cell wall; and so antibiotics were classified 
according to their target and mechanism of action and further sub-divided concerning their 
molecular structure (Becker, 2013; Bolhuis & Aldrich-Wright, 2014; Pucci & Bush, 
2013; Walsh, 2003) As peptidoglycan precursor are important component for the biosynthesis 
of PG and also important for induction of ampC-type beta-lactamases, we will describe in some 
details some of the inhibitors of this cellular target. 
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Figure 1.2. Outline of PG biosynthesis, PG recycling and ampC regulation in 
Gram-negative bacteria (Fisher & Mobashery, 2014; Johnson et al, 2013). 
Three main physiological events, described on the text, are summarized in this figure; 1st event 
is PG biosynthesis which occurs in the three cellular compartments (cytoplasm, inner 
membrane and periplasm), starting in cytoplasm (1,2) where UDP-MurNAc-pentapeptide is 
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formed by the action of AnmK, MurQ, NagA,GlmS, GlmM, GlmU, MurA-F and Mpl. Then lipid 
I and II are formed at the inner membrane by the action of MraY and MurG which is followed 
by the action of flippase which cause turning of lipid II from cytoplasmic side into the 
periplasmic side where PG precursors are added into PG strands (3) and inter-crosslinked (4) 
by the activity of HMM-PBPs (TGases, TPases); also, PG-pentapeptides are converted into 
tetrapeptides by the action of DD-CPases (LMM-PBPs). The 2nd event is PG turnover and 
recycling (steps 1-5) starting in the periplasm by the action of PG hydrolases (EPases, DD-
CPases, LTs and amidases AmiA-D in E. coli or AmpDh2-h3 in P. aeruginosa) producing free 
tri-, tetra- and pentapeptides (7a-c), GluNAc, MurNAc, GluNAc-anhMurNAc (9) and GluNAc-
anhMurNAc-peptides (tri-, tetra- or pentapeptides; 6a-c) which are transported into cytoplasm 
through NagE, MurP, Opp and AmpG. In cytoplasm, muropeptides (6a-c) are further degraded 
into anhMurNAc-peptides (tri-, tetra- or pentapeptides; 8a-c), free tri-, tetra- or pentapeptides 
(7a-c), GluNAc-anhMurNAc (9) and anhMurNAc and GluNAc (10) by the action of NagZ, LdcA 
and AmpD. Free peptides and sugar derivatives are then recycled into synthesis of lipid II (PG 
precursors). The 3rd event is regulation of expression of AmpC β-lactamase (step 6) in P. 
aeruginosa (but not in E. coli) by the action of UDP-MurNAc-pentapeptide (repression, basal 
AmpC level) and anhydromuropeptides (derepression, AmpC overproduction) upon binding to 
AmpR. Meanings of all symbols (e.g. MurA-G, PBPs, LTs, LdcA, etc.) are described in the text 
and in the abbreviation list.   
  
1.4.1. Inhibitors of Mur family and PG precursors   
Inhibition of Mur family and PG precursors lead to blocking of PG synthesis, cell wall 
degradation and bacterial cell death. Fosfomycin is a natural antibacterial compound produced 
by various Streptomyces and Pseudomonas species to inhibit MurA (fig. 1.3) and stops the 
construction of UDP-MurNAc and consequently, decreases in PG synthesis and cell growth, and 
ultimately cell lysis (Borisova et al, 2014; Nikolaidis et al, 2014). Tunicamycin blocks 
transglycosylation step of MurG while mersacidin (Type-B lantibiotics) inhibits PG 
biosynthesis by tight interaction with lipid II (Islam et al, 2012; Walsh, 2003). Ramoplanin and 
enduracidin (lipoglycodepsipeptides) have a higher affinity for Lipid II over lipid I which 
results in blocking the transglycosylation reaction of PG biosynthesis as shown in figure 1.3  
(Fang et al, 2006; Walsh, 2003). MoenomycinsA (MoeA) is a phosphoglycolipid which inhibits 
PG synthesis by blocking transglycosylase (TGase) subunit, while vancomycin is a glycosylated 
heptapeptide which blocks transpeptidation reaction (TPases) by binding D-Ala‒D-Ala of the 
peptide stems of PG precursors (Lipid II) and lead to inhibition of PG synthesis (fig. 1.3; 1.4) 
(Jia et al, 2013; Ostash & Walker, 2010; Tseng et al, 2014; Walsh, 2003). 
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Figure 1.3. Sub-cellular targets for antibiotic actions (Walsh, 2003). 
Different antibiotics with different targets [inhibition of cell wall biosynthesis (a), protein 
biosynthesis (b), DNA and RNA replication (c), and folate metabolism (d)] are shown. 
Vancomycin inhibits transpeptidase reaction by binding the peptide stem of PG. β-lactam 
antibiotics (e.g. penicillins and cephalosporins) bind and inhibit transpeptidases; and so inhibit 
cell wall biosynthesis. Also, cell-wall biosynthesis can be inhibited by fosfomycin which inhibits 
MurA; tunicamyin which inhibits MurG TGase and moenomycin which inhibits 
transglycosylases (TGases).  
 
 
Figure 1.4. Mechanism of antibiotic inhibition of bacterial cell wall biosynthesis 
(Tseng et al, 2014). 
Vancomycin binds D-Ala‒D-Ala of the pentapeptide stem in PG. β-lactam antibiotics bind the 
transpeptidase subunit (TPase) of PBPs. Moenomycins A (Moe A) blocks transglycosylation 
reaction by binding to the transglycosylase subunit (TGase) of PBPs. β-lactams block the active 
site of transpeptidase subunits of PBPs. Red colored T-shaped lines identify the target site for 
each of vancomycin, β-lactam antibiotics and Moe A. 
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1.4.2. β-lactam antibiotics  
They are a group of antimicrobial agents targeting PBPs in order to inhibit PG synthesis 
pathway by blocking TPase subunits and consequently inhibit bacterial growth (fig. 1.4; 1.3). 
They have various β-lactam ring systems (penam, cefem, penem, carbapenem and monobactam) 
involving a highly strained and reactive cyclic amide which mimics the terminal D-Ala‒D-Ala 
in the muropeptides. Hence they can bind to PBPs and cause irreversible inhibition of these 
PBPs by blocking their active site Ser [Fig. 1.7; i] (Fernandes et al, 2013; Johnson et al, 2013; 
Tseng et al, 2014; Walsh, 2003). β-lactam antibiotics are produced either by isolation of 
fermented natural compounds (e.g. penicillin) or by further synthetic or enzymatic modification 
of fermented natural compounds like many penicillins and most of cephalosporins (Elander, 
2003; Hamed et al, 2013; Kong et al, 2010).  
Penams (e.g. Penicillins): Penicillins have a bicyclic nucleus, 6-aminopenicillanic acid, 
6-APA (Fig. 1.5) (Kong et al, 2010). Ampicillin, amoxicillin, cloxacillin, floxacillin, 
mezlocillin, nafcillin and oxacillin are different derivatives of penicillin G and penicillin V 
which are sensitive to penicillinase (β-lactamase) action (fig. 1.7; ii), while methicillin and 
dicloxacillin are more stable forms against penicillinase. Also, carbenicillin and ticarcillin are 
penicillins more stable against P. aeruginosa and many Gram-negative rods (Elander, 2003; Tan 
& File, 1995). Penicillin G is active against Neisseria gonorrhoeae and Treponema pallidum. 
Both of penicillin G and V are susceptible to S. aureus. On the other hand, some penicillinase-
stable derivatives (e.g. oxacillin, dicloxacillin and floxacillin) that were developed are less 
effective (in blocking PBPs) than their parental sources (Becker, 2013; Fernandes et al, 2013).  
Cephems (e.g. Cephalosporins): Several generations (table 1.1) of cephalosporins were 
developed with an enhanced spectrum reaching 4th generation (e.g. cefepime, cefpirome) and 
5th generation (e.g. Ceftobiprole, Ceftaroline) with the broadest spectrum activities which are 
more effective against P. aeruginosa than antipseudomonal penicillins (Fernandes et al, 2013). 
They are derivatives of cephalosporin C (fig. 1.5) produced from Cephalosporium acremonium, 
and have a nucleus of 7-aminocephalosporinic acid, 7-ACA, (Kong et al, 2010). Also, They are 
not susceptible to β-lactamases produced by S. aureus (Becker, 2013). 
 
     
Figure 1.5. Chemical structures of penicillins and cephems (Fernandes et al, 2013). 
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Table 1.1. Various cephalosporin generations (Fernandes et al, 2013). 
 
 
Penems: have the broadest spectrum of antibacterial activity which make them resistant 
to hydrolysis by many β-lactamases including ESBL and AmpC enzymes (fig. 1.7) (Dalhoff et 
al, 2006; Papp-Wallace et al, 2011). According to structural differences, penems were sub-
divided into penems (e.g. faropenem) and carbapenems (e.g. doripenem, imipenem and 
meropenem, fig. 1.6) which are more effective than faropenem against P. aeruginosa and 
Enterobacteriaceae, (Dalhoff et al, 2006).   
Monobactams: They are monocyclic, N-sulfonated β-lactams, produced by bacteria. 
Aztreonam is a synthetic monobactam (fig. 1.6) resistant to hydrolysis by chromosomally 
encoded cephalosporinases and many plasmid-mediated β-lactamases such as TEM-1, TEM-2, 
OXA-2, and SHV-1 (Drawz & Bonomo, 2010). 
 
 
Figure 1.6. Chemical structures of penems and carbapenems (Dalhoff et al, 2006); 
aztreonam, sulbactam and tazobactam (Hamed et al, 2013). 
 
1.4.3. Bacterial resistance to β-lactams 
Antibiotic resistance is the ability of bacteria to accommodate and to grow in presence of 
challenging compounds like antibiotics. The intensive and prolonged clinical and agricultural 
use and misuse of antibiotics have triggered the worldwide spread of highly resistant pathogenic 
bacteria (Rodriguez-Rojas et al, 2013). Many resistance mechanisms were previously described 
like production of β-lactamase which is common in many Gram-negative bacteria; changes in β-
lactam targets (PBPs), e.g. Methicillin resistance in S. aureus (MRSA); decreased production of 
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outer membrane proteins (OMPs), e.g. loss of OprD increased resistance to some carbapenems 
in P. aeruginosa; increased efflux pumps and reduced membrane permeability which facilitate 
multidrug resistance in many Gram-negative pathogens especially in P. aeruginosa and 
Acinetobacter spp (Drawz & Bonomo, 2010). β-lactam hydrolysis and emergence of a broad 
spectrum β-lactamases are basic keys for bacterial resistance (Bush & Jacoby, 2010). 
 
1.4.4. β-lactamase inhibitors 
The developed bacterial resistance to most of clinically used β-lactam antibiotics 
pushed the investigators to search for some natural or synthetic compounds that can inhibit β-
lactamases, even though they may have a weak antibiotic effect (Hamed et al, 2013). Clavulanic 
acid, sulbactam, and tazobactam are clinically used as β-lactamase inhibitors. They share 
structural similarity with penicillin (fig. 1.6) and are effective against class A β-lactamases 
(including CTX-M and the ESBL derivatives of TEM-1, TEM-2, and SHV-1); and are generally 
less effective against class B, C, and D β-lactamases (fig. 1.7; table 1.2). Metallo-β-lactamases 
(MBLs) are resistant to all the mechanism-based inhibitors of the serine enzymes (Drawz & 
Bonomo, 2010; Hamed et al, 2013). It was found that the use of β-lactam inhibitors in 
combinations with β-lactam antibiotics (e.g. Amoxicillin/clavulanate, ampicillin/sulbactam, 
pipericillin/tazobactam, ticarcillin/clavulanate, cefoperazone/sulbactam) was more effective 
than their individual use (Drawz & Bonomo, 2010; Hamed et al, 2013; Pucci & Bush, 2013)  
 
1.5. β-lactamases 
 
1.5.1. Classification of β-lactamases 
β-lactamases are a group of chromosomally-encoded or plasmid-mediated enzymes that 
can hydrolyze β-lactam antibiotics. They were classified according to their molecular structure 
by Ambler into molecular classes A, B, C and D, where serine β-lactamases were grouped in 
classes A, C and D, while MBLs were grouped in class B. (Ambler, 1980; Hall & Barlow, 2005; 
Kong et al, 2010). Recently, functional classification was reported and divided β-lactamases 
concerning their activity behavior towards substrates and inhibitors (e.g. β-lactams, clavulanic 
acid, tazobactam and EDTA) into groups 1, 2, 3 and further divided into subgroups (a, b …). 
Also, in that study, both functional and molecular classifications of β-lactamases were 
mentioned in parallel (table 1.2). New candidates of β-lactamases emerged due to mutations in 
the existing ones and showed a broad spectrum activity (e.g. ESACs, group1e and ESBLs, 
group 2b). Functional classification of β-lactamases is very helpful in clinics to characterize and 
to deal with bacterial resistance challenges (Bush & Jacoby, 2010; Bush et al, 1995). 
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1.5.2.  Group 2 and 3 β-lactamases 
 
Functional group 2 β-lactamases (molecular classes A and D) is the largest group of β-
lactamases, due to emerging of new of ESBLs. This group is subdivided into subgroup 2a which 
include β-lactamases (e.g. PC1; predominant in Gram-positive cocci) with a relatively limited 
spectrum of hydrolytic activity; Subgroup 2b includes β-lactamases (e.g. TEM-1, TEM-2, and 
SHV-1 ) readily hydrolyze penicillins and early cephalosporins (e.g. cephaloridine and 
cephalothin); Subgroup 2be β-lactamases (e.g. TEM-3, SHV-2 and CTX-M-15) are active on 
penicillins, extended spectrum cephalosporins and monobactams; Subgroup 2br β-lactamases 
(e.g. TEM-30 and SHV-10) are active on penicillins; Subgroup 2ber β-lactamases (e.g. TEM-
50) are active on penicillins, extended spectrum cephalosporins and monobactams; Subgroup 2c 
β-lactamases (e.g. PSE-1, CARB-3) showed improved activity on carbencicillin; Subgroup 2ce 
β-lactamases (e.g. RTG-4) showed improved activity on carbenicillin and cefepime; Subgroup 
2d β-lactamases (e.g. OXA-1, OXA-10) showed improved activity on cloxacillin or oxacillin; 
Subgroup 2de β-lactamases (e.g. OXA-11, OXA-15) hydrolyze cloxacillin or oxacillin and 
oxyimino-β-lactams; Subgroup 2df β-lactamases (e.g. OXA-23, OXA-48) hydrolyze cloxacillin 
or oxacillin and carbapenems; Subgroup 2e β-lactamases (e.g. CepA) are active extended 
spectrum cephalosporins; Subgroup 2f β-lactamases (e.g. KPC-2, IMI-1,SME-1) displayed 
increased hydrolysis of carbapenems, oxyimino-β-lactams, cephamycins with variable profiles 
with clavulanic acid and tazobactam. β-lactamases of subgroups 2a, 2b, 2be, 2c, 2ce and 2e are 
inhibited by clavulanic acid or tazobactam while subgroups 2br and 2ber are resistant to 
clavulanic acid, tazobactam and sulbactam. Moreover, subgroups 2d, 2de and 2df displayed 
variable profiles with clavulanic acid and tazobactam (Bush & Jacoby, 2010).  
Functional group 3 (class B) of β-lactamases include subgroubs a and b which are 
Zn2+-metallo-β-lactamases (MBLs) and can be inhibited by EDTA but not by clavulanic acid 
and tazobactam. Subgroup 3a β-lactamases (e.g. IMP-1, VIM-1) are active on carbapenems but 
not monobactams. Subgroup 3b β-lactamases (e.g. CphA, Sfh-1) displayed preferential 
hydrolysis of carbapenems (Bush & Jacoby, 2010).  
 
1.5.3. AmpC β-lactamases 
AmpC β-lactamases are periplasmic enzymes, belong to group 1 class C serine β-
lactamases (table 1.2), active on cephamycins (e.g. cefoxitin) and more active on cephalosporins 
than bezylpenicillin while it showed low affinities to cefepime, cefpirome, and carbapenems 
(Bush & Jacoby, 2010; Jacoby, 2009). They are not inhibited by clavulanic acid but inhibited by 
cloxacillin, oxacillin, and aztreonam. AmpC enzymes were reported principally as 
chromosomally-encoded in many members of Proteobacteria; however plasmid- mediated 
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AmpC enzymes (e.g. ACT-1, CMY-2, FOX-1 and MIR-1) have emerged in the last two 
decades. AmpC is inducible by certain β-lactams (e.g. imipenem and cefoxitin) in many 
organisms (e.g. P. aeruginosa), but it is not induced in some others (e.g. E. coli). Extended-
spectrum AmpC β-lactamases (ESACs) like GC1 in E. cloacae and plasmid-mediated CMY-10, 
CMY-19, CMY-37 are categorized as subgroup 1e (Bush & Jacoby, 2010; Jacoby, 2009). 
AmpC overproduction confers resistance to most penicillins, β-lactamase inhibitor/β-lactam 
combinations and resistance to many broad-spectrum cephalosporins (e.g. cefotaxime, 
ceftazidime, and ceftriaxone) with reduced susceptibilities to carbapenem, cefepime and 
cefpirome (Jacoby, 2009; Mammeri et al, 2006; Rodriguez-Martinez et al, 2009). Infections due 
to AmpC-producing bacteria (e.g. P. aeruginosa) can be treated with carbapenems unless there 
is no carbapenem resistance which can arise by mutations that cause loss of outer membrane 
porin (reduce influx) or increase efflux by efflux pump activation (Jacoby, 2009). 
 
1.5.4. Mechanism of action  
The active site of these proteins (PBPs and β-lactamases) contains nine highly 
conserved residues; the catalytic serine is located at the beginning of α2 helix and followed by a 
lysine to form the S*XXK sequence; a second sequence, SxN, is located in a loop between helix 
α4 and α5; four conserved residues form the KTG(T/S) form the third sequence; and a ninth 
residue, a glycine (G) at the back portion of the active site, is also strictly conserved (Sauvage et 
al, 2008). The reaction between serine β-lactamases or Zn2+-dependent MBLs and common β-
lactam substrates (e.g. penicillin) produces labile acyl-enzyme complexes which easily can be 
hydrolyzed into inactive β-lactams and active enzymes (fig. 1.7 ii and v, respectively) while β-
lactam-based inhibitors (e.g. clavulanic acid) or carbapenems (e.g. imipenem) form stable 
inactive acyl-enzyme complexes with serine β-lactamases due to the formation of stable bond 
with the active site Ser [fig. 1.7 iii and iv, respectively] (Hamed et al, 2013). Physiologically, 
active site inactivation of PBPs by β-lactam antibiotics (fig. 1.7 i), follows the same mechanism 
of reaction producing an inactive acyl-enzyme containing a very stable bond with the active site 
Ser. Inactivation of some PBPs lead to overexpression of AmpC in many Gram-negative 
bacteria to hydrolyze the β-lactam antibiotic and to recover the vital activities of the PBPs for 
maintaining their cell wall (Kong et al, 2010).  
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Table 1. 2. Functional and structural classification of β-lactamases* (Bush & 
Jacoby, 2010). 
 
*Summary of functional classification of β-lactamases (Bush-Jacoby-Medeiros group, 1995), 
updated functional classification (Bush-Jacoby group, 2009) and structural classification 
(Molecular class, Ambler classification). β-lactamases were functionally classified (Bush-
Jacoby group, 2009; Bush-Jacoby-Medeiros group, 1995) regarding their activity behavior 
towards substrates and inhibitors (e.g. β-lactams, clavulanic acid (CA), tazobactam (TZB) and 
EDTA) into groups 1, 2, 3 and further divided into subgroups (a, b …). Also, they were 
classified according to their similarities in their molecular structure by Ambler into molecular 
classes A, B, C and D. More details of the activity, functionality, substrate, inhibitors and 
molecular class are described in the text. 
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Figure 1.7. Mechanism of action of β-lactamases and PBPs on β-lactams (Hamed et al, 2013). (i) The formation of inactive PBP‒penicillin complex. (ii) 
Hydrolysis penicillin by serine β-lactamases. (iii, iv) Inhibition of serine β-lactamases by clavulanic acid and imipenem, respectively. (v) Hydrolysis of 
penicillin by Zn2+-dependent metallo β-lactamases (MBLs). 
Introduction 
 
34 | P a g e  
 
Alaa Ropy_Doctoral Thesis 
 
1.5.5. AmpC structure 
The 3-D structure of E. coli AmpC showed that the active site residues are Ser64* (catalytic 
residue), Lys67, Gln120, Tyr150, Asn152, Lys315, Thr316 and Ala318 (Ser318 in some other 
types). These residues are conserved in all class C β-lactamases (Jacoby, 2009; Usher et al, 1998). 
Recently, 3-D structure of P. aeruginosa AmpC was developed and showed active site similarity to 
the E. coli with the exception of having Ser318 (Lahiri et al, 2013). ESACs differ from wild-type 
AmpC by amino acid substitutions or insertions in some regions in the vicinity of the active site 
(e.g. the Ω-loop, the H-10 helix, the H-2 helix and the C-terminal end of the protein) which improve 
affinities and reactions with more β-lactam substrates like broad spectrum cephalosporins [e.g. 
cefotaxime, ceftazidime] (Rodriguez-Martinez et al, 2009). Concerning their structural similarity, it 
was found that both class C β-lactamases and class C LMM-PBPs type-AmpH (e.g. R61 DD-
peptidase) have a close similarity in their general structure and conserved motifs near the active site 
serine (Jacoby, 2009; Sauvage et al, 2008). This suggests that both of them have a common ancestor 
and implies that class C β-lactamases may have a secondary peptidase activity (Bishop & Weiner, 
1992; Hall & Barlow, 2004; Joris et al, 1988; Kong et al, 2010). 
 
1.5.6. AmpC regulation in P. aeruginosa 
In P. aeruginosa, ampC is chromosomally encoded, expressed in low basal amount, and 
can be induced by β-lactam challenge. AmpC expression is regulated mainly by the enzymes; 
AmpG permease homologs (AmpG and AmpP or ampGh1), ampD amidase homologs (ampD, 
ampDh2 and ampDh3), ampR (LysR superfamily) and NagZ, and two competing AmpR-binding 
muropeptides; the first is suppressing peptide, UDP-MurNAc-pentapeptide, which set ampC 
expression at basal level while the second is inducing peptide, 1,6-anhydromuropeptide which 
triggers high ampC expression [fig. 1.2] (Fisher & Mobashery, 2014; Johnson et al, 2013; Lister et 
al, 2009). Normally, GlcNAc-MurNAc-1,6-anhydromuropeptides shed of from peptidoglycan and 
find its way to cytoplasm via AmpG permease (fig. 1.2; step 3), where it is processed by NagZ to 
generate MurNAc-1,6-anhydromuropeptides (fig. 1.2; step 4) which is then cleaved by AmpD to 
generate anhMurNAc and free tri-, tetra- and pentapeptides (fig. 1.2; step 5).  The inducing peptides 
replace UDP-MurNAc-pentapeptides from AmpR binding which in turn undergoes some 
conformational changes that lead to overexpression of AmpC (fig. 1.2; step 6). During β-lactam 
exposure, MurNAc-1,6-anhydromuropeptides accumulate in cytoplasm where AmpD activity is not 
enough to cleave them. So, these anhydromuropeptides can replace the suppressing peptides from 
AmpR binding until the β-lactam inducer is removed, and then the conditions can be reversed to the 
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normal. It is still unidentified the actual and the effector (ampC inducing) anhydromuropeptide 
although it was suggested to be compounds 8a, 8b or 8c in figure 1.2 (Fisher & Mobashery, 2014; 
Johnson et al, 2013; Lister et al, 2009). As AmpR binds to the ampR-ampC intergenic region, 
mutations in this region and in ampR could increase AmpC expression. AmpR plays a dual role, 
positively regulating ampC and negatively regulating the expression levels of chromosomally 
encoded class D β-lactamase poxB, recently described. Also, AmpR has been involved in the 
regulation of many virulence factors. Moreover, AmpR mutant showed a high constitutive 
expression of β-lactamases (Balasubramanian et al, 2012; Kong et al, 2010). The three AmpD 
homologues are responsible for a stepwise ampC upregulation mechanism. The inactivation of 
ampD leads to the constitutive hyperproduction (derepression) of AmpC β-lactamase (Juan et al, 
2006). It was reported that inactivation of nagZ or ampG were able to block ampC induction and 
restored the susceptibility of ampD or dacB laboratory mutants (Zamorano et al, 2010; Zamorano et 
al, 2011). Recently, mutation of the nonessential dacB gene encoding the DD-carboxypeptidase 
PBP4 was found to elicit AmpC expression in the absence of β-lactams (Moya et al, 2009). dacB 
mutations were also identified in β-lactam-resistant clinical isolates of P. aeruginosa, suggesting 
that loss of PBP4 function is a medically relevant resistance mechanism (Juan et al, 2006). In 
Aeromonas spp., induction of AmpC expression requires a specific, 1,6-anhydromuropentapeptide 
(Tayler et al, 2010). These observations suggest that loss of specific enzyme activities, rather than 
general inhibition of PG turnover, leads to AmpC induction. However, mechanism underlining the 
loss of PBP4 activity is unknown and it is not yet clear if it is the only one that triggers that 
response. Lately, two new gene mutants have been reported to be involved in AmpC overproduction 
through an AmpR-dependent mechanism. The first mutant, YT1677, had an insertion in mpl, which 
encodes UDP-N-acetylmuramate (L-alanyl-γ-D-glutamyl-meso-diaminopimelate ligase) which is 
involved in the recycling of cell wall components. The second mutant, YT7988, had an insertion in 
nuoN, which encodes NADH dehydrogenase I chain N. For the first mutant, it was considered that 
AmpC overproduction was related to cytosolic accumulation of cell wall components i.e. 1,6-
anhydromuropeptides. However, it is assumed that the mechanism involved for the second mutant 
was unclear, and although it is AmpR-dependent, it is thought there is another new regulatory 
mechanism for ampC expression or the cell wall recycling system (Tsutsumi et al, 2013). Also it 
was reported that single or double mutants of PBP4, or some lytic-transglycosylases, LTs, (e.g. 
SltB1, or MltB) had an increased ampC dependent β-lactam resistance, while it decreased with 
single mutants of other LTs (e.g. Slt or MltF). Also, it was suggested that there are at least two 
different pathways leading to AmpC expression and β-lactam resistance in P. aeruginosa (Cavallari 
et al, 2013). 
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2. Objectives of this study  
 
There were three main objectives beyond this work;  
The 1st objective was to characterize Pae-AmpC activity not only as a β-
lactamase but mainly to study the effect of AmpC expression on the PG 
composition in both of E. coli and P. aeruginosa, using wild type and mutant 
strains. 
The 2nd objective was to track the consequences on bacterial resistance and 
peptidoglycan composition after gene inactivation of the main LMM-PBPs 
(dacB, dacC and pbpG) in PAO1 as single and combined constructs and further 
to study the effects upon ampC inactivation within these mutants. Also, to go 
closer understanding the mechanism behind the relationship between 
inactivation of these LMM-PBPs and ampC induction in P. aeruginosa as 
previously identified for dacB mutant.  
The 3rd objective was to pursue the physiological role and activities of 
DacB, DacC and PbpG in the recovery of the rod shape in spheroplasts of P. 
aeruginosa. 
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Materials & Methods  
 
3. Materials & methods 
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3.12.2. HPLC analysis 
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3. Materials & Methods 
 
 
3.1 Bacterial strains and plasmids 
We worked in this study only with bacterial strains of E. coli and P. aeruginosa PAO1 wild 
type and mutants. All bacterial strains and plasmids used in this study are summarized in table 3.1 
where E. coli DH5α was used for cloning of Pae-ampC-encoding vectors; E. coli BL21(DE3) was 
used for expression, overproduction and purification of Pae-AmpC; E. coli  CS109, BL21(DE3) and 
DV900(DE3) were used to study the effect of Pae-AmpC on PG composition in vitro and in vivo; 
E. coli XL1-Blue was used for cloning of (dacC and pbpG) gene-specific inactivation vectors; E. 
coli S17.1λpyr was used as a carrier of gene-specific inactivation vectors (e.g. pEXTΔpbpG::Gm) 
for conjugation in the double recombination step during the construction process of mutants in 
PAO1.  PAO∆dacC, PAO∆pbpG, PAO∆dacB∆dacC, PAO∆dacB∆pbpG, PAO∆dacB∆ampC, 
PAO∆dacC∆ampC and PAO∆pbpG∆ampC, PAO∆dacC∆pbpG, PAO∆dacC∆pbpG∆ampC, 
PAO∆dacB∆dacC∆ampC, PAO∆dacB∆dacC∆pbpG, PAO∆dacB∆pbpG∆ampC, PAO∆dacB 
∆pbpG∆ampC∆dacC and PAO∆dacB∆dacC∆pbpG∆ampC are mutants of P. aeruginosa PAO1 that 
were constructed in this study starting from the wild type PAO1 while PAOΔdacB and PAOΔampC 
were provided from previous studies (Moya et al, 2009; Moya et al, 2008). These Pae mutants were 
used for characterization of the role of LMM-PBPs (dacB, dacC and pbpG) in PG composition, β-
lactam resistance and ampC regulation in P. aeruginosa. Plasmids pEX100Tlink and pUCGmlox 
were used in generation of gene-specific inactivation vectors. pCM157 plasmid was used for 
expression of cre recombinase after double recombination during the construction of Pae mutants to 
remove the gentamycin cassette from the constructed mutant genotypes. pEXTΔampC::Gm (Moya 
et al, 2008), pEXTΔdacB::Gm (Moya et al, 2009), pEXTΔdacC::Gm and pEXTΔpbpG::Gm are 
gene-specific inactivation vectors which were used for inactivation of ampC, dacB, dacC and pbpG, 
respectively in P. aeruginosa PAO1. pET28b plasmid was used in the construction of vectors (e.g. 
pET-F1, pET-F1:C3, pET-F1:C6, pET-F2, pET-F3, pET-F4, pET-F4:C3, pET-F4:C6, pET-F3-
TEV, pET-F3:C3-TEV, pET-F3:C6-TEV and pET-F4-TEV) encoding different forms of Pae-ampC 
(wild type and mutants described in table 4.1 and figure 4.1). These pET28b vectors were used for 
expression and overproduction of different Pae-AmpC forms in E. coli. pUCP24 plasmid was used 
for cloning and expression of different ampC forms (e.g. pUC-F3 and pUCP-F4 for expression of 
AmpC-F3 and AmpC-4, respectively) in P. aeruginosa of wild type PAO1 and mutants.        
Materials & Methods 
 
44 | P a g e  
 
Alaa Ropy_Doctoral Thesis 
 
Table 3.1. Bacterial strains and plasmids.  
Bacterial Strain or Plasmid Genotype/Characteristics Reference/Source 
E. coli   
DH5α F- φ80lacZ∆M15 ∆(lacZYA-rgF)U169 recA1 endA1 hsdR17(rk-, mk+) 
phoA supE44 thi-1 gyrA96 relA1 λ-  
Fermentation service,  CBMSO 
BL21(DE3) F-, ompT, hsdB (rB- mB-) gal, dcm (DE3).Encodes T7 RNA polymerase.  Fermentation service,  CBMSO  
CS109 Wild type E. coli Laboratory collection 
DV900 CS-109 Δ[ponB dacA dacB dacC 
dacD pbpG ampH ampC pbp4b]   
(Vega & Ayala, 2006) 
DV900(DE3) DV900 lysogenized by λDE3 lysogenization kit (Novagen, Merck KGaA, 
Darmstadt, Germany) 
This study  
 XL1-Blue  F´::Tn10 proA+proB_+lacIq Δ (lacZ)M15/recA1  endA1 gyrA96 (Nalr) thi 
hsdR17 (rk + mk +) mcrB1 
Laboratory collection 
S17.1λpyr recA pro (RP4-2Tet::Mu Kan::Tn7) Laboratory collection 
P. aeruginosa   
PAO1 Wild type reference strain.  Laboratory collection  
PAOΔampC PAO1 ΔampC::lox  (Moya et al, 2008) 
 PAOΔdacB PAO1 ΔdacB::lox  (Moya et al, 2009) 
PAOΔdacC PAO1 ΔdacC::lox This study  
PAOΔpbpG  PAO1 ΔpbpG::lox This study  
PAOΔdacBΔdacC PAO1 ΔdacB::lox ΔdacC::lox This study  
PAOΔdacBΔpbpG PAO1 ΔdacB::lox ΔpbpG::lox  This study  
PAOΔdacCΔpbpG  PAO1 ΔdacC::lox ΔpbpG::lox  This study  
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PAOΔdacBΔdacCΔpbpG  PAO1 ΔdacB::lox ΔdacC::lox ΔpbpG::lox  This study  
PAOΔdacBΔampC  PAO1 ΔdacB::lox ΔampC::lox  This study  
PAOΔdacCΔampC  PAO1 ΔdacC::lox ΔampC::lox This study  
PAOΔpbpGΔampC PAO1 ΔpbpG::lox ΔampC::lox This study  
PAOΔdacBΔdacCΔampC  PAO1 ΔdacB::lox ΔdacC::lox ΔampC::lox This study  
PAOΔdacBΔpbpGΔampC  PAO1 ΔdacB::lox ΔpbpG::lox ΔampC::lox This study  
PAOΔdacCΔpbpGΔampC  PAO1 ΔdacC::lox ΔpbpG::lox ΔampC::lox   This study  
PAOΔdacBΔpbpGΔampCΔdacC PAO1 ΔdacB::lox ΔpbpG::lox ΔampC::lox ΔdacC::lox This study  
PAOΔdacBΔdacCΔpbpG ΔampC  PAO1 ΔdacB::lox ΔdacC::lox ΔpbpG::lox ΔampC::lox This study  
Plasmids   
pEX100Tlink  Apr sacB, pUC19-based gene replacement vector with an MCS  (Quenee et al, 2005) 
pUCGmlox  Apr Gmr, pUC18-based vector containing the lox-flanked aacC1 gene  (Quenee et al, 2005) 
pCM157  Tcr, cre expression vector  (Quenee et al, 2005) 
pEXTΔampC::Gm   pEX100Tlink containing 5´and 3´ flanking sequence of ampC::Gm lox (Moya et al, 2008) 
pEXTΔdacB::Gm   pEX100Tlink containing 5´and 3´ flanking sequence of dacB::Gm lox (Moya et al, 2009) 
pEXTΔdacC::Gm    pEX100Tlink containing 5´and 3´ flanking sequence of dacC::Gm lox This study  
pEXTΔpbpG::Gm      pEX100Tlink containing 5´and 3´ flanking sequence of pbpG::Gm lox  This study  
pET28b+ Kanr, expression by T7 RNA polymerase. Fusion with poly His at amino 
terminal. 
Novagen 
pET-F1 pET28b expressing AmpC-F1 with C-terminal poly-His tag. This study  
pET-F1:C3 pET28b expressing AmpC-F1:C3 with C-terminal poly-His tag. This study  
pET-F1:C6 pET28b expressing AmpC-F1:C6 with C-terminal poly-His tag.  This study  
pET-F2 pET28b expressing AmpC-F2 with C-terminal poly-His tag.  This study  
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pET-F3 pET28b expressing AmpC-F3 with C-terminal poly-His tag.  This study  
pET-F4 pET28b expressing AmpC-F4 with C-terminal poly-His tag.  This study  
pET-F4:C3 pET28b expressing AmpC-F4:C3 with C-terminal poly-His tag.  This study  
pET-F4:C6 pET28b expressing AmpC-F4:C6 with C-terminal poly-His tag.  This study  
pET-F3-TEV pET28b expressing AmpC-F3-TEV with C-terminal poly-His tag and 
TEV protease recognition site.   
This study  
pET-F3:C6-TEV  pET28b expressing AmpC-F3:C6-TEV with C-terminal poly-His tag and 
TEV protease recognition site.   
This study  
pET-F3:C3-TEV pET28b expressing AmpC-F3:C3-TEV with C-terminal poly-His tag and 
TEV protease recognition site.   
This study  
pET-F4-TEV pET28b expressing AmpC-F4-TEV with C-terminal poly-His tag and 
TEV protease recognition site.   
This study  
pUCP24 Ampr, cloning and expression vector for P. aeruginosa.  Laboratory collection 
pUCP-F4 pUCP24 expressing AmpC-F4 with C-terminal poly-His tag.  This study  
pUCP-F3 pUCP24 expressing AmpC-F3 with C-terminal poly-His tag.  This study  
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3.2 Primers 
Pae-ampC (PA4110) was targeted by this study for functional characterization in bacterial 
resistance and PG composition of E. coli and P. aeruginosa. So, primers were designed for PCR 
amplification of PA4110 ampC gene of wild type and mutant forms in order to be cloned and 
expressed by recombinant vectors (e.g. pET28b and pUCP24) in the target bacterial strains.  
Primers used for PCR amplification of different forms of Pae-ampC (table 4.1; fig. 4.1) are 
summarized in table 3.2 and their uses in PCR-amplifications are summarized in table 3.4. All the 
PCR amplifications were cloned in pET28b plasmid. Primers T7-Fw and pET-Rv-PaeI were used to 
amplify ampC-F3 and ampC-F4 using the templates pET-F3 and pET-F4, respectively, to be cloned 
in the plasmid pUCP24 for ampC cloning and expression in P. aeruginosa. Primers T7-Fw and T7-
Rv were used for sequencing of ampC forms cloned in pET28b vector while primers M13-Fw (-21), 
M13-Rv and M13-Rv2 were used for sequencing of ampC forms cloned in pUCP24 vector. Primers 
PBP5-Fw and PBP5-Rv were used for amplification and sequencing of dacC gene (Pae-PBP5).  
Primers used for amplification of upstream (PCR1) and downstream (PCR2) regions of the 
target genes (ampC, dacB, dacC and pbpG) to be used in the construction of knock out mutants in 
PAO1 are summarized in table 3.3. All the used primers were synthesized by Sigma.  
 
3.3 Culture media for cell growth 
Luria-Bertani (LB) and SOC media were prepared as described previously (Wiley & Sons, 
2002). Agar, yeast extract, and tryptone were purchased from CONDA Pronadisa Micro & 
Molecular Biology, Spain while glucose and NaCl were purchased from Merck, EMD Millipore 
Corporation. Mueller-Hinton media (MHA) and cation adjusted Mueller-Hinton broth (CAMHB) 
were prepared following the provider´s instructions (Becton Dickinson, France S.A). For ampC 
expression, E. coli and P. aeruginosa strains transformed with recombinant vectors (encoding Pae-
ampC) were grown in LB liquid media (with a proper antibiotic) at 37°C with agitation (180 rpm). 
Also, for the construction of Pae mutants LB media was used with a proper antibiotic. For disc 
diffusion assay MHA plates were used. Mostly, LB media was used in this study, otherwise it will 
be mentioned. CAMHB media was used for production of imipenem-induced spheroplasts in P. 
aeruginosa.    
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Table 3.2. Primers used for PCR amplification and DNA sequencing.  
Name* Sequence (5´- 3´) Restriction 
Site* 
Reference/ 
Source 
ampC-Fw1 TTTCCATGGATGCGCGATACCAGATTCC   
NcoI 
 
This study 
 
ampC-Fw2 TTTCCATGGGCGATACCAGATTCCCCT 
ampC-Fw3 TTTCCATGGCCGGCGAGGCCCCGG 
ampC-Fw4 TTTCCATGGCCATGCGCGATACCAGATTCC 
ampC-Rv TTTGAATTCCGCTTCAGCGGCACCTTGC  EcoRI This study 
ampC-Rv-TEV TTTGAATTCCCCTGAAAATACAGGTTTTC-
CGCTTCAGCGGCACCTTGC 
EcoRI+ 
TEV site 
This study 
pET-Rv-PaeI GCATGCT TGTTAGCAGCCGGATCTCAG PaeI (SphI) This study 
T7-Fw TAATACGACTCACTATAG - Laboratory 
collection 
T7-Rv GCTAGTTATTGCTCAGCGG  - Laboratory 
collection  
M13-Fw (-21)  TGTAAAACGACGGCCAGT - Parque 
Científico de 
Madrid 
M13-Rv CAGGAAACAGCTATGACC  - 
M13-Rv2 ACACTTTATGCTTCCGGCTCG - This study  
PBP5-Fw GATCGGTTCGGCGGACGAGGT - This study 
PBP5-Rv ACGCTCGCAGGGGAATTCGAT - This study 
* Fw and Rv refer in the primer direction, forward and reverse, respectively. * Restriction sites 
used for cloning are underlined.  
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Table 3.3. Primers used for the construction of knockout mutants of ampC, dacB, dacC and pbpG in PAO1. 
Target gene Primer Name* Primer Sequence, 5´→3´ PCR Product (bp) Reference 
 
pbpG 
pbpG-F1-ERI -TCGAATTCCACTTTCAAAGCCCTACGTGC- PCR1= 375 This study 
pbpG-RI- HDIII -TCAAGCTTGCAGTTTCGAGTCGAGCACG- 
pbpG-F2-HDIII -TCAAGCTTCACTGCGATCCCGGCCGC- PCR2= 318 
pbpG-R2-BHI -TCGGATCCCAGTACCGGACCCAGGAGC- 
 
dacC 
dacCF-ERI -TCGAATTCACCTTGGCCAGCCGACGC- PCR1= 500 This study 
dacCIR-HDIII -TCAAGCTTCTCGGCCAGGGCGACGC- 
dacCIF-HDIII -TCAAGCTTGAAGTGAAAGCCGGCCTCG- PCR2= 400 
dacCR-BHI -TCGGATCCACGCTCGCAGGGGAATTCG- 
 
dacB 
dacB-F1-ERI -TCGAATTCCGACCATTCGGCGATATGAC- PCR1= 571 (Moya et al, 
2009) dacB-R1-HDIII -TCAAGCTTGTCGCGCATCAGCAGCCAG- 
dacB-F2-HDIII -TCAAGCTTGCCAGGGCAGCGTACCGC- PCR2= 693 
dacB-R2-BHI -TCGGATCCCGCGTAATCCGAAGATCCATC- 
 
ampC 
AmpC-F-ERI -TCGAATTCGCGCGCAGGGCGTTCAG- PCR1= 415 (Moya et al, 
2008) AmpC-I-R-HDIII -TCAAGCTTCGTCCTCTTACGAGGCCAGC- 
AmpC-I-F-HDIII -TCAAGCTTCAGGGCAGCCGCTTCGAC- PCR2= 448 
AmpC-R-BHI -TCGGATCCCAGGTTGGCATCGACGAAG- 
Primers used for PCR amplification of both upstream (PCR1) and downstream (PCR2) regions of target genes (pbpG, dacC, dacB and 
ampC) in P. aeruginosa PAO1 strain. * In each primer name, ERI, HDIII and BHI refer to the presence of the restriction sites 
(underlined sequences) of EcoRI, HindIII and BamHI; while F and R refer to the direction, forward and reverse, respectively.  
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3.4 DNA manipulation 
 
3.4.1 DNA purification and sequencing  
DNA purification was achieved by following the manufacturer’s instructions using the kits; 
Wizard® genomic DNA purification kit (Promega) for purification of chromosomal DNA; Wizard® 
Plus SV minipreps DNA purification system (Promega) for purification of plasmid DNA, while 
Wizard® SV gel and PCR clean-up system (Promega) was used for purification of PCR product and 
DNA fragments separated by agarose gel electrophoresis. The concentration of purified DNA was 
measured by NanoDrop N-1000 (Thermoscientific). Sequencing of PCR products and cloned genes 
was done at the Parque Científico de Madrid; sequence data were analyzed by Chromas LITE 
program and online NCBI blast tools. 
 
 
3.4.2 Agarose DNA electrophoresis 
This technique was used for separation, identification and purification of DNA fragments 
using 1x TAE electrophoresis buffer, 0.5 µg/ml ethidium bromide (for visualization of DNA bands) 
and 0.8-1.0 g% Agarose gel were used (Wiley & Sons, 2000). The used system units were Mini-
sub® cell GT (BIO-RAD) and sub-cell GT WIDE MINI (BIO-RAD). After run, DNA bands were 
visualized on DNA-gel scanner (Slite 140, ETNA, European Technological Network Aliance).  
 
 
3.4.3 PCR amplification 
For PCR amplification of the different forms of Pae-ampC, a 50 μl reaction contained 0.2 
mM dNTPs (BIOTOOLS, Spain), 0.2-1 µM forward and reverse primers (Sigma), 100ng DNA 
and1.25 U Pfu or GoTaq polymerase (Promega), (table 3.4).   
For colony PCR, each of the selected colonies was resuspended in 30 μl sterile distilled 
water and boiled for 10 min at 100°C. After that, cell suspensions were centrifuged at 14000 rpm 
for 5 min and then 1μl form the supernatant was used in the PCR reaction without the addition of 
any DNA or plasmid templates. Usually GoTaq (Promega) was used for colony PCR, while Pfu was 
used for PCR-mediated cloning.  
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Table 3.4. Conditions used for PCR amplification of different ampC forms.a 
Amplified  
ampC 
DNA template Forward primer Reverse primer Annealing 
Temp., °C 
ampC-F1 chromosomal 
DNA, PAO1 
0.2 μM ampC-Fw1 0.2 μM ampC-RV 62 
ampC-F1:C3 pET-F1:C3 
(pGEM-19) 
0.2 μM ampC-Fw1 0.2 μM ampC-RV 62 
ampC-F1:C6 pET-F1:C6 
(pGEM-13) 
0.2 μM ampC-Fw1 0.2 μM ampC-RV 62 
ampC-F2 chromosomal 
DNA, PAO1 
0.2 μM ampC-Fw2 0.2 μM ampC-RV 62 
ampC-F3 chromosomal 
DNA, PAO1 
1 μM ampC-Fw3 0.2 μM ampC-RV 68 
ampC-F4 chromosomal 
DNA, PAO1 
0.2 μM ampC-Fw4 0.2 μM ampC-RV 65 
ampC-F4:C3 pET-F1:C3 0.2 μM ampC-Fw4 0.2 μM ampC-RV 65 
ampC-F4:C6 pET-F1:C6 0.2 μM ampC-Fw4 0.2 μM ampC-RV 65 
ampC-F4-TEV pET-F4 0.2 μM ampC-Fw4 0.2 μM ampC-Rv-TEV 65 
ampC-F3-TEV pET-F3 1 μM ampC-Fw3 0.2 μM ampC-Rv-TEV 68 
ampC-F3:C3-
TEV 
pET-F3:C3 1 μM ampC-Fw3 0.2 μM ampC-Rv-TEV 68 
ampC-F3:C6-
TEV 
pET-F3:C6 1 μM ampC-Fw3 0.2 μM ampC-Rv-TEV 68 
ampC-F3* pET-F3 1  μM T7-Fw 0.2  μM pET-Rv-PaeI 57 
ampC-F4* pET-F4 1  μM T7-Fw 0.2  μM pET-Rv-PaeI 57 
a For all PCR amplifications of ampC, we used 100 ng of DNA template except for some 
cases (*) where 300 ng of pET-F3 and pET-F4 were used. The extension temperature was 
72°C for all reactions.  * Only those two amplifications were used for ampC-F3 and ampC-
F4 cloning in pUCP24 plasmid to be cloned in P. aeruginosa. All the other amplifications 
were cloned in pET28b plasmid to be cloned and expressed in E. coli. 
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3.4.4 ampC cloning and expression using pET28b plasmid  
The plasmid pET28b was used for cloning, expression of various Pae-ampC forms (wild 
type and mutants) in E. coli to characterize the effect of AmpC activity on PG composition and 
bacterial resistance. pET28b plasmid has kanamycin resistance marker (Knr) and multiple cloning 
sites. Expression of ampC from pET28b recombinant vectors was achieved under the control of T7 
promoter of T7 RNA polymerase and lac operator for control of induction with IPTG. Cloning 
within pET28b can provide the cloned gene with N-terminal and/or C-terminal poly-His tag.  
In this study, cloning of different forms of Pae-ampC in pET28b was done in the restriction 
sites of EcoRI and NcoI (fig. 3.1). Moreover, all the developed AmpC proteins were designed to 
have C-terminal His-tag. The plasmid pET28b was digested with EcoRI and NcoI (Fermentas life 
sciences) overnight at 37°C, and then they were purified by the proper kit (section 3.4.1). After that, 
the digested and purified pET28b was then incubated overnight with alkaline phosphatase (Calf 
Intestinal, CIAP, Promega) at 37°C, and then purified as mentioned above. The purified pET28b 
was then ligated by T4 DNA ligase (Promega) overnight at 16°C with each of the purified and 
digested (with EcoRI and NcoI)  PCR products of ampC-F1, ampC-F1:C3, ampC-F1:C6 ampC-F2, 
ampC-F3, ampC-F4, ampC-F4:C3, ampC-F4:C6, ampC-F3-TEV, ampC-F3:C3-TEV, ampC-F3:C6-
TEV and ampC-F4-TEV to produce pET-F1, pET-F1:C3, pET-F1:C6, pET-F2, pET-F3, pET-F4, 
pET-F4:C3, pET-F4:C6, pET-F3-TEV, pET-F3:C3-TEV, pET-F3:C6-TEV and pET-F4-TEV,  
respectively (table 3.1 ). These recombinant vectors were used to transform DH5α which then was 
platted on LB plates containing a 30 μg/ml kanamycin and incubated overnight at 37°C. Selected 
transformants were examined by colony-PCR (addendum, fig. A.1), digestion with EcoRI and NcoI 
and finally DNA sequencing. After that, the recombinant vectors carrying the confirmed ampC 
sequence were used to transform E. coli BL21(DE3) and DV900(DE3) for AmpC expression, 
functional characterization and PG analysis. Restriction and ligation conditions were followed 
according to the manufacturer´s recommendations. For expression of the different AmpC forms 
from pET-ampC recombinant vectors, Bl21(DE3) and DV900(DE3) transformants of pET-ampC 
were cultivated in LB media supplemented with different concentrations of IPTG (indicated in 
results), for different incubation periods at 37°C with agitation. Where, pET-ampC was used to 
refer to the different pET28b recombinant vectors encoding for various ampC forms mentioned 
above.  
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3.4.5 ampC cloning and expression using pUCP24 plasmid  
The plasmid pUCP24 was used for cloning in the wild type and some mutants of P. 
aeruginosa PAO1; for functional characterization of some Pae-AmpC forms on β-lactam resistance 
and PG composition in P. aeruginosa. pUCP24 has a gentamycin resistance marker (aacC1) and 
multiple cloning sites as those present in the plasmid pUCP18 (West et al, 1994). Also pUCP24 has 
lac promoter and lacZα gene which encodes for β-galactosidase that cleaves X-Gal producing blue 
colored transformants while interruption of lacZα gene by gene cloning develops white 
transformants when X-Gal is supplemented into the growth medium. Cloning of ampC-F3 and 
ampC-F4 in pUCP24 was done in the restriction sites of XbaI and PaeI (fig. 3.2). Using pET-F4 and 
pET-F3 as a templates, T7-Fw and pET-Rv-PaeI primers and Pfu polymerase, PCR products For 
ampC-F4 and ampC-F3 were produced (table 3.4) which were then digested as well as the pUCP24 
vector with PaeI (Thermo Scientific) in buffer B for two hours at 37°C and then for another 2 hours 
with 2-fold excess XbaI (Thermo Scientific) and then purified as mentioned in section 3.4.1. After 
that they were ligated with T4 DNA ligase (Thermo Scientific) to produce pUCP-F4 and pUCP-F3, 
respectively. The ligation products were transformed into DH5α and then platted on LB plates 
containing 10 μg/ml gentamycin, 10 mg/ml X-Gal (Sigma) and 0.5 mM IPTG and incubated 
overnight at 37°C, and then white colonies were selected and tested for having pUCP-F3 and 
pUCP-F4 by colony PCR and DNA sequencing. The verified pUCP-F3 and pUCP-F4 recombinant 
plasmids were used to transform the wild type PAO1 and some of the constructed Pae mutants to 
study the complementation in ampC mutants and to follow the expression effect of AmpC on 
bacterial resistance and PG composition of P. aeruginosa. For expression of ampC-F3 and ampC-
F4 in P. aeruginosa, transformants of pUCP24-F3 and pUCP-F4 were cultivated in LB media 
supplemented with 10 μg/ml gentamycin and different concentrations of IPTG (indicated in results), 
for different incubation periods at 37°C with agitation. 
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Figure 3.1. Outline of Pae-ampC cloning region in pET28b vector.  
All the ampC forms described in table 4.1 and figure 4.1 were cloned in pET28b vector in the restriction sites of EcoRI and NcoI (*). 
Expression in pET28b is achieved under the control of T7 promoter (T7 RNA polymerase) and lac operator. The pET28b plasmid 
(5368 bp) has a kanamycin resistance marker, and multiple cloning sites. All the cloned ampC forms (ampC-F1, ampC-F1:C3, ampC-
F1:C6 ampC-F2, ampC-F3, ampC-F4, ampC-F4:C3, ampC-F4:C6, ampC-F3-TEV, ampC-F3:C3-TEV, ampC-F3:C6-TEV and ampC-
F4-TEV) have C-terminal poly-His tag, but only ampC-F3-TEV, ampC-F3:C3-TEV, ampC-F3:C6-TEV and ampC-F4-TEV have the 
TEV site upstream to the C-terminal His-tag. The site of ATG initiation codon of various AmpC forms is colored in blue.  
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Figure 3.2. Outline of Pae-ampC cloning region in pUCP24 vector.  
Expression in pUCP24 is achieved under the control of lac promoter. pUCP24 plasmid (4036 bp) has gentamycin resistance marker, multiple 
cloning sites and lacZα for white/blue colony discrimination. Both of ampC-F3 and ampC-F4 were retrieved from pET28-F3 and pET-F4, 
respectively (fig. 3.1), by PCR amplification (table 3.4) and then were cloned in pUCP24 vector within the restriction sites of XbaI and PaeI (*). 
As shown, pUCP-F3 and pUCP-F4 which encode ampC-F3 and ampC-F4, respectively, have two RBS (and two ATG starting codons) one is 
original from pUCP24 plasmid and the other is external from pET28b. Using these recombinant vectors (pUCP-F3 and pUCP-F4), ampC 
expression from the first ATG (in red color) with the 1st RBS (of pUCP24) will not produce ampC sequence but rather a short ended and different 
sequence; only the 2nd ATG starting codon (in blue color) can produce ampC expression.     
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3.4.6 Bacterial transformation  
Transformation is one way and an important step in gene cloning to introduce the 
recombinant vectors (encoding the gene under study) into bacterial cells for further gene 
characterization, expression and overproduction. Competent cells were provided from the 
fermentation service at CBMSO or prepared as described previously (Wiley & Sons, 1997). For 
transformation by heat-shock, 5 µl of the ligation product was mixed with 100 µl of competent 
cells of E. coli strain (e.g. DH5α, DV900 (DE3), XL1-Blue or S17.1 strains) and kept on ice for 
30 minutes and then heat chocked at 42 ºC for 1 minute, and then was left on ice for 2 minutes. 
After that, 1 ml LB was added and cell suspension was incubated at 37ºC and 180 rpm for 1 
hour. Finally, the culture was plated into LB plates, with a proper antibiotic, overnight at 37ºC. 
For transformation by electroporation, 1-5 µl of the plasmid (e.g. pEXTΔpbpG::Gm) was mixed 
with 100 µl of competent cells of P. aeruginosa or E. coli Bl21(DE3) and left on ice for 10 
minutes. The mixture was transferred to a chilled 0.2 cm electroporation cuvette and 
electroporated at 25 μF, 2.5 kV and 200 Ω, and then 1 ml SOC media was added immediately to 
the cell suspension mixture and incubated at 37ºC and 180 rpm for 1 hour. The culture was 
plated into LB plates, with the proper antibiotic overnight at 37ºC. 
 
 
3.5 Protein manipulation 
 
3.5.1 Estimation of protein concentration 
It was achieved using BIO-RADTM DC protein assay by following the provider´s 
instructions. Standard curve was developed with each assay using BSA (Sigma). Absorbance 
was measured at 750 nm on U-2000 spectrophotometer (HITACHI).  
 
3.5.2 SDS-PAGE electrophoresis 
Polyacrylamide gel electrophoresis technique was used to separate mixture of proteins 
which can be visualized by direct Coomassie staining or by western blot. The different buffers 
(Tris-Glycine-SDS) and run conditions were done as described (Wiley & Sons, 2006). 8-10% 
acrylamide gels and Tris-glycine/SDS were used as electrophoresis buffer. The used system was 
MINI PROTEAN® TETRA CELL (BIO-RAD). Also, Pre-stained molecular markers (SeeBlue® 
Plus-2, Invitroen) were utilized.  
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3.5.3 Western blot 
After SDS-PAGE electrophoresis run, proteins were transferred from gel into 
immobilon-P transfer membrane (Millipore Co.) using the system CriterionTM blotter (BIO-
RAD). Briefly, after 2 h blotting at 45 V and 350 mA using blotting buffer 
(Tris/Gly/SDS/Methanol), the membrane was immersed in blocking buffer (Tris-buffered 
saline-0.05% Tween 20, TBS-T) containing 3% (W/V) nonfat dry milk for 1h with shaking. 
Then, the membrane was incubated for 1h at room temperature with 3000 fold diluted antibody, 
anti-His-tagged rabbit IgG (SC-803; Santa Cruz Biotechnology, Heidelberg, Germany), in TBS-
T buffer. After that, the membrane was washed three times by incubation with fresh TBS-T for 
10 min with shaking. Then, the blot was incubated overnight at 4°C with the 2nd antibody goat 
anti-rabbit IgG–horseradish peroxidase (HRPO, 3000 fold diluted in TBS-T; GAR-HRPO 170-
651; Bio-Rad, Hercules, CA), with shaking. After that, the blot was washed three times as 
mentioned above, then it was incubated for 30 seconds with visualization solution for HRPO 
and then it was exposed to X-ray in KODAK X-OMAT 2000 processor. The visualization 
solution was prepared just before its use and it was prepared as two 1 ml solutions of 100mM 
Tris-HCL, pH 8.0; the 1st contained 5 µl luminol [200x stock solution, 88.6mg luminol (Sigma) 
in 1ml DMSO] and 4.3 luciferin [218x stock solution, 10 mg D-luciferin (Roche Diagnostics) in 
2.1 ml 100mM Tris-HCL, pH 8.0]; the 2nd solution contained 15% H2O2 (Merck). Before use, 
both solutions were mixed together to form the visualization solution for HRPO. Photographs of 
both of X-ray films and stained gels were developed by gel scanner (GS-800 BIO-RAD) using 
Quantity One program. 
 
 
3.5.4 β-lactamase activity assay 
This assay was used to characterize β-lactamase activities of wild type Pae-AmpC and 
some mutants. For each assay, 2 µl sample was mixed with 988 µl PBPs (1x, pH 7.5) and 10 µl 
nitrocefin stock solution (500 µg/ml, Oxoid, Cambridge, United Kingdom), then incubated in a 
dark place at 23° for 15 min then centrifuged at 14000 rpm for 2 min. The supernatant 
absorbance was measured at 486 nm on U-2000 spectrophotometer (HITACHI). One milliunit 
β-lactamase activity is defined as 1 nanomole of nitrocefin hydrolyzed per min per microgram 
of protein. It was modified from a previous method (Kong et al, 2005).  
Values of Vmax and Km of purified AmpC forms were identified (using nitrocefin as a 
substrate) from a plot of the equation of Lineweaver-Burk double reciprocal plot which was 
driven from the Michaelis-Menten equation (Crowe & Bradshaw, 2010);  
Materials & Methods 
 
58 | P a g e  
 
Alaa Ropy_Doctoral Thesis 
 
(1 / v) = (1 / Vmax) + (Km / Vmax) (1 / [S])  
Where (1 / v) is y-axis; (1 / [S]) is x-axis; (1 / Vmax) is y-intercept and (Km / Vmax) is plot slope. 
Also, Vmax is the maximum reaction velocity (activity); Km is Michaelis constant and is defined 
by the substrate concentration producing half of maximum activity on a given enzyme substrate.  
 
3.5.5 Bocillin-FL test 
Bocillin-FL test was done to analyze the cellular PBPs pattern by fluorescence scanning 
after incubation of cell membrane fraction with Bocillin-FL which has the ability to bind HMM-
PBPs (e.g. PBP1a, PBP1b, PBP2 and PBP3) and LMM-PBPs (e.g. DacB, DacC and PbpG). 
Briefly, 100µg membrane proteins were incubated with 10 µM Bocillin-FL (Invitrogen, 
Carlsbad, CA) in 1x PBS (pH 7.5) at 37°C for 30 min and then, a proper volume of loading 
sample buffer was added. The samples were left at 100°C for 10 min, centrifuged in Eppendorf 
centrifuge at maximum speed for 5 min and loaded to 8% acrylamide gels in SDS-PAGE 
system and run at 90V. After the run was complete, the gels were being left in fixing solution 
(10% methanol and 7% acetic acid) for 1-2 hours then visualized on a Thyphon 9410 variable-
mode imager (General Electric) at 588 nm, with a 520BP40 emission filter. For the 
determination of the cefoxitin 50% inhibitory concentrations (IC50) for the different PBPs, 
100µg membrane proteins were incubated firstly with serial concentrations from 0 to 1500 
µg/ml of cefoxitin at 37°C for 30 min and then they were incubated with Bocillin-FL at 20 μM 
at 37ºC for 30 min and processed as described above. IC50 was calculated as the cefoxitin 
concentration producing a 50% reduction of Bocillin-FL binding for each individual PBP. In 
this assay a previously described method was used with some modifications (Gonzalez-Leiza et 
al, 2011). 
 
3.5.6 MALDI-TOF 
It is a mass spectrometric analysis-based technique which was used to identify protein bands 
(e.g. AmpC precursor and mature forms) separated by SDS-PAGE. Also, it was used to identify 
unknown muropeptides produced from PG analysis by HPLC. MALDI-TOF was done by the 
unit of proteomics at the Center of Molecular Biology "Severo Ochoa" (CBMSO).  
 
3.5.7 Cell fractionation for protein localization 
Fresh LB cultures of Bl21(DE3), DV900(DE3) and PAO1 strains, harboring inducible 
ampC vector, were induced at OD=0.3 with IPTG for 1-3 h at 37°C with 180 rpm agitation. The 
cells were collected by centrifugation at 5000 rpm for 15 min at 4°C. The cells were re-
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suspended in ice-cold 1x PBS, pH 7.5, and lysed by sonication on ice. A small portion of the 
total sonicate was left on ice, while the other portion was centrifuged at 85000 rpm for 40 min at 
4°C. The cell extract (supernatant) was left on ice. The cell pellet (membranes) was re-
suspended in a proper volume of ice-cold 1x PBS, pH 7.5. Ice-reserved cell fractions were 
checked for AmpC presence by SDS-PAGE, western blot and β-lactamase activity, and then 
stored at -20°C. 
 
3.6 AmpC purification 
Purification of an overproduced cellular protein from other contaminating proteins is 
very important especially for activity characterization and protein X-ray crystallization. 
Purification can be achieved by various chromatographic techniques. In this study, we have 
used Ni2+-affinity chromatography to purify AmpC proteins which have poly-His tag where 
Ni2+-carrying beads trap Poly-His tag-containing AmpC proteins which can be eluted later by 
high concentration of imidazole after removal of the contaminating proteins by washing buffer 
(Wiley & Sons, 1996).       
All AmpC forms were over-produced by IPTG induced pET28b-ampC recombinant 
vectors in Bl21(DE3). For large AmpC production, transformed Bl21(DE3) cells were grown 
with agitation in a 30 L fermenter (Biostat UD30, B. Braun Biotech) in LB medium 
supplemented with 30 μg/ml kanamycin (Kn) at 37°C and induced at OD600 ~ 0.3 with 1 mM 
IPTG for 3 h in case of AmpC-F3 and AmpC-F3-TEV; and induced with 0.1 mM IPTG for 1 h 
in case of AmpC-F2, AmpC-F4, AmpC-F4:C3 and AmpC-F4:C6. After that, cells were 
collected, resuspended in 1x phosphate buffer (43 mM Na2HPO4 and 14 mM KH2PO4, pH 7.5), 
broken within French pressure cell (American Instrument co, Urbana, III) at 20000 psi and 
further centrifuged at 50000 rpm for 30 min at 4°C. Both of supernatant and pellet were either 
stored at -20°C or used in the next step of purification.  
The proteins, AmpC-F3 and AmpC-F3-TEV, were purified from the supernatant 
which passed twice through the Ni-NTA column equilibrated with 1x phosphate buffer (10 mM 
imidazole, pH7.5). Unbound proteins were washed away with 1x phosphate buffer (50 mM 
imidazole, pH7.5). Bound AmpC was then eluted with 250 mM imidazole (Merck, Germany) in 
phosphate buffer, pH 7.5. The Ni-NTA column (QIAGEN GmbH) was regenerated with 500-
1000 mM imidazole, and then it was recharged with NiSO4.6H2O and equilibrated for another 
purification cycle (Wiley & Sons, 1996). The eluted fractions were then dialyzed against 20 
mM Tris HCl, pH 7.5 with three buffer changes (for 2 h each and the third was left overnight) at 
4°C with agitation. Analyzing the purified samples with SDS-PAGE revealed that there was 
three other faint protein bands which were eliminated by passing the previous purification batch 
through Sephadex G-25-80 (Pharmacia Fine Chemicals Co.) column equilibrated with 20 mM 
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Tris HCl (500 mM NaCl, pH7.5). Highly purified fractions were mixed and concentrated using 
Amicon® Ultra Centrifugal Filters (Ultracel®-30K; Millipore Ireland Ltd) on Megafuge 2.0 R 
Heraeus (SEPATECH) at 4° C. The concentrated AmpC-F3 and AmpC-F3-TEV were stored at 
-20°C. The peptide sequence of AmpC-F3 was identified by MALDI-TOF analysis. For 
elimination of His-tag from AmpC-F3-TEV, it was incubated with TEV protease (1 mg enzyme 
for 80 mg protein) with rotation at 4°C. We found that after 1 h the produced AmpC-F3-TEV, 
that had His-tag eliminated, was formed as insoluble precipitate although the precursor AmpC-
F3-TEV (with His-tag) was soluble. The insoluble AmpC-F3-TEV (without His-tag) was 
collected by centrifugation and resuspended in 20 mM tris-HCl, 0.5% Sarkosyl, 100 mM NaCl, 
pH7.5, and then it was dialyzed three times as described above against the buffer 20 mM tris-
HCl, 100 mM NaCl, pH7.5. The purified AmpC-F3-TEV (without His-tag) was tested for 
successful His-tag loss by western blot. Both AmpC-F3 and AmpC-F3-TEV (without His-tag) 
were sent to be crystalized. The proteins AmpC-F3:C3-TEV, AmpC-F3:C6-TEV and AmpC-
F4-TEV were not purified.   
The majority of AmpC-F2, AmpC-F4, AmpC-F4:C3 and AmpC-F4:C6 were found 
insoluble in the membrane pellet fraction. They were extracted by resuspension of the pellet 
fraction in phosphate buffer containing 3 M guanidine HCl (Gn-HCl; Sigma) at pH 7.5 and 
centrifuged at 50000 rpm for 15 min at 4°C. The extract was passed directly through Ni-NTA 
column equilibrated with 1x phosphate buffer (3 M imidazole, pH 7.5). Unbound proteins were 
washed away by 1x phosphate buffer (3 M Gn-HCl, 20 mM imidazole, pH 7.5) while bound 
AmpC was then eluted by 250 mM imidazole (in the equilibration buffer) and dialyzed against 
20 mM Tris HCl, pH 7.5 as mentioned above. We found that all of these AmpC forms re-
precipitated during the first dialysis incubation. So, they were harvested by centrifugation, 
resuspended in 20 mM tris-HCl, 2% Sarkosyl (Sigma), 100 mM NaCl, pH7.5 and dialyzed 
against buffer 20 mM tris-HCl, 0.2% Triton X-100 (Sigma), 100 mM NaCl, pH7.5 or buffer 20 
mM Tris, 300 mM NaCl, 0.15% sarkosyl, pH 7.5. SDS-PAGE and western blot showed that 
AmpC-F2, AmpC-F4, AmpC-F4:C3 and AmpC-F4:C6 were highly purified. After their 
purification, all purified AmpC samples were stored at -20°C. 
Theoretical isoelectric points and molecular masses of purified AmpC forms were 
identified using online ExPASy tools. The purified AmpC proteins were used for 
characterization of their β-lactamase activities on nitrocefin, X-ray crystallography and 
for in vitro reactions with the purified PG and individual muropeptides as described 
later.  
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3.7 Construction of PAO1 mutants  
Our goal is to construct several mutants of LMM-PBPs [dacB (gene PA3047), dacC 
(gene PA3999), pbpG (gene PA0869)] and ampC (gene PA4110) in P. aeruginosa PAO1 strain 
wild type and mutants to pursue their physiological role in PG composition, bacterial resistance 
and ampC regulation in P. aeruginosa. The procedure is based on using cre-lox method (fig. 
3.3) which depends on double recombination between gene-specific inactivation vector and the 
target chromosomal gene (in PAO1). The used gene-specific inactivation vector in this study is 
pEX100Tlink vector which has a cloned DNA fragment (PCR1-lox-aacC1-lox-PCR2) 
containing PCR1 (gene upstream sequence), PCR2 (gene downstream sequence), two lox 
sequences and gentamycin resistance marker (aacC1). Also, pEX100Tlink  vector has 
ampicillin resistance marker and sacB for sucrose sensitivity. After double recombination, the 
next step is to eliminate the gentamycin cassette (aacC1) by cre recombinase (Moya et al, 2009; 
Quenee et al, 2005).   
Previously constructed gene-specific inactivation vectors (pEXTΔampC::Gm and 
pEXTΔdacB::Gm) were used for the generation of dacB and ampC mutants in P. aeruginosa 
PAO1strain (Moya et al, 2009; Moya et al, 2008). These two gene-specific inactivation vectors 
and single mutants of dacB and ampC were used in this study also to construct double and 
multiple mutants in PAO1 strain. In this study we have constructed the gene-specific 
inactivation vectors for pbpG and dacC which were used for the generation of many single and 
combined mutants of LMM-PBPs and ampC (described below).  
 
Construction of gene-specific mutagenesis vectors 
For amplification of  both upstream (PCR1) and downstream (PCR2) regions of the 
gene to be deleted, a 50 µl PCR reaction contained 1.5 mM MgCl2 (sigma), 0.2mM dNTPs 
(Bioline), 1µM forward and reverse primers (Sigma), 10% DMSO (sigma), 2.5 U AmpliTaq 
GoldTM (Roche), 1x Buffer for AmpliTaq and 100ng DNA. For the construction of pbpG and 
dacC gene-specific mutagenesis vectors, both upstream (PCR1) and downstream (PCR2) 
regions of each gene were amplified using the corresponding primers in table 3.3. Then, the 
product, PCR1 was digested with EcoRI (HF, New England Biolabs) and HindIII (HF, New 
England Biolabs), while PCR2 was digested with BamHI (HF, New England Biolabs) and 
HindIII. In the same time pEX100Tlink (with deleted HindIII site) was digested with EcoRI and 
BamHI. The three digestion products were ligated in one reaction using T4 DNA ligase (New 
England Biolabs) to produce pEXTΔpbpG and pEXTΔdacC. The ligation products were used to 
transform E. coli XL1-Blue strain by heat chock. The colonies were selected with 50 µg/ml 
ampicillin LB agar plates and tested by colony PCR. The plasmids, pEXTΔpbpG and 
pEXTΔdacC were digested with HindIII. The lox-flanked gentamicin resistance cassette 
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(aacC1) was extracted from pUCGmlox after digestion with HindIII, using High pure PCR 
product purification kit (Roche). The aacC1 fragment was ligated within the linearized 
pEXTΔpbpG and pEXTΔdacC to produce both pbpG and dacC gene-specific mutagenesis 
vectors which will have the formula: pEXTΔpbpG::Gm and pEXTΔdacC::Gm respectively 
which were used to transform XL1-blue strain. Transformants were selected with 50 µg/ml 
ampicillin and 10 µg/ml gentamicin LB agar plates. The extracted plasmids, pEXTΔpbpG::Gm 
and pEXTΔdacC::Gm were used to transform E. coli S17.1 λ pyr helper strain and selected as 
done previously. The right clones were verified by digestion with restriction enzymes, colony 
PCR (addendum, fig. A.2) and DNA sequencing.  
 
Double recombination and removal of gentamycin cassette 
Knockout mutants were generated by conjugation between PAO strain (receptor) and E. 
coli S17.1 λ harboring gene-specific mutagenesis vector (donor), followed by selection of 
double recombinants using LB plates supplemented with 5% sucrose, 1 μg/ml cefotaxime and 
30 μg/ml gentamicin. Double recombinants were checked by first screening for carbenicillin 
(200 μg/ml) susceptibility and afterwards by PCR amplification and sequencing. For the 
removal of the gentamicin resistance cassettes, plasmid pCM157 was electroporated into the 
different mutants. Transformants were selected in LB plates containing a 250 μg/ml 
tetracycline. One transformant for each mutant was grown overnight in 250 μg/ml tetracycline 
LB broth in order to allow the expression of the cre recombinase. Plasmid pCM157 was then 
cured from the strains by successive passages in LB broth. Selected colonies were then screened 
for their tetracycline (250 μg/ml) and gentamicin (30 μg/ml) susceptibilities and checked by 
PCR amplification and DNA sequencing. Double, triple, and quadruple mutants were then 
generated sequentially following the same procedure (addendum, Fig. A.3→A.7). 
 
 
3.8 Estimation of ampC expression by RT-PCR 
The expression of ampC in P. aeruginosa was determined by RT-PCR for the 
constructed mutants and PAO1 (as a control) following previously described protocols (Juan et 
al, 2006). For the quantification of ampC induction, the strains were incubated in the presence 
of 50 μg/ml of cefoxitin. Briefly, total RNA from logarithmic-phase-grown LB cultures was 
obtained with an RNeasy minikit (Qiagen, Hilden, Germany). 50 ng of purified RNA was then 
used for one-step reverse transcription and real-time PCR using a QuantiTect SYBR green 
reverse transcription-PCR kit (Qiagen) in a SmartCycler II apparatus (Cepheid, Sunnyvale, 
CA). Previously described conditions and primers were used (Juan et al, 2006). The rpsL 
housekeeping gene was used to normalize the expression levels, and results were always 
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referenced against PAO1 basal expression. All RT-PCRs were performed in duplicate, and the 
mean values of mRNA expression resulting from three independent experiments were 
considered in all cases. This assay was done as a cooperative work by  Gabriel Cabot, Irina 
Sánchez-Diener, Bartolome Moya and Antonio Oliver (Servicio de Microbiología and Unidad 
de Investigación, Hospital Universitario Son Espases, Palma de Mallorca, Spain). 
 
3.9 Antimicrobial susceptibility testing 
 
Disk diffusion was used for determination of bacterial resistance to β-lactams in Bl21 
(DE3) and PAO1 mutants transformed with pET-ampC and pUCP-ampC respectively using 
antibiotic disks; cefoxitin (FOX-30 µg), ceftriaxone (CRO-30 µg), imipenem (IMI-10 µg), 
chloramphenicol (C-30 µg), aztreonam (ATM-30 µg), amoxacillin/clavulanic acid (AMC-
20+10 µg), Amikacin (AN-30 µg) and ticarcillin (TIC-75 µg) (BioMerieux® sa, France). 
Inoculum was prepared using growth method and used to inoculate MHA plates as described 
previously (CLSI, 2012b). For determination of antimicrobial susceptibility of the constructed 
PAO1 mutants, MICs of ampicillin, piperacillin, aztreonam, cefotaxime, ceftazidime, cefepime, 
cefoxitin, imipenem, meropenem, and vancomycin were determined by microdilution in 100 μl 
of cation-adjusted Müller-Hinton broth following the Clinical Laboratory Standards Institute 
guidelines (CLSI, 2012a).  
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 Figure 3.3. Outline for gene-knockout inactivation of pbpG and dacC in P. aeruginosa by 
cre-lox method.   
The target gene in red color (e.g. pbpG or dacC) was knocked out and substituted by a DNA 
fragment having PCR1, 2 lox sequences and PCR2 within two steps, firstly the chromosomal 
target gene (pbpG or dacC) in the receptor strain (P. aeruginosa) was exchanged for the 
fragment PCR1-lox-aacC1-lox-PCR2 of the gene-specific mutagenesis vector from the donor 
strain (e.g. S17/pEXTΔpbpG::Gm) by double recombination. The second step is the elimination 
of the gentamycin cassette (aacC1) by cre recombinase. The gene-specific mutagenesis vector is 
a recombinant pEX100Tlink vector having the fragment PCR1-lox-aacC1-lox-PCR2 within the 
multicloning region where PCR1 and PCR2 are the upstream and downstream DNA sequences 
of the target gene. The pEX100Tlink and gene-specific inactivation vectors has genes of sacB 
(sucrose sensitivity) and bla (ampicillin resistance). 
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3.10 Production of imipenem-induced round cells of PAO1 wild type and mutants  
The objective of this experiment is to identify the physiological role of LMMs-PBPs in the 
recovery of rod shape after elimination of imipenem from the culture media. This effect of 
imipenem on P. aeruginosa was reported in a previous study (Monahan et al, 2014).  
Spheroplasts of the wild type PAO1 and all the constructed Pae mutants including the 
quadruple mutant PAOΔdacBΔdacCΔpbpGΔampC were obtained after incubation with 5x 
MICs of IMI in CAMHB media supplemented with 0.5 M sucrose for 4 hours at 37°C without 
agitation. After that round cells were collected at 6000 rpm for 10 min and resuspended in 0.5 
M sucrose supplemented CAMHB medium without imipenem and left for recovery overnight at 
37°C without agitation. Both round and recovered cells were tested for their PG composition by 
HPLC, their morphology by phase-contrast and fluorescence microscopy and their pattern of 
PBPs by Bocillin-FL binding test.     
 
3.11 Confocal microscopic analysis 
Cell preparation for microscopic examination was carried out from overnight cultures of 
PAO1 wild type and mutant strains. They were used to inoculate new LB media and left to grow 
at 37°C and 180 rpm for about 8 hours. The optical density was measured at 600 nm every one 
hour on U-2000 spectrophotometer (HITACHI). Also at different time intervals, the cell 
morphology was tested in vivo (phase-contrast) using equipment of fluorescence resonance 
energy transfer (FRET) comprising Axiovert200 inverted microscope (Zeiss) coupled to a 
monochrome CCD camera. Also, imipenem-induced round cells and their recovered rods of 
PAO1 wild type and mutants were tested by phase-contrast and fluorescence microscopy using 
CYTO 9 dye (green fluorescence staining) following the provider´s instructions (LIVE/DEAD® 
BacLight Bacterial Viability Kit; Molecular Probes, Inc.) where cells stained with CYTO 9 
produce green color and considered to be viable.   
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3.12 Peptidoglycan (PG) manipulation  
 
3.12.1 Preparation of PG  
PG was prepared from E.coli and P. aeruginosa wild type and mutants to be analyzed 
by HPLC in order to study the effect of AmpC activity on PG composition; also, to highlight the 
role of LMM-PBPs (DacB, DacC and PbpG) on PG composition. The used method was adapted 
from a previous study (Gonzalez-Leiza et al, 2011). 
For P. aeruginosa, wild type and the different mutants of PAO1 were cultured in LB 
medium treated with and without 50 µg/ml cefoxitin (FOX) at 37°C and 185 rpm agitation until 
OD600 ̴ 0.75-0.8 was achieved, the cells were collected by centrifugation at 5000 rpm/min at 4°C 
and resuspended in 1x PBS buffer, pH 7.5. One fraction from this cell suspension was left at -
20°C for membrane preparation (see below). The rest of cell suspension was added drop by 
drop to an equal volume of boiling 6% SDS (Merck, Germany) solution with strong stirring. 
The final cell-SDS suspension was left under boiling conditions for 12 hours with stirring.  
For E coli (e.g. Bl21(DE3), DV900(DE3), CS109), overnight culture of one colony was 
1:100 diluted in fresh LB media with specific antibiotic and left growing at 37°C and 185 rpm 
agitation until the exponential phase (OD600 ̴ 0.75-0.8) was achieved, then the cells were 
harvested and added to boiling SDS solution as described above. The cell-SDS suspension was 
left under boiling conditions with stirring for 3-4 hours and overnight at room temperature.   
The cell-SDS suspensions were centrifuged at 60000 rpm for 10 min to collect the 
sacculi from the pellet fraction which was then washed with warm sterile milli-Q water, three or 
more times, until no SDS was detected (no foam appears). Sacculi were suspended in 10 ml of 
10 mM Tris-HCl (pH 7.2) and digested with 100 µg/ml α-amylase (EC 3.2.1.1; Sigma-Aldrich, 
Saint Louis, MO) for 1 h at 37°C and then with 100 µg/ml pre-activated pronase E (EC 
3.4.24.4; Merck, Darmstadt, Germany) at 60°C for 90 min. The enzymes were inactivated by 
boiling for 20 min in 1% (ﬁnal concentration) SDS. PG was collected and washed as described 
above. One part of undigested PG was stored at 4°C for in vitro assays. The other part of PG 
was digested with 100 µg/ml Cellosyl muramidase (Hoechst AG, Frankfurt, Germany) in 50 
mM phosphate buffer (pH 4.9) at 37°C overnight. The enzyme was inactivated by boiling the 
sample for 10 min in a water bath and centrifuged in Eppendorf centrifuge at 14000 rpm for 5 
min to remove insoluble debris. The supernatant was mixed with 1/3 volume of 0.5 M sodium 
borate buffer (pH 9.0) and reduced with excess sodium borohydride (NaBH4) for 30 min at 
room temperature. The pH was tested with pH indicator strips (Acilit, Merck) and adjusted to 
pH 3 with orthophosphoric acid. All samples were filtered (Millex-GV filters; 0.22-µm pore 
size, 2.5-mm diameter; Millipore, Cork, Ireland) or centrifuged at maximum speed for 10 min., 
then stored at -20°C until its injection in the HPLC.  
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3.12.2 HPLC analysis 
Breeze 2 HPLC System (Waters Breeze™ 2 HPLC System, with 1525 Binary HPLC 
Pump) was used. Sodium phosphate buffers (A) pH4.35 with 0.2% sodium azide and sodium 
phosphate buffer (B), pH 4.95 with 15% methanol (Merck, Germany) were used. It was 
modified from previously reported method (Glauner, 1988; Gonzalez-Leiza et al, 2011). During 
the HPLC run of digested PG, some unknown peaks (muropeptides) were collected, lyophilized 
and sent to be identified by MALDI-TOF. Some other well-known muropeptides (e.g. M5, M4, 
D44 and D45) were collected for in vitro reactions. Quantification of muropeptides was 
achieved from their integrated areas in the HPLC chromatogram.  
 
3.12.3 Effect of Pae-AmpC on the whole PG and individual muropeptides in 
vitro 
To confirm if Pae-AmpC has DD-peptidase activity in vitro, the purified AmpC proteins 
(wild type and mutants) were incubated with purified muropeptides or whole peptidoglycan. 
 
In vitro assay using the whole PG 
A 250 μl reaction contained about 160 µg of undigested purified PG with various 
concentrations (indicated in results) of purified AmpC at 37 or 42°C for variable periods (1→24 h) in 
buffer 20 mM tris-HCl, pH7.5, and then boiled for 15 min. After that, muramidase was added to the 
reaction mixture which was incubated at 37°C overnight. Reduction of digested PG was done as 
described before (Section 3.11.1) and then it was subjected to HPLC analysis. 
 
In vitro assay using individual muropeptides 
A 250 μl reaction contained purified AmpC of various concentrations (indicated in results) 
were incubated in buffer 20 mM tris-HCl, pH7.5 with a different amounts (indicated in results) of the 
individual purified muropeptides (e.g. M4, M5, D44 and D45) at 37 or 42°C for variable periods 
(1→24 h), then the reaction was boiled for 2 min, centrifuged at 14000 rpm for 10 min and injected 
into the HPLC or stored at -20°C until being used.   
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4. Results  
 
 
4.1. Functional characterization of Pae-AmpC β-lactamase in some E. coli and 
P. aeruginosa PAO1 strains 
 
4.1.1. Summary 
 
The aim of this chapter is to characterize the activity of AmpC β-lactamase (Pae-AmpC) 
of Pseudomonas aeruginosa PAO1 strain; also to study the effect of ampC expression in 
bacterial resistance and PG composition and to analyze the effect of some uncharacterized 
mutations on the activity of Pae-AmpC and on the profile of bacterial resistance. For that 
purpose we did the next steps: a) cloning of the wild type Pae-ampC [precursor form 
(ampC-F1) and mature form (ampC-F3 and ampC-F3-TEV)] and wild type Pae-AmpC 
having modified signal peptide sequence (ampC-F2, ampC-F4 and ampC-F4-TEV) and 
some mutants of Pae-ampC having single nucleotide mutation [T728→C (e.g. ampC-F4:C3), 
C152→T (e.g. ampC-F4:C6)] in some wild type and mutant strains of E. coli and P. 
aeruginosa PAO1; b) pursuing AmpC activity and expression by SDS-PAGE, western blot, 
β-lactamase activity assay; c) analyzing the change in bacterial resistance after ampC 
expression using disc diffusion assay; d) purification of some AmpC forms by Ni-affinity 
chromatography for functional characterization and X-ray crystallization; and e) pursuing 
the effect of AmpC activity on PG composition of E. coli and P. aeruginosa by HPLC 
analysis of their PG after ampC expression (in vivo assay). Also, AmpC effect on PG was 
analyzed by HPLC after direct reaction of purified Pae-AmpC with both the whole PG and 
individual muropeptides which were purified from the given bacterial strains (in vitro 
assays). Most remarkable data are: 1) we found that ampC-F1, ampC-F1:C3 and ampC-
F1:C6 were not expressed; 2) AmpC-F4 had the highest β-lactamase activity and caused the 
largest increase in bacterial resistance; 3) the two mutants AmpC-F4:C3 and AmpC-F4:C6 
had a very low β-lactamase activity and a little effect on the profile of bacterial resistance; 
4) data obtained from HPLC analysis of PG composition in vivo support the previous 
suggestion that AmpC can have DD-carboxypeptidase or DD-endopeptidase activity (due to 
structural similarities). Also, in vitro assays showed and confirmed that only AmpC-F3 had 
DD-peptidase activity.  
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4.1.2. Pae-ampC cloning 
 
Outline of the cloned Pae-ampC forms  
The cloned forms of Pae-ampC from PAO1 are ampC-F1 (the wild type ampC, 
precursor form); ampC-F2 is an ampC mutant with G4→C single nucleotide mutation which 
corresponds to R2→G amino acid mutation in the signal peptide; ampC-F3 is the mature form of 
Pae-ampC with an insertion of ATG as initiation codon; ampC-F4 is a designed ampC form 
with insertion of two codons (ATG GCC) before the starting codon of wild type ampC sequence 
inserting the two amino acids M1 A2 to the AmpC protein; ampC-F3-TEV and ampC-F4-TEV 
have the same sequence of ampC-F3 and ampC-F4 respectively but with extra sequence at C-
terminal which encodes amino acids (E N L Y F Q G) that constitute the recognition site for 
TEV protease; ampC-F1:C3, ampC-F3:C3-TEV and ampC-F4:C3 have the same sequence of 
ampC-F1, ampC-F3-TEV and ampC-F4, respectively, but with T728→C single nucleotide 
mutation (we called it C3 mutation) which correspond to single amino acid change (P243→L); 
ampC-F1:C6, ampC-F3:C6-TEV and ampC-F4:C6 have the same sequence of ampC-F1, ampC-
F3-TEV and ampC-F4, respectively, but with C152→T single nucleotide mutation (we called it 
C6 mutation) which correspond to single amino acid change I51→T. All these ampC forms have 
a sequence for poly-His tag at C-terminal. Only ampC-F3:C3-TEV, ampC-F3:C6-TEV and 
ampC-F4-TEV have TEV site sequence upstream to the sequence of the C-terminal poly-His tag 
(fig. 4.1; table 4.1). As described above, the nomenclature of each ampC form involves ampC at 
the beginning then F1, F2, F3 and F4 (referring to the Forward primer used in amplification, 
table 3.2); C3 and C6 referring to the mutations T728→C and C152→T which were first observed 
in a previous unpublished study (our laboratory collection), respectively. The nomenclature also 
involved the word TEV referring to the presence of a sequence coding for recognition site of 
TEV protease. In figure 4.1, we have an illustrative diagram for the different forms of Pae-
AmpC proteins that were produced by expression of all the above described ampC constructs. 
All AmpC forms produced were expected to be periplasmic, except AmpC-F2 having a charge 
defect in the signal peptide, and AmpC-F3, AmpC-F3-TEV, AmpC-F3:C3-TEV and AmpC-
F3:C6-TEV that were produced as cytoplasmic forms because they do not have the signal 
peptides. 
 
Cloning of Pae-ampC in pET28b 
All ampC forms ampC-F1, ampC-F2, ampC-F3, ampC-F4, ampC-F1:C3, ampC-F1:C6, 
ampC-F4:C3, ampC-F4:C6, ampC-F3-TEV, ampC-F3:C3-TEV ampC-F3:C6-TEV and ampC-
F4-TEV were successfully cloned in pET28b plasmid producing respectively the recombinant 
vectors pET-F1, pET-F2, pET-F3, pET-F4, pET-F1:C3, pET-F1:C6, pET-F4:C3, pET-F4:C6, 
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pET-F3-TEV, pET-F3:C3-TEV, pET-F3:C6-TEV and pET-F4-TEV (table 3.1). All of these 
clones were transformed in DH5α (for cloning) and Bl21(DE3) [for ampC expression and 
characterization]. Due to their high ampC expression profile and other interesting results 
(described later), only the recombinant vectors pET-F2, pET-F4, pET-F4:C3, pET-F4:C6 and 
pET-F3 were used to transform DV900 for functional characterization of ampC in this strain. 
All clones were confirmed by DNA electrophoresis of their colony PCR (addendum, figure A. 
1) and by DNA sequencing. For simplification we used pET-ampC to refer to all the cloned 
Pae-ampC forms in the vector pET28b unless there is something special to describe for any of 
these constructs.  
 
Cloning of Pae-ampC in pUCP24 
From all previously cloned ampC forms in E. coli, only ampC-F3 and ampC-F4 were 
selected to be cloned in P. aeruginosa because both forms produced relevant results (described 
later) respect to β-lactamase activity, bacterial resistance and effect on PG composition. Both of 
ampC-F3 and ampC-F4 were cloned in pUCP24 vector producing the recombinant vectors 
pUCP-F3 and pUCP-F4 respectively which were transformed into DH5α and some PAO1 
mutant strains and were confirmed by colony PCR and by DNA sequencing.  
The selected PAO1 mutant strains used for cloning of pUCP-F3 and pUCP-F4 are 
PAO∆ampC, PAO∆dacB∆pbpG∆ampC, PAO∆dacB∆dacC∆ampC and PAO∆dacB∆dacC 
∆pbpG∆ampC. These mutants have ampC deletion and some special characteristics concerning 
their PG composition where PAO∆dacB∆dacC∆pbpG∆ampC has a very large amount of penta 
muropeptides resembling PG composition of E. coli DV900 with which ampC-F3 produced 
some DD-peptidase activity (section 4.1.8) and it was interesting to compare this activity with a 
similar PG composition from P. aeruginosa; also, PAO∆dacB∆dacC∆ampC has a considerable 
increase in penta muropeptides but with larger amounts of tetra muropeptides; both of 
PAO∆ampC and PAO∆dacB∆pbpG∆ampC have a normal penta and tetra muropeptides and 
they were selected because ampC complementation in PAO∆ampC would give us the normal 
effect of AmpC activity without interfering with the effect of inactivation of PBPs, also 
PAO∆dacB∆pbpG∆ampC is a special mutant because it lacks the activity of the main DD-
endopeptidases (dacB and pbpG) and it was interesting to pursue the effect of ampC expression 
in this mutant; more detailed information about these mutants is described in section 4.2.   
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Table 4.1. Mutations and changes in the main sequence of the cloned Pae-ampC 
constructs. 
Pae-ampC form/ 
namea 
Nucleotide changeb Amino acid changec 
ampC-F1 - - 
ampC-F1:C3 T728→C mutation P243→L 
ampC-F1:C6 C152→T mutation I51→T  
ampC-F2 G4→C R2→G 
ampC-F3 A1TG insertion as a start codon   M insertion before  A26 
ampC-F3-TEV A1TG insertion as a start codon   M insertion before  A26 
ampC-F3:C3-TEV T728→C mutation P243→L 
ampC-F3:C6-TEV C152→T mutation I51→T 
ampC-F4 A1TG GCC insertion M A insertion before M1 
ampC-F4-TEV A1TG GCC insertion M A insertion before M1  
ampC-F4:C3 T728→C mutation and ATG GCC 
insertion 
P243→L mutation and M 
A insertion before M1  
ampC-F4:C6 C152→T mutation and ATG GCC 
insertion  
I51→T mutation and M A 
insertion before M1 
a  The cloned Pae-ampC forms from PAO1 were named referring to their corresponding 
forward primers (F1→F4), the presence of C3 or C6 mutationsb and the presence of 
recognition site of TEV protease. Nucleotide changesb and its corresponding amino 
acid changesc within different ampC constructs are shown compared to the wild type 
PAO1 ampC where ampC-F1 is the wild type Pae-ampC; ampC-F2 is an ampC mutant 
with G4→C single nucleotide mutation; ampC-F3 is the mature form of ampC with an 
insertion of ATG as initiation codon while ampC-F4 is a designed ampC form with 
insertion of two codons (ATG GCC) before the starting codon of wild type Pae-ampC 
sequence. All ampC constructs that have C3 or C6 in their nomenclature refer to 
mutations that were previously found (laboratory collection) in transformants colonies 
number 3 and 6 with sense single nucleotide mutations, T728→C and C152→T, 
respectively. All ampC constructs were designed to have C-terminal His-tag. More 
information about these constructs is shown in figure 4.1.    
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Figure 4.1. Schematic outline of general structures and amino acid sequences of the 
studied Pae-AmpC forms.  
Main amino acid sequences of AmpC forms are colored in black while amino acid 
changes and extra-amino acids are colored in red. TEV: Cleavage site for TEV 
protease. Nomenclature of AmpC forms was described within table 4.1. AmpC-F1 is the 
wild type Pae-AmpC; AmpC-F2 is AmpC mutant with R2→G point amino acid 
mutation; AmpC-F3 is the mature form of Pae-AmpC with an insertion of amino acid M 
as a peptide initiator in translation; while AmpC-F4 is AmpC form with insertion of two 
amino acids (M A) before M1 of the main amino acid sequence of wild type AmpC. All 
AmpC forms that have C3 or C6 in their nomenclature refer to the presence of point 
amino acid mutation P243→L and I51→T, respectively, compared to the wild type AmpC. 
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4.1.3. Pae-ampC expression 
 
Pae-ampC expression in E. coli Bl21(DE3) and DV900(DE3) 
The recombinant vectors of pET-ampC were used for expression of their encoded ampC 
forms in Bl21(DE3) and DV900(DE3) under IPTG induction. Bl21(DE3)/pET-ampC 
and DV900(DE3)/pET-ampC were used to refer respectively to Bl21(DE3) and DV900(DE3) 
transformed with some pET28b recombinant vectors encoding for various ampC forms which 
were described in table 4.1. For detection of the expressed AmpC form by SDS-PAGE and 
western blot after induction with IPTG, cell fractionation was done as described in section 3.5.7 
and samples from total sonicate, cell extract and cell membrane pellet were loaded to detect and 
to localize AmpC forms in these fractions (fig. 4.2, 4.3, 4.4, 4.5). For overproduction of AmpC 
forms in transformants of Bl21(DE3) (fig. 4.2, 4.3, 4.5) harboring pET-F1, pET-F2, pET-F3, 
pET-F4, pET-F1:C3, pET-F1:C6, pET-F4:C3 and pET-F4:C6 and transformants of 
DV900(DE3) (fig. 4.4) harboring pET-F2, pET-F4, pET-F4:C3 and pET-F4:C6; cells were 
induced with 0.1 mM IPTG in LB media for 1 h at 37°C with agitation. DV900(DE3) 
transformed with pET-F3 was induced with 1 mM IPTG (fig. 4.4) due to low production of 
AmpC-F3 with 0.1 mM IPTG in Bl21(DE3) (fig. 4.3). The production of AmpC-F1, AmpC-
F1:C3 and AmpC-F1:C6 was too low and cannot be detected by SDS-PAGE and western blot 
(fig. 4.2), while, all of AmpC-F2, AmpC-F4, AmpC-F4:C3 and AmpC-F4:C6 were produced in 
a large amount which can be detected by SDS-PAGE and western blot (fig. 4.2, 4.3, 4.4). 
AmpC-F3 was produced in a low amount that can be detected only by western blot (fig. 4.4). 
For transformants of Bl21(DE3) harboring pET-F3, pET-F3-TEV, pET-F3:C3-TEV, pET-
F3:C6-TEV and pET-F4-TEV we found that the best production conditions for AmpC-F3 was 
induction with 1 mM IPTG for three hours; while, AmpC-F3-TEV, AmpC-F3:C3-TEV and 
AmpC-F3:C6-TEV were produced after induction with 2 mM IPTG for 3 h at 37 °C. On the 
other hand, 0.1 mM IPTG was enough to overproduce AmpC-F4-TEV in two hours (fig 4.5). 
Induction with 1 mM IPTG caused overproduction of AmpC-F2, AmpC-F4, AmpC-F4:C3 and 
AmpC-F4:C6 which were too lethal to both of Bl21(DE3) and DV900(DE3) causing a decrease 
in cell growth and some cell lysis. 
Detection of AmpC proteins of cellular fractions of Bl21(DE3)/pET-ampC by SDS-
PAGE and western blot showed that under induction conditions the majority of AmpC-F2 was 
produced as a precursor form and was present in membrane fraction (fig. 4.2); AmpC-F4:C3 
and AmpC-F4:C6 (precursor and mature forms) were found only in the membrane fraction (fig. 
4.3). Most of mature form AmpC-F4 was found in the cell extract while the majority of its 
precursor form was found in the membrane fraction (fig. 4.3). Mature form AmpC-F3 was not 
detected under these conditions (0.1mM IPTG induction for 1 h) but it was found in a low 
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amount in the cell extract after induction with 1 mM IPTG for 1h (fig. 4.3, 4.4, 4.5). No AmpC 
form of the different constructs was found in fractions of non-induced Bl21(DE3) cells. 
Equivalent results were obtained from cellular fractions of DV900(DE3)/pET-ampC with IPTG 
induction (fig. 4.4), with the exception of a considerable soluble amount of the mature and a 
dimeric AmpC forms in all non-induced samples, indicating some escape from the T7 promoter 
on those strains. Another difference with expression on DV900(DE3) transformants is that most 
of the precursor and mature form of AmpC-F4 were found in the membrane fractions of induced 
cells (fig. 4.4).  
Cellular fractions were tested for β-lactamase activity (table 4.2) where fractions of 
Bl21(DE3)/pET-F4 showed the highest activity in fractions of total sonicate and cell extract; 
cellular fractions of Bl21(DE3)/pET-F2 displayed a medium β-lactamase activity; cellular 
fractions of Bl21(DE3)/pET-F3, Bl21(DE3)/pET-F4:C3 and Bl21(DE3)/pET-F4:C6 displayed 
lower β-lactamase activities. Concerning transformants of DV900(DE3), cellular fractions of 
DV900(DE3)/pET-F4 and DV900(DE3)/pET-F2 showed high β-lactamase activities in fractions 
of total sonicate and cell extract; cellular fractions of DV900 (DE3)/pET-F3 displayed a low β-
lactamase activities while cellular fractions of DV900(DE3)/pET-F4:C3 and DV900 
(DE3)/pET-F4:C6 showed very low β-lactamase activities.  
 
Pae-ampC expression in PAO1 
The vectors pUCP-F3 and pUCP-F4 were used for complementation studies in some 
PAO1 mutants (PAO∆dacB∆pbpG∆ampC, PAO∆dacB∆dacC∆ampC, PAO∆dacB∆dacC 
∆pbpG∆ampC and PAO∆ampC) which have ampC deletion. We observed a low production 
of AmpC-F3 and AmpC-F4 from Pae (P. aeruginosa) transformants of pUCP-F3 and pUCP-F4, 
respectively, after induction with 1mM IPTG for 3 hours in LB media at 37 °C with agitation. In 
this case both of AmpC-F3 and AmpC-F4 were detected only by western blot and they were not 
detected by SDS-PAGE; western blots of samples from cellular fractions of total sonicate 
displayed the bands of both of AmpC-F3 and AmpC-F4 in both of induced and non-induced 
fractions with no difference, indicating that IPTG induction did not help in AmpC production 
from pUCP-F3 and pUCP-F4; also, blots shows that there is a basal production of AmpC-F3 
and AmpC-F4 (fig.4.6).  
β-lactamase activity assays of cellular fractions from total sonicate of all above 
described Pae transformants showed that activity of AmpC-F4 was also very high when 
compared with AmpC-F3 in all Pae transformants, as has been shown previously with E. coli 
transformants. The values of β-lactamase activity (table 4.3) were very close in cellular 
fractions with IPTG induction compared with those without induction which are in perfect 
accordance with data obtained from their production in figure 4.6.  
Results 
 
78 | P a g e  
 
Alaa Ropy_Doctoral Thesis 
 
             Bl21(DE3)/pET-ampC 
 
 
                         Total sonicate                           Cell extract                       Cell membrane                                      
 
Figure 4.2. Detection of AmpC-F1, AmpC-F1:C3, AmpC-F1:C6 and AmpC-F2 in 
cellular fractions (total sonicate, cell extract and cell membrane) of Bl21(DE3).   
After 1 h of induction (37 °C) by 0.1mM IPTG of Bl21(DE3) harboring pET-F1, pET-
F1:C3, pET-F1:C6 and pET-F2, cells were collected, sonicated and fractionated 
(section 3.5.7). AmpC forms were then detected in Coomassie-stained 8% SDS-PAGE 
gels (upper panel) and in the corresponding western blot (lower panel). An equivalent 
of 0.2 UOD was loaded from each fraction of both of non-induced (NI) and induced (I) 
cells. AmpC-F1, AmpC-F1:C3 and AmpC-F1:C6 were not detected while AmpC-F2 was 
found mostly in the pellet fraction as a precursor form (P). S: standard protein 
molecular mass markers.  
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Bl21(DE3)/pET-ampC 
 
                        
                      Total sonicate                         Cell extract                Cell membrane 
 
Figure 4.3. Detection of AmpC-F4, AmpC-F4:C3, AmpC-F4:C6 and AmpC-F3 in 
cellular fractions (total sonicate, cell extract and cell membrane) of Bl21(DE3).  
After 1 h of induction (at 37 °C) by 0.1mM IPTG of Bl21 (DE3) harboring pET-F4, pET-
F4:C3, pET-F4:C6 and pET-F3, cells were collected, sonicated and fractionated 
(section 3.5.7). AmpC forms were then detected in Coomassie-stained 8% SDS-PAGE 
gels (upper panel) and in the corresponding western blot (lower panel). An equivalent 
of 0.2 UOD was loaded from each fraction of both of non-induced (NI) and induced (I) 
cells. Mature form of AmpC-F4 was detected mainly in cell extract while its precursor 
form was detected mostly in the membrane fraction; both precursor (P) and mature (M) 
forms of AmpC-F4:C3 and AmpC-F4:C6 were observed mainly in the membrane 
fraction while AmpC-F3 was not detected under these conditions. S: standard protein 
molecular mass markers.  
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   DV900 (DE3)/pET-ampC 
  
                 Total sonicate                      Cell extract                         Cell membrane  
Figure 4.4. Detection of AmpC-F4, AmpC-F4:C3, AmpC-F4:C6, AmpC-F2 and 
AmpC-F3 in cellular fractions (total sonicate, cell extract and cell membrane) of 
DV900 (DE3).   
DV900 (DE3) harboring pET-F4, pET-F4:C3, pET-F4:C6 and pET-F2 were induced by 0.1mM 
IPTG at 37 °C for 1 h and then cells were collected, sonicated and fractionated (section 3.5.7). 
DV900(DE3)/pET-F3 was induced by 1 mM IPTG for 1 h.  AmpC forms were then detected in 
Coomassie-stained 8% SDS-PAGE gels (upper panel) and in the corresponding western blot (lower 
panel). An equivalent of 0.2 UOD was loaded from each fraction of both of non-induced (NI) and 
induced (I) cells. Both of precursor (P) and mature (M) forms of AmpC-F4, AmpC-F4:C3 and 
AmpC-F4:C6 were detected mainly in the membrane fraction while AmpC-F3 mature form was 
detected in the cell extract. D is expected to be a dimeric form of AmpC. S: standard protein 
molecular mass markers. 
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Figure 4.5. Expression of AmpC-F3, AmpC-F3-TEV and AmpC-F4-TEV in Bl21(DE3) transformants. 
 Expression of AmpC-F3, AmpC-F3-TEV and AmpC-F4-TEV in Bl21(DE3)/pET-F3, Bl21(DE3)/pET-F3-TEV and Bl21(DE3)/pET-F4-TEV, 
respectively, was done with different IPTG concentrations and different incubation times (down-up writing) in LB media at 37°C. Different AmpC 
forms were analyzed by western blot in fractions of total sonicate, cell extract and cell membrane pellet. The best expression conditions (bold; 
underlined) were 1mM IPTG/3 h, 2 mM IPTG/3 h and 0.1 mM IPTG/2 h for production of AmpC-F3, AmpC-F3-TEV and AmpC-F4-TEV, 
respectively. The forms ampC-F3:C3-TEV and ampC-F3:C6-TEV were expressed like ampC-F3-TEV with 2 mM IPTG/3 h (fig. not shown for 
simplification). The bands appearing below the AmpC-F3 band may be due to some protein degradations or other protein background. * Purified 
AmpC-F2 and AmpC-F4 were used as controls. P stands for precursor form while M stands for the mature form. 
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Table 4.2. β-lactamase activity of different forms of AmpC expressed in BL21(DE3) 
and DV900(DE3) after IPTG induction. 
 
E. coli 
Strain 
 
Plasmid 
 
IPTG 
mM 
µmole/min/UODa 
Total  
sonicate 
fraction 
  Cell 
extract 
fraction 
Cell 
membrane 
fraction 
 
BL21(DE3) 
pET-F4 0 27.1 25.8 11 
0.1 526.4 329.0 153 
pET-F4:C3 0 1.3 0.7 0.5 
0.1 10.5 3.4 2.5 
pET-F4:C6 0 0.8 0.4 0.3 
0.1 32.1 28.4 5 
pET-F2 0 6.5 5 1.3 
0.1 113.4 36.1 38 
pET-F3 0 1.2 0.8 0.1 
1 28.2 24.4 1 
pET-F1 0 0.8 0.6 0.1 
1 27.5 6.7 1.1 
pET-F1:C3 0 0.7 0.4 0.05 
1 0.9 0.5 0.2 
pET-F1:C6 0 0.9 0.7 0.04 
1 5 2.7 1 
 
DV900(DE3)  
pET-F4 0 9.5 6.3 2.6 
0.1 196 75.4 128.2 
pET-F4:C3 0 0.53 0.32 0.16 
0.1 3.5 1.4 2 
pET-F4:C6 0 0.13 0.12 0 
0.1 2.2 0.74 1.5 
pET-F2 0 63.3 52.8 4.2 
0.1 260.3 86.8 181 
pET-F3 
 
0 1.1 0.9 0 
0.1 26.4 23.8 0 
1 46.9 42 0 
a β-lactamase Activity using nitrocefin as a substrate was detected in cellular fractions (total 
sonicate, cell extract and  cell membrane) and expressed in µmole/min/UOD. Expression of ampC 
forms in BL21(DE3) and DV900(DE3) using pET28b-ampC vectors was done under non-induction 
and induction conditions with 0.1 or 1 mM IPTG for 1 h at 37 °C. UOD stands for Unit of Optical 
Density. 
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Figure 4.6.  Pae-AmpC expression in PAO1 mutants transformed with pUCP-F3 and pUCP-F4. 
Western blot analysis of cellular fractions (total sonicate) of PAO1 mutants (PAO∆dacB∆pbpG∆ampC, PAO∆dacB∆dacC∆ampC, 
PAO∆dacB∆dacC∆pbpG∆ampC and PAO∆ampC) transformed with pUCP-F3 (A) or pUCP-F4 (B) after induction by 1mM IPTG for 
3 h at 37 °C. The vector pUCP-F3 produces AmpC-F3 while pUCP-F3 produces AmpC-F4. * Both of purified AmpC-F3 (A) and 
AmpC-F4 (B) were used as positive controls. No difference was observed for production of AmpC-F3 and AmpC-F4 in non-induced 
(NI) and induced fractions (I). P stands for precursor form while M stands for the mature form.   
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Table 4.3.  β-lactamase activity of some PAO1 mutants transformed with pUCP-F3 
and pUCP-F4.  
 
Strain 
 
Plasmid 
 
IPTG (mM) 
Sp. Act.a 
µmole /min/mg 
PAO∆dacB∆pbpG∆ampC pUCP-F4 0 673.3 
1 555.6 
PAO∆dacB∆dacC∆ampC pUCP-F4 0 686.8 
1 521.8 
PAO∆dacB∆dacC∆pbpG∆ampC pUCP-F4 0 568.5 
1 518.7 
PAO∆ampC pUCP-F4 0 591.5 
1 526.6 
PAO∆dacB∆pbpG∆ampC pUCP-F3 0 27.2 
1 28.2 
PAO∆dacB∆dacC∆ampC pUCP-F3 0 19.1 
1 19.2 
PAO∆dacB∆dacC∆pbpG∆ampC pUCP-F3 0 27.4 
1 26.5 
PAO∆ampC pUCP-F3 0 38.9 
1 40.4 
a β-lactamase specific activities (Sp. Act.) of AmpC-F4 and AmpC-F3 on nitrocefin were 
detected in cellular fractions (total sonicate) and expressed in µmole/min/mg. Production 
of AmpC-F4 and AmpC-F3 forms by pUCP-F4 and pUCP-F3 respectively in different 
transformants of mutants of P. aeruginosa PAO1 was done under non-induction and 
induction conditions with 1 mM IPTG for 3 h at 37 °C. 
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4.1.4. Pae-AmpC purification and characterization  
Purification of AmpC-F4, AmpC-F4:C3, AmpC-F4:C6, AmpC-F2, AmpC-F3 (with His tag) 
and AmpC-F3-TEV (without His-tag; symbol: ΔHis) from transformants of Bl21(DE3) was 
previously described in section 3.6. The final purified batches of AmpC-F4, AmpC-F2, AmpC-
F4:C3 and AmpC-F4:C6 were resuspended in buffer 20 mM Tris-HCl, 0.2% Triton X-100, 100 mM 
NaCl, pH 7.5 or buffer 20 mM Tris-HCl, 300 mM NaCl, 0.15% sarkosyl, pH 7.5. While, AmpC-F3 
(with poly-His tag, symbol: +His) and AmpC-F3-TEV (+His) were solubilized in buffer 20 mM 
Tris HCl (pH 7.5), and AmpC-F3-TEV (ΔHis) in 20 mM Tris-HCl, 100 mM NaCl, pH 7.5. These 
final purification batches were analyzed by SDS-PAGE and western blot, which displayed that all 
of AmpC-F4, AmpC-F4:C3 and AmpC-F4:C6 have two bands where the upper corresponds to the 
precursor form (large amount) and the lower corresponds to the mature form (lower amount); 
AmpC-F2 has mostly one band of the precursor form; AmpC-F3 and AmpC-F3-TEV (+His) have 
one band of the mature form; the band of AmpC-F3-TEV (ΔHis) was not detected by western blot 
which confirmed the elimination of poly-His tag from AmpC-F3-TEV (+His) upon TEV protease 
treatment (fig. 4.7).   
The purified Pae-AmpC forms were characterized by identification of their molecular masses, 
theoretical isoelectrical points, Km and Vmax in vitro assays as described in section 3.5.4. We found 
that the mature form AmpC-F3 had the highest activity (Vmax = 100 µmol/min/mg) on nitrocefin 
while AmpC-F4, AmpC-F2, AmpC-F4:C3 and AmpC-F4:C6 had Vmax values 12.5, 5, 2.5 and 2.5 
µmol/min/mg, respectively. AmpC-F3, AmpC-F4, AmpC-F2, AmpC-F4:C3 and AmpC-F4:C6 
displayed Km values 10, 11.3, 10.5, 13.5 and 16.8 µM, respectively (table 4.4).   
 
4.1.5. Pae-AmpC structure and crystallization 
As shown in figure 4.1, AmpC-F4 (and AmpC-F4-TEV), AmpC-F4:C3 and AmpC-F4:C6 
have the same amino acid sequence of AmpC-F1 (Wild type), AmpC-F1:C3 and AmpC-F1:C6, 
respectively, but with two extra-amino acids (M A) at the N-terminal at the beginning of their 
amino acid sequence. AmpC-F2, AmpC-F1:C3 (also AmpC-F4:C3 and AmpC-F3:C3-TEV) and 
AmpC-F1:C6 (also AmpC-F4:C6 and AmpC-F3:C6-TEV) have single amino acid mutations 
R2→G, P243→L and I51→T respectively. AmpC-F3, AmpC-F3-TEV, AmpC-F3:C3-TEV and 
AmpC-F3:C6-TEV are soluble forms of AmpC without signal peptides. AmpC-F1, AmpC-F1:C3, 
AmpC-F1:C6, AmpC-F4, AmpC-F4-TEV, AmpC-F4:C3, AmpC-F4:C6 and AmpC-F2 are 
periplasmic forms having signal peptide of AmpC which involves the first 26 amino acids up to A26. 
All produced AmpC forms have poly-His tag at their C-terminal which can be eliminated from 
those forms that have TEV site by the activity of TEV protease (fig. 4.1).  All the produced AmpC 
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forms except those having TEV site have extra amino acids (N398 S S S V D K L A A A L E H H 
H H H H416) at their C-terminal which are due to the multiple cloning sites and hexa-His tag from 
pET28b. Also, AmpC forms that have TEV site, have C-terminal extra amino acids (E398 N L Y F 
Q G N S S S V D K L A A A L E H H H H H H423 ) due to the TEV site (underlined), multiple 
cloning sites and hexa-His tag from pET28b; TEV protease cleaves between the two amino acids 
Gln (Q) and Gly (G). These amino acid sequences deduced from the sequenced clones and MALDI-
TOF analysis correlate perfectly with the expression patterns shown above. 
The 3-D structure of AmpC β-lactamase from P. aeruginosa (Smith et al, 2013) was solved 
by X-ray crystallography and is discussed later in section 5.2. Because AmpC-F3 showed a 
secondary DD-peptidase activity (section 4.1.8), both AmpC-F3 forms (with and without His-tag) 
were purified and sent for crystallographic analysis to obtain the 3-D structure but unfortunately it 
has not been achieved any AmpC-F3 crystals by the time of submission of this study.  
 
 
Table 4.4. Characterization of the purified Pae-AmpC forms.   
 
Purified AmpC 
 
Vmax 
 
Km (µM) 
 
M.M. (kDa) 
 
pI   
AmpC-F4 12.5 11.3 45.7 8.3 
AmpC-F4:C3 2.5 13.5 45.7 8.3 
AmpC-F4:C6 2.5 16.8 45.7 8.3 
AmpC-F2 5 10.5 45.4 7.8 
AmpC-F3  100 10 43 7.9 
Vmax is the maximum activity on substrate (nitrocefin) expressed in µmol/min/mg. Km is the 
substrate concentration (nitrocefin) producing half of maximum activity.  Vmax and Km were 
calculated from the β-lactamase activity of different forms of Pae-AmpC on nitrocefin. 
Both of Vmax and Km were calculated as described in section 3.5.4. M.M.: molecular mass; 
pI: theoretical isoelectric point (online ExPASy tools). AmpC-F3 displayed a very high 
activity as shown in bold for its Vmax value. 
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Figure 4.7. Analysis of the purified Pae-AmpC forms by SDS-PAGE and western blot. 
Purified AmpC-F4, AmpC-F4:C3, AmpC-F4:C6, AmpC-F2, AmpC-F3 (with poly-His tag), AmpC-F3-TEV (with poly-His tag; symbol: +His )  and 
AmpC-F3-TEV (without poly-His tag; symbol: ΔHis) were analyzed by SDS-PAGE (A) and western blot (B); where the Purified AmpC-F4, AmpC-
F4:C3 and AmpC-F4:C6 displayed two bands corresponding to precursor (upper band; P) and mature (lower band; M) forms; AmpC-F2 
displayed mostly the precursor form while AmpC-F3 and AmpC-F3-TEV displayed only the mature form. In western blot (B), Band of AmpC-F3 
(ΔHis) disappeared confirming the loss of poly-His tag. The final preparations of  AmpC-F4, AmpC-F2, AmpC-F4:C3 and AmpC-F4:C6 were in 
buffer 20 mM tris-HCl, 0.2% Triton X-100, 100 mM NaCl, pH7.5 while AmpC-F3 (with poly-His tag) and AmpC-F3-TEV (+His) were in buffer  20 
mM Tris HCl, pH 7.5 and AmpC-F3-TEV (ΔHis) was in 20 mM tris-HCl, 100 mM NaCl, pH7.5. S: standard protein molecular mass markers. 
Black arrows (dashed) refer to bands of precursor (P) and mature forms (M) of AmpC forms.  
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4.1.6. Effect of Pae-ampC expression on bacterial resistance 
 
Pae-ampC expression and bacterial resistance in E. coli Bl21(DE3) 
Disk diffusion assay showed that β-lactamase activities of AmpC forms were variable in 
Bl21(DE3)/pET28-ampC using 0.05 mM IPTG-MHA plates. We found that among the tested 
AmpC forms, AmpC-F4 was the most active on nitrocefin in total cell extract assay; but strain 
Bl21(DE3)/pET-F4 showed resistance to amoxacillin/clavulanic acid (AMC) and decreased 
susceptibilities to cefoxitin (FOX), ceftriaxone (CRO), imipenem (IMI) and ticarcillin (TIC). 
Bl21(DE3)/pET-F2 showed resistance to AMC and also decreased susceptibilities to cefoxitin 
(FOX), ceftriaxone (CRO), aztreonam (ATM) and ticarcillin (TIC), while AmpC-F4:C3 and F4:C6 
showed very low β-lactamase activities as they only decreased susceptibility to AMC in strains 
Bl21(DE3)/pET-F4:C3 and Bl21(DE3)/pET-F4:C6. AmpC-F3 did not change the resistance 
susceptibilities to the used β-lactams even AMC (table 4.5). Also, we found that some clear 
inhibition zones (Symbol: CZ) were surrounded by a partial growth zone (Symbol: PZ) or had some 
resistant colonies (symbol: CR) growing inside it (table 4.5, 4.6). 
 
Pae-ampC expression and bacterial resistance in some Pae mutants  
Complementation of ampC deletion was studied by disk diffusion assay in some Pae 
mutants, PAO∆ampC, PAO∆dacB∆pbpG∆ampC, PAO∆dacB∆dacC∆ampC and 
PAO∆dacB∆dacC∆pbpG∆ampC (table 4.6). MHA plates were used without IPTG additions for 
disk diffusion because data of AmpC production from Pae transformants of pUCP24-F3 and 
pUCP24-F4 showed that there was no big difference in the levels of AmpC using IPTG induction 
conditions and normal basal conditions (fig. 4.6). In this assay, the same Pae mutants transformed 
with pUCP24 were used as a negative control for β-lactamase level. Basal level of AmpC-F4 
expressed by pUCP-F4 showed resistance to AMC, CRO and TIC, and decreased susceptibilities to 
ATM and IMI in all tested mutants. In the other hand, basal level of AmpC-F3 showed little change 
and deceased susceptibilities to AMC in all Pae mutants, and only to CRO and TIC in the four 
deletions Pae mutant (table 4.6). 
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Table 4.5. Disc diffusion assay for Pae-AmpC expression in Bl21(DE3)/pET-ampC. 
BL21 (DE3)/ 
pET-ampC b 
   
IPTG (mM)c 
Diameter of inhibition zone (mm)a  
AMC ATM IMI C FOX CRO TIC AN 
 
pET-F4 
0 17 34 27 33 22 28 27 26 
0.05 0 34 24 35 18 20 25 27 
 
pET-F4:C3 
0 22 32 31 38 23 33 30 28 
0.05 14(CZ), 
27(PZ) 
33 31 38 23 30 29 28 
 
pET-F4:C6 
0 24 38 31 34 28 36 31 28 
0.05 18(CZ), 
23(PZ) 
38 31 34 28 36  31 28 
 
pET-F2 
0 14 33 26 32 24 28 29 26 
0.05 0 (CZ),  
19(PZ) 
31(CZ), 
38(PZ) 
28 34 17(CZ), 
22(PZ) 
18(CZ), 
27(PZ) 
18(CZ), 
29(PZ) 
28 
 
pET-F3 
0 24 35 30 33 25 32 29 26 
0.05 23 38 30 35 25 32 33 29 
aAmoxacillin/clavulanic acid (AMC), aztreonam (ATM), imipenem (IMI), chloramphenicol (C), cefoxitin (FOX), ceftriaxone (CRO), 
ticarcillin (TIC) and amikacin (AN). CZ: clear inhibition zone; PZ: partial growth zone occurred around the clear inhibition zone; all 
values that are not marked by CZ or PZ are considered CZ. b E. coli Bl21(DE3) harboring pET-F4, pET-F2, pET-F3, pET-F4:C3 and 
pET-F4:C6 produce AmpC-F4, AmpC-F2, AmpC-F3, AmpC-F4:C3 and AmpC-F4:C6, respectively. c The assay was done using MHA 
plates without IPTG (non-induction conditions; values shown in bold) and with 0.05 mM IPTG (induction conditions) for 16 hours.  
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Table 4.6. Disc diffusion assay for complementation of ampC deletion in some PAO1 mutants.  
 
Transformant Pae Strainb 
Diameter of inhibition zone (mm)a 
FOX AMC ATM CRO TIC IMI 
CZ PZ CZ PZ CZ CZ PZ CZ PZ CZ 
PAO∆ampC/ pUCP24* 0  10 21 23 22 17 24 12 18 36 
PAO∆ampC/ pUCP24-F4 0 - 0 - 15 0 - 0 - 26 
PAO∆ampC/ pUCP24-F3 0 - 17 CR - 26 21 CR - 2 - 37 
PAO∆dacB∆pbpG∆ampC/ pUCP24*  0 12 22 26 25 19 26 19 29 36 
PAO∆dacB∆pbpG∆ampC/ pUCP24-F4 0 - 0 - 13 0 - 0 - 25 
PAO∆dacB∆pbpG∆ampC/ pUCP24-F3 0 - 17 CR - 26 1.8 CR - 17 CR - 36 
PAO∆dacB∆dacC∆ampC/ pUCP24* 0 10 22 - 27 22 - 20 - 37 
PAO∆dacB∆dacC∆ampC/ pUCP24-F4 0 - 0 - 18 0 - 0 - 28 
PAO∆dacB∆dacC∆ampC/ pUCP24-F3 0 - 18 CR - 27 20 - 21 - 38 
PAO∆dacB∆dacC∆pbpG∆ampC/ pUCP24* 0 10 20 23 25 22 - 20 - 36 
PAO∆dacB∆dacC∆pbpG∆ampC/ pUCP24-F4 0 - 0 - 14 0 - 0 - 22 
PAO∆dacB∆dacC∆pbpG∆ampC/ pUCP24-F3 0 - 15 CR - 24 10 - 14 23 35 
a Cefoxitin (FOX), ceftriaxone (CRO), imipenem (IMI), aztreonam (ATM), amoxacillin/clavulanic acid (AMC), and ticarcillin (TIC). 
CZ: clear inhibition zone; PZ: partial growth zone occurred around the clear inhibition zone; CR: resistant colonies appeared in the 
clear inhibition zone. The assay was done using MHA plates without IPTG for 16 hours. b Transformants of pUCP-F3 and pUCP-F4 
produce AmpC-F3 and AmpC-F4, respectively. * Pae mutants transformed with pUCP24 vector used as a negative control for AmpC 
production whose data are shown in bold values.    
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4.1.7. Effect of Pae-ampC expression on PG composition (in vivo) 
 
 HPLC analysis of muropeptides and PG structure 
HPLC analysis of muropeptides prepared by digestion of PG described in section 3.12 is 
important information because it gives us an image about PG structure and its main constituents 
(muropeptides) as shown in figure 4.8. Muropeptides can be classified according to their structures 
into monomers (e.g. M2, M3, M4 and M5), Dimers (e.g. D43, D44 and D45), Trimers (e.g. T443, 
T444 and T445), anhydro-muropeptides (e.g. M4N, D44N and T44N), lipo-muropeptides, having a 
link to Braun’s lipoprotein (e.g. M3L), and Dap-Dap (D-D) muropeptides, having a LD type 
crosslink between the Dap of adjacent glycan chains (e.g. D34D). Chromatograms of HPLC 
analysis of PG from the wild type E. coli Bl21(DE3) showed that PG is composed mainly of 
monomers muropeptides (M3, M4G, M4, M2, M5, M3L), dimers muropeptides (D33D, D34D, 
D43, D44, D45), trimers muropeptides (T443, T444), and anhydromuropeptides (D44N and 
T444N); while PG of E. coli DV900(DE3) is composed of monomers muropeptides (M3, M4, 
M5G, M2, M5, M3L), dimers muropeptides (D34D, D43, D44, D45G, D45), trimers muropeptides 
(T443, T445), and anhydromuropeptides (D45N and T445N). Muropeptides M4N, M5N, D43N, 
D44N, D45N, T443N, T444N, T445N have the same structures of M4, M5, D43, D44, D45, T443, 
T444, T445, respectively, but with anhydro-N-acetylmuramic acid instead of N-acetylmuramic acid 
(fig. 4.8). PG analysis of the wild type E. coli CS109 and the wild type P. aeruginosa PAO1 
displayed a similar HPLC chromatograms like the wild type E. coli Bl21(DE3) while the 
constructed PAO1 mutants PAOΔdacBΔdacCΔpbpG and PAOΔdacBΔdacCΔpbpGΔampC 
displayed a similar HPLC chromatograms like E. coli mutant DV900(DE3) (not shown). 
 
Pae-ampC expression and PG composition in E. coli Bl21(DE3) and 
DV900(DE3) in vivo  
E. coli Bl21(DE3) and DV900(DE3) transformants of pET-F4, pET-F4:C3, pET-F4:C6, 
pET-F2 and pET-F3 were grown in LB media +/- IPTG at 37°C with agitation; then PG was 
prepared at the exponential phase and analyzed by HPLC. No big differences were found in all 
transformants under no-induction, indicating no major effect of the presence of the different 
plasmids in any of the two reference strains. In Bl21(DE3)/pET-F4, Bl21(DE3)/pET-F4:C3 and 
Bl21(DE3)/pET-F4:C6, we found that under IPTG induction conditions, PG analysis of 
transformants showed that there was an increase in monomers, anhydro-muropeptides and 
pentapeptides and a decrease dimers and trimers beside low crosslinking degree and lower cell 
length, but actually small changes in Bl21(DE3)/pET-F2 and Bl21(DE3)/pET-F3 (table 4.7).  
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As modifications in PG reflect a global structural change, these data may indicate, not a 
direct and specific activity of the produced proteins on the metabolism of PG, but most probably an 
effect of the overproduction, or IPTG induction itself. PG analysis of IPTG-induced 
DV900(DE3)/pET-F4, DV900(DE3)/pET-F4:C3 and DV900(DE3)/pET-F4:C6 transformants 
displayed only small increases in anhydro-muropeptides and crosslinking, and also small decrease 
in cell length, while no significant change on pentapeptides was encountered (table 4.8). And, again 
no differences were found in DV900(DE3)/pET-F2 or DV900(DE3)/pET-F3 under induction 
conditions. These changes do not suggest any enzymatic activity for Pae-AmpC on PG of this 
heterologous strain. 
 
Pae-ampC expression and PG composition in PAO1 in vivo 
Transformants of PAO∆ampC, PAO∆dacB∆dacC ∆ampC, PAO∆dacB∆pbpG∆ampC and 
PAO∆dacB∆dacC∆pbpG∆ampC harboring pUCP24, pUCP-F3 and pUCP-F4 were grown in LB 
media without IPTG addition at 37°C with agitation where pUCP24 transformants were used as a 
negative control for AmpC production, while transformants of pUCP-F3 and pUCP-F4 were used 
for expression of ampC-F3 and ampC-F4, respectively. For the control strains (plasmid pUCP24), 
there was no changes in PG structure, is spite of those changes already seen in the PG of the 
parental mutants strains. HPLC analysis of PG of these transformants shows that there was some 
increase in crosslinking and anhydro-muropeptides and a slight decrease in cell length compared 
with the control strains (table 4.9). Also, these data indicate no major effect of Pae-AmpC-F3 and 
Pae-AmpC-F4 on the whole PG structure of Pae, in spite of the large β-lactamase activity displayed 
by Pae-AmpC-F4 (table 4.3) on these strains, and the low expression level of these proteins (fig. 
4.6). 
 
4.1.8. Effect of the purified Pae-AmpC forms on PG composition and 
individual muropeptides (in vitro) 
 
Effect of Pae-AmpC on whole PG composition (in vitro) 
In vitro activity of purified AmpC forms on PG of E. coli CS109 and DV900 was followed. 
We found that incubation of (0.4-2 µg/µl) AmpC-F4, AmpC-2, AmpC-F3, AmpC-F4:C3 and 
AmpC-F4:C6 with the whole PG of each of CS109 and DV900 at 37°C for up to 24 hours (as 
described in section 3.12.3) produced no significant structural change while extending incubation 
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(42 h) time at 37°C produced some interesting changes in PG composition especially with AmpC-
F3; indicating that AmpC may has a secondary DD-peptidase activity (table 4.10a).  
 In case of incubation with PG of the wild type E. coli CS109 for 42 hours there was a 
decrease in anhydro-muropeptides, correlated with the decrease in crosslinking and produced an 
increase in monomers and a decrease in dimers and trimers only with AmpC-F3(b) (three month old 
purified sample) (table 4.10a). Moreover, analysis of individual muropeptides revealed there were a 
decrease in D44 and an increase in M4 beside the decrease in the crosslinking degree which 
indicates that there was some DD-EPase activity (table 4.10a).   
 In case of incubation of different AmpC forms with PG of DV900 for 42 hours, there was 
also an increase in monomers and decrease in dimers and trimers only with AmpC-F3 (table 4.10a). 
Again, analysis of individual muropeptides after treatment with AmpC-F3 of PG of DV900 shows a 
large increase in M4 and D44 and a decrease in M5, D45, T445, D45N and T445N (table 4.10b). 
This indicates that AmpC-F3 acted as DD-CPase and DD-EPase on the whole PG of E. coli DV900. 
The fact that in the old preparation of AmpC-F3 the decrease of M5 is higher and the decrease of 
D45 is smaller, and the increase of M4 and D44 are smaller, compared with the fresh preparation of 
AmpC-F3, indicates that freezing may favor the DD-EPase activity of the sample. 
 
Effect of Pae-AmpC on individual purified muropeptides (in vitro)  
Trying to reinforce or confirm data on isolated whole PG in vitro described in the previous 
paragraph, we performed analysis with individual purified muropeptides. The reaction involved 
incubation of (0.4-2 µg/µl) AmpC-F4, AmpC-2, AmpC-F3, AmpC-F4:C3 and AmpC-F4:C6 with 
each of the individual purified muropeptides (M4, M5, D44 and D45) within different conditions 
[temperature (37 and 42°C) and +/- 50 mM NaCl addition, various AmpC concentrations] and was 
continued as described in section 3.12.3. The results showed that a concentration of up to 2 µg/µl of 
AmpC-F4, AmpC-F2, AmpC-F4:C3 and AmpC-F4:C6 had no activity on the muropeptides; while 
0.4 µg/µl AmpC-F3 (b) [three-month old purified AmpC-F3] displayed DD-EPase activity on D44 
(5 ng/μl) and D45 (10 ng/μl) at 42°C for 24 hours however there was no activity on M4 (4ng/μl) 
and M5 (16 ng/μl), (fig. 4.9 and 4.10). Newly purified AmpC-F3(a) (fig. 4.10) was less active than 
the three-month old purified AmpC-F3(b) which also showed some protein degradation (fig. 4.9). 
These data confirm the DD-EPase activity of AmpC-F3 on isolated muropeptides, but it was not 
detected DD-CPase activity on the purified monomers muropeptide. As this last activity was clearly 
seen on whole isolated PG of DV900, it may indicate that particular conformations of the 
muropeptides on the whole structure are required for bringing out that activity.  
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Figure 4.8. Muropeptides structures and chromatograms of HPLC analysis of PG of E. coli Bl21(DE3) and DV900(DE3). 
* Chromatograms of HPLC analysis (lower panel) of PG from E. coli Bl21(DE3) showed that PG is composed of muropeptides M3, M4G, M4, 
M2, M5, M3L, D34D, D43, D44, D45, T443, T444, D44N and T444N while PG of E. coli DV900(DE3)  is composed of muropeptides M3, M4, 
M5G, M2, M5, M3L, D34D, D43, D44, D45G, D45, T445, D45N and T445N. ** In the upper panel, there are chemical structures of common 
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muropeptides in PG of E. coli and P. aeruginosa; where, G: N-acetylglucosamine; M: N-acetylmuramic Acid; M2: disaccharide dipeptide M3: 
disaccharide tripeptide; M4: disaccharide tetrapeptide; M4G: disaccharide tetrapeptide with Gly at position number 4 (not shown);   M5: 
disaccharide pentapeptide where L-Ala, D-Glu, Dap, D-Ala and D-Ala occupy positions of numbers 1, 2, 3, 4 and 5, respectively, also L-Ala is 
linked to N-acetylmuramic acid ; M5G: disaccharide pentapeptide with Gly at position number 5 (not shown);  M3L: disaccharide tripeptide 
bound to Braun’s lipoprotein (not shown); D44: crosslinked-dimer of disaccharide tetrapeptide-disaccharide tetrapeptide; D34D: Dap-Dap 
crosslinked-dimer of disaccharide tripeptide-disaccharide tetrapeptide; D43: crosslinked-dimer of disaccharide tetrapeptide-disaccharide 
tripeptide; D45: cross-linked-dimer of disaccharide tetrapeptide-disaccharide pentapeptide; T443: crosslinked-trimer of disaccharide 
tetrapeptide-disaccharide tetrapeptide-disaccharide tripeptide; T444: crosslinked-trimer of disaccharide tetrapeptide-disaccharide tetrapeptide- 
disaccharide tetrapeptide; T445: crosslinked-trimer of disaccharide tetrapeptide-disaccharide tetrapeptide-disaccharide pentapeptide; anhydro-
muropeptides M4N, M5N, D43N, D44N, D45N, T443N, T444N, T445N have the same structures of muropeptides M4, M5, D43, D44, D45, 
T443, T444, T445, respectively, but with anhydro-N-acetylmuramic acid instead of N-acetylmuramic Acid (not shown for simplification).          
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Table 4.7. HPLC analysis of muropeptides prepared from PG of induced E. coli Bl21 (DE3)/pET-ampC. 
 
BL21(DE3)/pET-ampCb 
 
IPTG 
Muropeptides (% Molar)a    
Mono Di Tri D-D Lpp Anhy Penta  Crosslink D-D/T Length 
pET-F4 0 64.62 33.16 2.22 5.63 12.43 1.94 0.51 37.6 14.96 51.55 
0.1 73.72 25.8 0.48 7.01 18.22 5.25 8.3 26.76 26.18 19.06 
pET-F4:C3 
 
0 66.22 31.69 2.09 5.07 11.96 2.13 0.76 35.86 14.15 46.88 
0.1 71.32 27.99 0.69 9.71 15.39 5.71 6.31 29.37 33.07 17.3 
pET-F4:C6 0 66.07 32.76 1.17 8.69 6.83 2.16 0.75 35.1 24.75 46.75 
0.1 83.53 15.75 0.71 3.23 24.87 5.88 3.57 17.18 18.79 17.02 
pET-F2 0 61.93 35.61 2.46 8.91 12.7 3.38 0.92 40.52 21.98 29.62 
0.1 62.05 36.19 1.76 8.13 8.75 4.6 1.6 39.71 20.46 21.74 
pET-F3  0 63.37 33.79 2.85 5.9 9.16 3.08 0.92 39.48 14.93 32.46 
1 61 36.32 2.68 7.83 6.95 3.5 1.31 41.68 18.78 28.78 
a Relative abundance in % molar of different types of muropeptides; Mono: monomeric muropeptides (e.g. M4, M5); Di: dimeric muropeptides 
(e.g. D43, D44, D45); Tri: trimeric muropeptides (e.g. T444 and T445); Lpp: Muropeptides bound to Braun’s Lipoproteins (e.g. M3L); Anhy: 
anhydromuropeptides (e.g. D44N, T444N); Crosslink: degree of crosslinking in percentage; D-D: total muropeptides that have Dap-Dap cross-
linking (e.g. D34D); D-D/T: ratio of Dap-Dap crosslinking to the total crosslinking. length: measurement for PG length. PG was prepared as 
described in section 3.12. b E. coli Bl21(DE3) transformed with pET-F4, pET-F4:C3, pET-F4:C6, pET-F2 and pET-F3 which were induced with 
0.1 or 1 mM IPTG as indicated in the table. Relevant changes in PG composition are shown in bold.  
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Table 4.8. HPLC analysis of muropeptides prepared from PG of induced E. coli DV900 (DE3)/pET-ampC.  
 
DV900(DE3)/pET-ampCb 
 
IPTG (mM) 
Muropeptides (% Molar)a    
Mono Di Tri D-D Lipo Anhy Penta crosslink D-D/T Length 
pET-F4 0 59.6 35.2 2.7 1.1 1.2 5.1 71 40.7 2.6 19.6 
0.1 57 37.4 3.3 1.3 1.5 8.2 71 44.1 2.9 12.2 
pET-F4:C3  0 63.5 32.8 2.1 0.9 1 4.1 75.7 36.9 2.3 24.3 
0.1 60.4 36.6 1.2 0.9 0.8 7.1 76.4 39 2.3 14 
pET-F4:C6 0 67.8 28.7 1.9 0.7 1.6 3.9 76.7 32.4 2.2 25.9 
0.1 64.6 32 1.9 0.7 1.5 7.9 77 35.8 1.9 12.7 
pET-F2 0 58.8 36.2 2.8 1.2 3.3 5.5 69.1 41.7 2.9 18.3 
0.1 58.1 37.4 2.5 1.1 2.1 6.9 73.7 42.4 2.5 14.5 
pET-F3 0 60.6 35.4 2 0.7 1 4.8 76.2 39.5 1.7 20.7 
1 59.3 36.5 2 1 0.6 4.6 81.1 40.6 2.4 21.9 
a As described previously within table 4.7. Induced (0.1 or 1 mM IPTG) and non-induced cells were collected. b DV900(DE3) transformed with 
pET-F4, pET-F4:C3, pET-F4:C6, pET-F2 and pET-F3.   
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Table 4.9. HPLC analysis of muropeptides prepared from PG of PAO1/pUCP24-ampC.  
 
PAO1 Mutantb 
Harboring 
Plasmid 
Muropeptides (% Molar)a    
Mono Di Tri D-D Lpp Anhy Penta Crosslink D-D/T Length 
PAO∆ampC pUCP24 62.6 34.2 3.2 1.4 1.4 9.6 2.6 40.6 3.5 10.4 
PAO∆ampC pUCP24-F4 59.8 36.4 3.7 1.6 1.3 11 2.1 43.9 3.6 9.1 
PAO∆ampC pUCP24-F3 57.4 38.3 4.3 2.2 1.9 11.7 2 46.8 4.6 8.5 
PAO∆dacB∆dacC ∆ampC pUCP24 58.8 36.3 4.9 2.2 3.6 12.4 31 46.1 4.7 8.1 
PAO∆dacB∆dacC ∆ampC pUCP24-F4 57.8 38 4.2 1.3 1.8 11.8 28.9 46.4 2.9 8.5 
PAO∆dacB∆dacC ∆ampC pUCP24-F3 56.8 38.5 4.8 1.5 2.6 12.4 34 48 3.1 8.1 
PAO∆dacB∆ pbpG ∆ampC pUCP24 54.5 39.9 5.6 2.3 3.6 11.8 5.4 51.2 4.5 8.5 
PAO∆dacB∆ pbpG ∆ampC pUCP24-F4 49.7 43.2 7.1 2.4 3.1 13.5 3.5 57.4 4.1 7.4 
PAO∆dacB∆ pbpG ∆ampC pUCP24-F3 48.5 44 7.4 2.6 3.6 13.6 3.6 58.9 4.5 7.4 
PAO∆dacB∆dacC pbpG ∆ampC pUCP24 54.2 40.2 5.6 0.8 1.9 9.9 66.9 51.5 1.5 10.1 
PAO∆dacB∆dacC pbpG ∆ampC pUCP24-F4 51.4 42.2 6.5 0.8 2.2 11.5 69.1 55.1 1.4 8.7 
PAO∆dacB∆dacC pbpG ∆ampC pUCP24-F3 52.1 41.7 6.2 1 2.2 10.3 68.6 54.1 1.8 9.7 
a As described previously within table 4.7. b Different PAO1 mutants transformed with pUCP24, pUCP-F4 and pUCP-F3 vectors where 
transformants of pUCP24 vector were used as a control negative for AmpC production.  The vectors pUCP-F3 and pUCP-F4 encode ampC-F3 
and ampC-F4, respectively. 
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Table 4.10a. HPLC PG analysis of E. coli DV900 and CS109 after incubation with different forms of Pae-AmpC in vitro. 
 Reaction with 
CS109 PGb 
 
T (°C) 
 
Time (h) 
Muropeptides (% Molar)a  
crosslink 
 
D-D/T 
 
Length Mono Di Tri Gly D-D Lpp Anhy Penta M4* D44* 
DV900-CTRL 37 42 60 35.9 4.1 5.3 0.9 1.5 4 85 3.3 4 44.1 1.9 25.11 
AmpC-F4 37 42 59.5 36.2 4.3 5.6 0.9 0.9 4.1 85 3.4 4.1 44.8 2.1 24.5 
AmpC-F4:C3 37 42 60 36 4.1 5.6 0.9 0.7 3.9 85.3 3.5 3.9 44.1 2 25.9 
AmpC-F4:C6 37 42 60.4 35.8 3.8 5.5 0.9 1.1 3.7 85.2 3.4 3.8 43.4 2 26.9 
AmpC-F2 37 42 59.5 36.6 4 5.6 0.6 0.7 3.8 86.4 3 4.3 44.5 1.5 26.5 
AmpC-F3(a) 37 42 61.7 35.3 3.1 5.2 0.7 1.3 2.8 67.8 13.5 5.3 41.4 1.8 35.3 
AmpC-F3(b) 37 42 68.6 28.8 2.5 5 0.8 1 1.3 67.1 15.4 5.9 33.9 2.4 74.2 
CS109-CTRL 37 42 60.3 37 2.7 7.7 4.4 16.6 5.5 0 22.1 18.5 42.4 10.3 18.3 
AmpC-F3(a) 37 42 61.1 36.5 2.4 6.3 4.3 15.8 5.3 0 23.2 18.9 41.4 10.5 18.7 
AmpC-F3(b) 37 42 71 27.9 1.1 6.9 3.5 14.9 3.1 0 31 15.5 30.1 11.6 32.7 
a As described previously within table 4.7. b In vitro reactions (250 μl)  contained AmpC-F4 (2 μg/μl), AmpC-F2 (2 μg /μl), AmpC-F4:C3 (2 μg 
/μl), AmpC-F4:C6 (2 μg /μl) or AmpC-F3 (0.4 μg /μl) with whole PG of  and E. coli DV900 and E. coli CS109 (italic writing, the last three rows) 
were left at 37°C for 42 h, and then were manipulated as described in section 3.12.3; where DV900-CTRL: control negative without AmpC 
treatment; CS109-CTRL: negative control without AmpC addition; AmpC-F3(a) is a newly purified AmpC-F3 while AmpC-F3(b) is  a purified 
AmpC-F3 stored for 3 months (or more) at -20 °C. *selected muropeptides (M4 and D44) were included due to some relevant changes. 
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Table 4.10b. Selected muropeptides from HPLC analysis of PG of DV900 after incubation with different forms of Pae-AmpC in vitro. 
Reaction with 
DV900 PGb 
 
T (°C) 
 
Time (h) 
Selected Muropeptides (% Molar)a 
M4* M5 D44* D45 T445 D45N T445N 
DV900-CTRL 37 42 3.3 29.7 4 32.3 3.7 3.4 1.6 
AmpC-F4 37 42 3.4 28.8 4.1 31.8 3.7 3.4 1.7 
AmpC-F4:C3 37 42 3.5 29.1 3.9 31.9 3.5 3.3 1.5 
AmpC-F4:C6 37 42 3.4 28.8 3.8 31.7 3.3 3.1 1.5 
AmpC-F2 37 42 3 30.5 4.3 33.6 3.5 3.3 1.6 
AmpC-F3 (a) 37 42 13.5 20.4 5.3 31.2 2.9 2.6 0.8 
AmpC-F3 (b) 37 42 15.4 25.6 5.9 27.4 2.5 1.3 0.4 
a Relative abundance in % molar of some selected muropeptides (M4, M5, D44, D45, T445, D45N and T445N) due to the presence of some 
interesting changes in their occurrence in PG of DV900 upon AmpC treatment in vitro. b The same reactions described in table 4.10a. *Data are 
mentioned before in table 4.10a and was repeated in this table to be compared with the other muropeptides. 
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Figure 4.9. Effect of AmpC-F3(b) activity on individual muropeptides M4, M5, D44 and 
D45 at 37 and 42°C (in vitro). In vitro reactions (250 μl) contained AmpC-F3(b) (0.4 μg /μl) 
with each of individual muropeptides M4 (4ng/ μl), M5 (16 ng/ μl), D44 (5 ng/ μl) and D45 (10 
ng/ μl) were left at 37 or 42°C for 24 h, and then were manipulated as described in section 
3.12.3. * AmpC-F3(b) is  a purified AmpC-F3 stored for 3 months (or more) at -20 °C, which 
showed by HPLC analysis some protein degradations. a Reaction conditions were described 
over each data series where the ones that displayed considerable changes were shown on bold 
letters; where 42°C for 24 h was the best conditions for yielding some DD-endopeptidase 
activities on D44 and D45. Some other reactions contained individual muropeptides without 
any AmpC additions to be a negative control for DD-peptidase activities.  
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Figure 4.10. Effect of AmpC-F3(a) activity on individual muropeptides M4, M5, 
D44 and D45 at 42°C (in vitro).  
* In vitro reactions of 250 μl, contained freshly prepared AmpC-F3(a) (0.8 or 1.6 μg/μl) 
with each of individual muropeptides D44 (2 ng/ μl) and D45 (4 ng/ μl) were left at 
42°C for 24 h, and then were manipulated as described in section 3.12.3. ** AmpC-
F3(a) is a freshly purified AmpC-F3 which showed less DD-endopeptidase activity than 
AmpC-F3(b) on D44 and D45 at 42°C for 24 h. AmpC-F3(a) displayed no activity on 
M4 and M5 (not shown).  
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4.2. Role of LMM-PBPs in ampC regulation, β-lactam resistance and 
peptidoglycan structure in P. aeruginosa 
 
4.2.1. Summary 
The aim of this chapter is to highlight the role of the LMM-PBPs PBPs [DacB (PBP4), 
DacC (PBP5) and PbpG (PBP7)] in peptidoglycan structure, AmpC regulation and β-lactam 
resistance and morphology in P. aeruginosa. To fulfill this objective, we constructed several 
mutants as single and combined constructs of dacB, dacC, pbpG and ampC in P. aeruginosa 
PAO1 strain to compare the effect of inactivation of these LMM-PBPs in presence and in 
absence of AmpC activity on PG composition, ampC regulation and bacterial resistance. The 
constructed mutants were further checked by microscopy to identify morphological changes, 
tested for their PG composition by HPLC analysis and tested for their ampC expression by RT-
PCR. Bocillin-FL test was done to confirm the inactivation of these LMM-PBPs in the 
constructed mutants and also to identify affinities to cefoxitin to LMM-PBPs. The results 
showed that mutants having single and combined dacB deletions had high ampC expression 
with the increase in bacterial resistance to β-lactam antibiotics except for imipenem and 
meropenem. Single mutations of dacC and pbpG did not changed the profile of ampC 
expression, and only dacC single and combined mutations produced maximum increase of PG 
pentapeptides. DacB and PbpG had higher affinities than DacC to cefoxitin. The triple mutant 
of dacB, dacC and pbpG displayed the largest increase in ampC expression and bacterial 
resistance to β-lactams. Microscopic examination of all the constructed mutants showed that 
they still retain their rod shape morphology similar to their parental PAO1 strain. 
 
4.2.2. The constructed PAO1 mutants 
Single and combined double and multiple mutants of dacB, dacC, pbpG and ampC were 
constructed (section 3.7) in P. aeruginosa PAO1 strain to study their physiological role in PG 
composition and bacterial resistance in P. aeruginosa. Also, it was aimed to study the role of the 
LMM-PBPs dacB, dacC and pbpG in ampC expression and regulation P. aeruginosa.  
 
The constructed gene-specific inactivation vectors  
Gene-specific mutagenesis vectors for inactivation of ampC and dacB were constructed 
in previous studies (Moya et al, 2009; Moya et al, 2008) and were used also in this study to 
knock out ampC and dacB and to form combined and multiple mutants of dacB, dacC, pbpG 
and ampC. Both of pbpG and dacC gene-specific mutagenesis vectors (pEXTΔpbpG::Gm and 
pEXTΔdacC::Gm) were constructed in this study, transformed in E. coli XL1 and S17λ and 
confirmed by colony PCR, digestion by restriction enzymes and DNA sequencing. Both of 
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pEXTΔpbpG::Gm and pEXTΔdacC::Gm have a lox flanked gentamycin resistance cassette 
(Gm, aacC1 gene), PCR1 (pbpG or dacC gene upstream fragment) and PCR2 (pbpG or dacC 
gene downstream fragment) which were cloned in the vector pEX100Tlink (Fig. 3.3). These 
two vectors were used for inactivation of pbpG and dacC genes, respectively, in P. aeruginosa 
PAO1 wild type and mutants. Confirmation of pbpG gene-specific mutagenesis vector 
(pEXTΔpbpG::Gm) was done by agarose gel electrophoresis of colony PCR of its transformants 
in E. coli XL1 blue with the vector pEXTΔpbpG::Gm whose PCR amplification product has a 
size (>1.5 kbp) higher than the positive controls for PCR amplification of pbpG gene using 
PAO1 DNA (addendum, figure A. 2a). Also, pEXTΔpbpG::Gm was confirmed by treatment 
with restriction enzymes HindIII, EcoRI and BamHI (not shown). Also, the verification of dacC 
gene-specific mutagenesis vector (pEXTΔdacC::Gm) was done by treatment with restriction 
enzymes HindIII, EcoRI and BamHI, where treatment with HindIII only produced two 
fragments, correspond to pEXTΔdacC Opened Vector (higher size, >7 kbp) having the vector 
pEX100Tlink with PCR1 and PCR2 in one DNA fragment and the other was aacC1 fragment of 
gentamycin cassette (lower size <1.5 kbp). Digestion of pEXTΔdacC::Gm with three enzymes 
HindIII, EcoRI and BamHI produced the 4 fragments [(lane 4): pEX100Tlink Opened Vector 
(~6.17 kbp), aacC1 fragment (<1.5 kbp), dacC-PCR1 (0.5 kbp) and dacC-PCR2 (0.4 kbp) 
(addendum, figure A. 2b)]. Confirmation of pEXTΔpbpG::Gm and pEXTΔdacC::Gm was done 
by colony PCR and restriction enzymes also in E. coli S17λ b. Also, DNA sequencing was done 
for all the constructs. 
 
Double recombination, removal of gentamycin cassette and verification of Pae 
mutants  
The construction of mutants in P. aeruginosa PAO1 was done using two bacterial 
strains; the first was donor strain (E. coli S17λ) having the gene-specific mutagenesis vectors 
S17/pEXTΔdacB::Gm, pEXTΔdacC::Gm, pEXTΔpbpG::Gm and S17/pEXTΔampC::Gm for 
inactivation of dacB, dacC, pbpG and ampC, respectively. The second strain was the receptor 
strain which was either of PAO1 wild type or mutant having the target gene to be inactivated. 
The construction of mutants in P. aeruginosa by cre-lox method depended on double 
recombination between the chromosomal target gene and DNA fragment (PCR1-lox-aacC1-lox-
PCR2) of the gene-specific inactivation vector. The gentamycin cassette (aacC1) was then 
eliminated by cre recombinase (fig.3.3). 
The two mutants PAOΔampC and PAOΔdacB were constructed from the wild type 
PAO1 in previous in studies (Moya et al, 2009; Moya et al, 2008). All the other Pae mutants 
summarized in table 3.1 were constructed in this study and confirmed for their gene inactivation 
by colony PCR amplification and agarose DNA electrophoresis. So that, single, double, triple 
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and quadruple PAO1 mutants of dacB, dacC, pbpG and ampC deletion were constructed from 
PAO1 and confirmed by colony PCR amplification of the target gene (addendum, figure A. 3-
7).  
The mutants PAOΔpbpG, PAOΔdacBΔpbpG and PAOΔpbpGΔampC were constructed 
from the wild type PAO1, PAOΔdacB and PAOΔampC, respectively, by double recombination 
with pEXTΔpbpG::Gm which produced the positive genotypes PAOΔpbpG::Gm, 
PAOΔdacBΔpbpG::Gm and PAOΔampCΔpbpG::Gm, respectively, which were then confirmed 
by colony PCR for removal of their gentamycin cassette producing the genotypes PAOΔpbpG, 
PAOΔdacBΔpbpG and PAOΔpbpGΔampC, respectively.   
The mutants PAOΔdacCΔampC, PAOΔdacCΔpbpG, PAOΔdacC, PAOΔdacBΔdacC 
and PAOΔdacBΔdacCΔpbpG were constructed from PAOΔampC, PAOΔpbpG, PAO1, 
PAOΔdacB and PAOΔdacBΔpbpG, respectively, by double recombination with 
pEXTΔdacC::Gm which produced the positive genotypes PAOΔampCΔdacC::Gm, 
PAOΔpbpGΔdacC::Gm, PAOΔdacC::Gm, PAOΔdacBΔdacC::Gm and 
PAOΔdacBΔpbpGΔdacC::Gm, respectively, which were then confirmed by colony PCR for 
removal of their gentamycin cassette producing the genotypes PAOΔdacCΔampC, 
PAOΔdacCΔpbpG, PAOΔdacC, PAOΔdacBΔdacC and PAOΔdacBΔdacCΔpbpG, 
respectively.  
The mutants PAOΔdacBΔampC and PAOΔdacBΔpbpGΔampC were constructed from 
PAOΔdacB and PAOΔdacBΔpbpG, respectively, by double recombination with 
pEXTΔampC::Gm which produced the positive genotypes PAOΔdacBΔampC::Gm, and 
PAOΔdacBΔpbpGΔampC::Gm, respectively, which were then confirmed by colony PCR for 
removal of their gentamycin cassette producing the genotypes PAOΔdacBΔampC  and 
PAOΔdacBΔpbpGΔampC, respectively. 
The mutants PAOΔdacBΔdacCΔampC, PAOΔdacCΔpbpGΔampC and PAOΔdacB 
ΔdacCΔpbpGΔampC were constructed from PAOΔdacBΔdacC, PAOΔdacCΔpbpG and 
PAOΔdacBΔdacCΔpbpG, respectively, by double recombination with pEXTΔampC::Gm which 
produced the positive genotypes PAOΔdacBΔdacCΔampC::Gm, 
PAOΔdacCΔpbpGΔampC::Gm and PAOΔdacBΔdacCΔpbpGΔampC::Gm, respectively, which 
were then confirmed by colony PCR for removal of their gentamycin cassette producing the 
genotypes PAOΔdacBΔdacCΔampC, PAOΔdacCΔpbpGΔampC and PAOΔdacB 
ΔdacCΔpbpGΔampC, respectively.   
The mutant PAOΔdacBΔpbpGΔampCΔdacC was constructed from PAOΔdacB 
ΔpbpGΔampC by double recombination with pEXTΔdacC::Gm which produced the positive 
genotype PAOΔdacBΔpbpGΔampCΔdacC::Gm which was then confirmed by colony PCR for 
removal of its gentamycin cassette producing the genotypes PAOΔdacBΔpbpGΔampCΔdacC. 
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The constructed mutants were checked for loss of DacB, DacB and PbpG by Bocillin-
FL test as described in section 4.2.4.  
 
4.2.3. Growth rates and microscopic examination of PAO1 mutants  
The growth rates in LB media at 37°C with agitation of single, double and multiple 
PAO1 mutants were not affected by deletion of dacB, dacC, pbpG and ampC when compared 
with the wild type (fig. 4.11). Microscopic examination (phase-contrast) was performed after 2, 
3, 4, and 5 hours and overnight growth for all the constructed mutants and the wild type PAO1. 
By comparing with the wild type, all mutants showed a rod shape with little differences in 
cellular width and diameter in some of them; only microscopic images after 4 hours were shown 
in figure 4.12 but the other images of all the constructed mutants at 2, 3 and 5 hours and 
overnight displayed a close morphological similarity to the wild type. 
 
4.2.4. Bocillin-FL test of PAO1 mutants  
The Bocillin-FL binding pattern of PBPs [PBP1a, PBP1b, PBP2, PBP3, PBP4 (DacB), 
PBP 5 (DacC) and PBP 7 (PbpG)] were checked up through fluorescence scanning of SDS-
PAGE of membrane extracts from the different mutants; the Bocillin-FL binding reaction 
involved incubation of 100 µg of cell membrane proteins (from FOX-induced and non-induced 
cells) with 10 µM Bocillin-FL in 1x PBS (pH 7.5) at 37°C for 30 min (section 3.5.5). The 
observed patterns of the PBPs in both of membranes of non-induced (fig. 4.13) and FOX-
induced cells (fig. 4.14) were almost similar and these PBPs patterns correlated perfectly with 
the loss of the expected LMM-PBP for each mutant except for the two mutants PAO∆dacB and 
PAO∆dacB∆pbpG which had unpredictably undetected DacC even thought that DacC was 
clearly detected in their corresponding mutants with ampC deletion (i.e. PAO∆dacB∆ampC and 
PAO∆dacB∆pbpG∆ampC) respectively. Therefore, these results strongly suggests that the high 
amounts of AmpC produced by DacB mutants (see below) significantly compromises the 
Bocillin-FL concentration required for DacC visualization. For analysis of the cefoxitin affinity 
for PBPs in cell membranes of PAO1, PAO∆ampC and PAO∆dacB∆pbpG∆ampC, 100 µg of 
cell membrane proteins were incubated with serial concentrations of cefoxitin for 30 min at 
37°C and then incubated with 10 µM Bocillin-FL in 1x PBS (pH 7.5) at 37°C for 30 min; the 
results displayed that LMM-PBPs (e.g. DacB, DacC and PbpG) had higher affinity to FOX than 
HMM-PBPs (e.g. PBP3, PBP2, PBP1a and PBP1b); DacB (PBP4) and PbpG (PBP7) are more 
sensitive to FOX than DacC (PBP5) which displayed a close behavior similar to PBP3; while 
PBP1b has the lowest affinity to FOX. IC50 values of FOX binding affinity for DacB, PbpG and 
DacC were of 1.45, <1.5 and 9.1 μg/ml, respectively in the wild type while they were 1.3, <1.5 
and 6.5, respectively in PAO∆ampC. IC50 for FOX and DacC of PAO∆dacB∆pbpG∆ampC was 
7.7 μg/ml (table 4.11). These data demonstrates that DacB and PbpG were very sensitive to 
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FOX while DacC was more resistant. Gene sequencing of dacC in PAO∆dacB and 
PAO∆dacB∆pbpG showed no mutations; indicating that the disappearance of DacC in Bocillin-
FL binding test was not due to a genetic-driven structural change but rather was due to high 
AmpC production in these two mutants (see next section).  
 
4.2.5. Effect of LMM-PBPs inactivation on ampC expression and β-lactam 
resistance in PAO1 mutants 
We have found that among the studied LMM-PBPs in PAO1, dacB mutant is the only single 
LMM-PBP mutant that was able to produce high basal ampC expression which caused a marked 
increase in the MICs for the antipseudomonal penicillins (piperacillin), cephalosporins (cefotaxime, 
ceftazidime, and cefepime) and monobactams (aztreonam) (table 4.12). The double mutant of dacB 
and dacC produced 10-fold increase in ampC expression compared to dacB mutant alone. The triple 
mutant of dacB, dacC and pbpG had the maximum basal increase in ampC expression and β-lactam 
resistance. Under FOX induction, there was a basal-level related increase in ampC expression in all of 
single, double and triple mutants which can be explained mainly by FOX blocking of DacB activity. 
The data suggest that dacC inactivation can largely turn on ampC expression only when DacB is 
inactive. The mutants PAO∆dacB∆dacC∆pbpG and PAO∆dacB∆dacC had the highest and the same 
MICs for CAZ (16µg/ml), ATM (16µg/ml), PIP (128 µg/ml) and CTX (512 µg/ml). Also PAOΔdacB 
and PAOΔdacBΔpbpG had high MICs [CAZ (8 µg/ml), ATM (8 µg/ml), PIP (16 µg/ml) and CTX 
(256 µg/ml)] but it was less than that of the mutant PAO∆dacB∆dacC∆pbpG which showed maximum 
ampC expression. However, all of PAOΔdacB, PAOΔdacBΔpbpG, PAO∆dacB ∆dacC∆pbpG and 
PAO∆dacB∆dacC had the same MIC for CEF (4 µg/ml).  The wild type PAO1 and all mutants with 
active AmpC seemed to have the same MIC for FOX (1026 µg/ml) indicating that ampC induction in 
the wild type was enough to produce the maximal MIC for FOX. There was no change in MICs of 
MER and IMI within the different PAO1 mutants. MICs of vancomycin correlated to the level of 
pentapeptides and not to ampC expression. The wild type PAO1 and all mutants with active AmpC 
had the same MIC for AMP (1024 µg/ml) with the exception of the two mutants PAO∆dacC and 
PAOΔdacBΔpbpG having MICs for AMP of 1536 and 2048 µg/ml, respectively. Both of dacC and 
pbpG mutants had no significant MIC change except for the decrease in piperacillin susceptibility in 
the PAOΔdacC mutant. We found that the MICs for nearly all β-lactams decreased in the 
PAOΔdacCΔampC mutant compared to PAOΔampC mutant, and this effect was further enhanced in 
the PAO∆dacB∆dacC∆pbpG∆ampC mutant, suggesting that LMW PBPs, particularly DacC, play a 
role in the intrinsic level of β-lactam resistance in P. aeruginosa (table 4.12). 
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Figure 4.11. Growth curves of the constructed PAO1 mutants. 
Optical densities at 600 nm of cellular growth of the wild type and all constructed 
PAO1 mutants, in LB media at 37°C with agitation (180 rpm), were recorded every one 
hour (h). Results show that profiles of cellular growth of all constructed mutants in 
PAO1 are of close similarity to the one displayed by the wild type PAO1. 
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PAO1                                             PAOΔdacB                                   PAOΔdacC 
 
                            
PAOΔampC                                PAOΔdacBΔampC                      PAOΔdacCΔampC 
 
                
 PAOΔpbpG                              PAOΔpbpGΔampC       
 
Figure 4.12. Microscopic examination of the constructed PAO1 mutants. 
Phase-contrast microscopic images of the constructed mutants are shown. Scale bars (white 
color) are 2 µm. As shown on this page and on the next page, all the constructed Pae mutants 
including the triple mutant (PAOΔdacBΔdacCΔpbpG) and the quadruple mutants 
(PAOΔdacBΔdacCΔpbpGΔampC and PAOΔdacBΔpbpGΔampCΔdacC) still retain their rod 
shape phenotype similar to the wild type PAO1. 
Fig. is continued on the next page. 
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PAOΔdacBΔdacC                    PAOΔdacBΔpbpG                       PAOΔdacCΔpbpG 
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PAOΔdacBΔdacCΔpbpG   PAOΔdacBΔdacCΔpbpGΔampC  PAOΔdacBΔpbpGΔampCΔdacC 
 
Figure 4.12 continued. Microscopic examination of the constructed PAO1 mutants. 
The wild type and all constructed PAO1 mutants were grown in LB media at 37°C while their 
microscopic examination was done after 4 hours in vivo using equipment of fluorescence 
resonance energy transfer (FRET) comprising Axiovert200 inverted microscope (Zeiss) coupled 
to a monochrome CCD camera. The images of the constructed mutants are of close similarity to 
the wild type PAO1. Scale bars (white color) are 2 µm.  
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Table 4.11. Estimated IC50 values for cefoxitin within cell membranes of the wild 
type and some PAO1 mutants using Bocillin-FL test.  
Strain IC50- FOX (µg/ml)a 
 PBP1a PBP1b PBP2 PBP3 DacB DacC PbpG 
PAO1 6.4 30.7 16.4 8 1.45 9.1 < 1.5 
PAO∆ampC 4.75 27.2 15.4 7.7 1.3 6.5 < 1.5 
PAO∆dacB∆pbpG∆ampC 4.25 29 13.1 6.2 0 7.7 0 
a IC50- FOX is the cefoxitin (FOX) concentration producing a 50% reduction of Bocillin-FL 
binding for each individual PBP. The reaction contained 100 µg membrane proteins which 
were incubated with serial concentrations of cefoxitin for 30 min at 37°C then incubated with 
10 µM Bocillin-FL in PBS (1x-pH 7.5) at 37°C for 30 min. The results show that LMM-PBPs 
(e.g. DacB, DacC and PbpG) have high affinity to FOX than HMM-PBPs (e.g. PBP3, PBP2, 
PBP1a and PBP1b); DacB (PBP4) and PbpG (PBP7) are more sensitive to FOX than DacC 
(PBP5) while PBP1b have the least affinity to FOX.  
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Figure 4.13. Bocillin-FL binding test of cell membranes of PAO1 mutants under non-induction conditions.    
The Pattern of PBPs (at left) of all the constructed mutants and their parental wild type PAO1are shown. The reactions contained 100 µg 
membrane proteins which were incubated with 10 µM Bocillin-FL in 1x PBS (pH 7.5) at 37°C for 30 min. Bocillin-FL binding of cell membranes 
from Pae mutants that were grown without induction confirms the deletions of dacB, DacC and pbpG in the construed mutants. In case of the 
wild type we can see the bands corresponding to PBP1a, PBP1b, PBP2, PBP3, PBP4 (DacB), PBP5 (DacC) and PBP7 (PbpG). DacC was not 
detected in the mutants PAOΔdacB and PAOΔdacBΔpbpG (*) but it was detected in their corresponding mutants with ampC deletion 
PAOΔdacBΔampC and PAOΔdacBΔpbpGΔampC (**), respectively; also, DacC was highly increased in PAOΔampC and PAOΔpbpGΔampC 
when compared with the wild type PAO1 and PAOΔpbpG. The data shows that DacC occurs in a higher proportion when compared with the 
other PBPs in mutants of ampC.   
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  Figure 4.14. Bocillin-FL binding test of cell membranes of PAO1 mutants previously induced with cefoxitin.    
 *, ** Bocillin-FL assay of cell membranes from mutants pre-treated with FOX showed the same results without induction, described previously (Fig. 4.13).  
 
Please, take in your account that the order of the samples is not as shown in figure 4.13  
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Table 4.12. MICs and ampC expression under basal and cefoxitin induction conditions for all studied mutants a.  
 
Strain 
MICs (µg/mL)b ampC expressionc 
CAZ CEF ATM PIP IMI MER CTX FOX VAN AMP Basal Induced* 
PAO1 1 1 4 2 0.5 0.5 12 1024 512 1024 - 347 ± 59 
PAOΔampC 1 1 4 2 ≤0.12 0.25 8 64 512 32 - - 
PAOΔdacB 8 4 8 16 1 0.5 256 1024 512 1024 47 ± 29 569 ± 166 
PAOΔdacBΔampC 1 0.5 2 2 ≤0.12 0.25 8 96 512 32 - - 
PAOΔdacC 0.75 0.5 2 4 0.5 0.5 8 1024 1024 1536 1.3 ± 0.4 542 ± 380 
PAOΔdacCΔampC 0.75 0.5 2 2 ≤0.12 0.25 4 64 4096 16 - - 
PAOΔpbpG 1 1 4 4 1 0.5 16 1024 512 512 0.6 ± 0.3 305 ± 152 
PAOΔpbpGΔampC 1 0.5 3 4 ≤0.12 0.25 8 96 512 32 - - 
PAOΔdacBΔdacC 16 4 16 128 0.5 0.5 512 1024 2048 1024 478 ± 5.1 840 ± 245 
PAOΔdacBΔdacCΔampC 1 0.5 2 2 ≤0.12 0.25 4 64 4096 16 - - 
PAOΔdacBΔpbpG 8 4 8 16 0.5 0.25 256 1024 512 2048 45 ± 32 326 ± 106 
PAOΔdacBΔpbpGΔampC 0.75 0.5 2 2 ≤0.12 0.5 6 64 4096 32 - - 
PAOΔdacCΔpbpG 1 0.5 2 6 0.5 0.25 8 1024 1024 1024 1.4 ± 0.7 162 ± 87 
PAOΔdacCΔpbpGΔampC 0.75 0.5 2 3 ≤0.12 0.25 4 64 4096 24 - - 
PAOΔdacBΔdacCΔpbpG 16 4 16 128 0.5 0.5 512 1024 4096 1024 1207 ± 193 5742 ± 1975 
PAOΔdacBΔpbpGΔampCΔdacC 0.5 0.5 2 2 ≤0.12 ≤0.12 4 64 4096 16 - - 
PAOΔdacBΔpbpGΔdacCΔampC 0.5 0.5 1 2 ≤0.12 ≤0.12 4 64 4096 16 - - 
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a Cooperative work was done by Gabriel Cabot, Irina Sánchez-Diener, Bartolome Moya and Antonio Oliver (Servicio de 
Microbiología and Unidad de Investigación. Hospital Universitario Son Espases. Palma de Mallorca. Spain). b  MICs of ceftazidime 
(CAZ), cefepime (CEP), aztreonam (ATM), piperacillin (PIP), imipenem (IMI), meropenem (MER), cefotaxim (CTX), cefoxitin (FOX), 
vancomycin (VAN) and ampicillin (AMP). c Expression of ampC was determined by RT-PCR for non-induced (basal)  and 50 μg/ml 
cefoxitin treated (induced) PAO1 wild type and mutants. Median values of 3 experiments are shown. Relevant data are shown in bold 
letters. dacB mutant caused large increase in ampC expression and bacterial resistance (to β-lactams except IMI and MER) which 
increased by further deletion of dacC and pbpG. Data of ampC expression show that the increase in bacterial resistance to β-lactams 
was related to a parallel increase in ampC expression except for VAN which was related to the level of penta peptides in PG of each 
PAO1 strain. The triple mutant PAOΔdacBΔdacCΔpbpG displayed the largest ampC expression. Both of PAOΔdacBΔdacCΔpbpG and 
PAOΔdacBΔdacC displayed the same resistance profile with the examined β-lactam antibiotics. PAOΔdacB mutant displayed high 
ampC expression and β-lactam resistance when compared with other single mutants. 
.
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4.2.6. PG composition of the constructed PAO1 mutants 
PG composition of cells untreated and treated with FOX was revealed by HPLC analysis 
(section 3.12) of the constituting muropeptides (tables 4.13 and 4.14, respectively). PG analysis of 
untreated single mutant cells showed that there was a large increase in penta muropeptides only 
when DacC was inactivated and this effect was enhanced by further inactivation of DacB and PbpG 
which produced a maximal penta muropeptides in the triple mutant. The data indicates that DacC 
has the main role in the DD-CPase activity in P. aeruginosa. There was no penta increase within the 
PG of dacB and pbpG single mutants, and only small increase (7.1 % mol) in the dacC single 
mutant (table 4.13). However, when those mutants were grown with 50 µg/ml cefoxitin (FOX), 
only dacC mutant shows a large increase in penta (38.8 % mol) most probably due to the inhibition 
of a DD-CPase activity (table 4.14). This result may indicate a low affinity of DacB or PbpG by 
cefoxitin, or some enhanced effect of DacC over the two other DD-CPases. Data on the high FOX 
affinity (IC50) of DacB (1.45 µg/ml) and PbpG (<1.5 µg/ml) (table 4.11) and PG analysis of double 
mutant indicate that the effect must be mainly due to some kind of interaction of DacC with the two 
other DD-CPases, because PG analysis of PAO∆dacB∆dacC shows a high increase (28.6 % mol) 
and PAO∆pbpG∆dacC a moderate increase (9.8 mol%), but double mutant PAO∆dacB∆pbpG had 
no effect (2.5 % mol) on penta composition of PG (table 4.13). When induced by cefoxitin, the 
effect is exacerbated with values of 39.8 and 44.0 % mol for both double mutants 
PAO∆dacB∆dacC and PAO∆pbpG∆dacC, respectively, but again no increase for 
PAO∆dacB∆pbpG mutant (table 4.14). Without FOX treatment, the penta increase in 
PAO∆dacB∆dacC∆ampC (32.0 % mol) is four times higher than that in PAO∆dacC∆ampC (8.0 % 
mol) (table 4.13), however their corresponding penta increase with FOX treatment is more or less 
the same (62.3 and 63.1 % mol) and it is very close to that observed in the triple mutant (65.5 % 
mol) and so did the mutant PAO∆pbpG∆dacC∆ampC (64.5 % mol) (table 4.14). This indicates 
several conclusions: 1) DacB complements the DD-CPase activity when dacC is absent, 2) with less 
efficiency PbpG complements that activity when dacC or dacB are absent, 3) DacC is the major 
DD-CPase in PAO1 because the mutant PAO∆dacB∆pbpG has no significant penta increase, and 4) 
these three PBPs are expected to have an interaction and a synergetic effect respect to the total DD-
CPase activity in the cell. PG of the mutant PAO∆dacB∆pbpG had less monomers, more dimers, 
more anhydromuropeptides and a higher crosslinking when compared with the PAO1 wild type; 
this data must be related to the inhibition of a DD-endopeptidase (DD-EPase) activity, suggesting 
also these PBPs may have this type of activity (table 4.13). 
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Table 4.13. HPLC analysis of muropeptides prepared from PG of the constructed Pae mutants under non-induction conditions.  
 
Strain 
Muropeptides (% Molar)a    
Mono Di Tri D-D Lpp Anh Penta Crosslink D-D/T Length 
PAO1 57.8 38.3 3.9 1.9 3.1 8.7 1.6 46.1 4.1 11.5 
PAO∆dacB 56.1 39 4.8 1.5 3.7 9.6 2.4 48.9 3.1 10.5 
PAO∆dacC 59.3 37.1 3.6 1.1 3.2 9.1 7.1 44.4 2.4 11 
PAO∆pbpG 58.7 37.2 4.1 1.5 2.8 9.4 1.4 45.4 3.2 10.7 
PAO∆dacB∆dacC 58.4 36.7 4.8 1.1 3.4 9.4 28.6 46.6 2.3 10.7 
PAO∆dacB∆pbpG* 54.5 39.5 5.9 1.5 3.3 14.2 2.5 51.6 2.9 7 
PAO∆dacC∆pbpG 55.9 39.4 4.6 1.2 3.3 8.9 9.8 48.8 2.6 11.2 
PAO∆dacB∆dacCpbpG 54.7 40 5.2 1.3 2.4 7.6 66.4 50.6 2.5 13.2 
PAO∆ampC 59.9 36.3 3.8 1.2 3.3 9 2.5 43.8 2.8 11.1 
PAO∆dacB∆ampC 54.2 40.3 5.4 2.1 4.1 10.3 2.5 51.2 4.1 9.8 
PAO∆dacC∆ampC 59.7 36.6 3.7 1.1 3.2 9.1 8 44.1 2.4 11 
PAO∆pbpG∆ampC 56.4 38.6 4.9 1.5 3.7 9.7 2.5 48.5 3.1 10.3 
PAO∆dacB∆dacC∆ampC 59.4 36.1 4.4 1 2.5 7.9 32 45.2 2 12.6 
PAO∆dacB∆pbpG∆ampC* 49.4 43.5 7 1.7 3.6 11.3 3.7 57.8 3 8.8 
PAO∆dacC∆pbpG∆ampC 54.9 39.9 5.1 1.8 3.7 9.4 9.4 50.4 3.5 10.7 
PAO∆dacB∆dacCpbpG∆ampC 54.8 40 5.1 0.6 2.1 7.2 67.6 50.4 1.1 13.9 
PAO∆dacB∆pbpG∆ampC∆dacC 53 40.4 6.5 1.5 2.4 8.8 65.9 53.6 2.8 11.4 
a As described previously within table 4.7. The interesting changes are shown in bold letters. dacC single and combined mutants displayed large 
increase in penta peptides in their PG due to inhibition of DD-CPase activity. *dacB and pbpG double mutant showed an increase in monomers, a 
decrease in dimers and trimers and an increase in crosslinking due to inhibition of  DD-EPase activity.  
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Table 4.14. HPLC analysis of muropeptides prepared from PG of the constructed Pae mutants treated with FOX. 
 
Strain 
Muropeptides (% Molar)a    
Mono. Di. Tri. D-D Lpp Anh. Penta. Crosslink D-D/T Length 
PAO1 55.5 39.3 5.1 1.9 3.7 10.1 4.4 49.9 3.7 9.9 
PAO∆dacB 57.1 37.2 5.6 1.7 3.4 13.7 3.7 48.6 3.5 7.3 
PAO∆dacC 55.2 39.6 5.1 1.2 2.5 8.2 38.8 50.1 2.3 12.3 
PAO∆pbpG 56.6 37.9 5.4 1.9 3.6 8.9 4.2 49 3.9 11.3 
PAO∆dacB∆dacC 58.8 36.7 4.4 1.1 3.2 8.1 39.8 45.8 2.4 12.4 
PAO∆dacB∆pbpG 51 42.1 6.8 2.1 4.9 12.3 4 56.1 3.7 8.2 
PAO∆dacC∆pbpG 54.3 40.3 5.3 1 2.6 7.5 44 51.3 1.8 13.4 
PAO∆dacB∆dacCpbpG 54.8 39 6 1.1 3.1 9.3 66 51.6 2.1 10.8 
PAO∆ampC 54.9 40.3 4.6 1.3 2.6 7.2 14 50 2.6 14 
PAO∆dacB∆ampC 55.8 39.5 4.5 1.3 3.4 7.7 16.5 48.9 2.7 13.1 
PAO∆dacC∆ampC 58.1 37 4.8 1.4 3.4 7.5 62.3 46.9 3 13.3 
PAO∆pbpG∆ampC 53.9 40.6 5.4 1.8 3.1 8.2 14.1 51.7 3.5 12.3 
PAO∆dacB∆dacC∆ampC 56.9 37.6 5.3 1.2 2.6 7.5 63.1 48.8 2.5 13.3 
PAO∆dacB∆pbpG∆ampC 53.4 40.6 5.8 1.9 3.6 8.3 14.7 52.8 3.6 12 
PAO∆dacC∆pbpG∆ampC 55.8 38.5 5.5 1.3 2.8 7.3 64.6 50.2 2.5 13.7 
PAO∆dacB∆∆dacCpbpG∆ampC 57 37.2 5.6 1.3 2.7 6.7 63.1 49.1 2.7 15 
PAO∆dacB∆pbpG∆ampC∆dacC 57.2 36.7 5.9 1 2 7.4 65.5 49 1.9 13.5 
a As described previously within table 4.7 and 4.15. FOX induction caused some increase the level of pentapeptides in all PAO1 wild 
and mutants. The double mutant of  dacC and ampC showed a very close level of penta peptides (maximum penta level) as found in PG 
of the tripe mutant of dacB, dacC and pbpG and its quadruple mutant with ampC deletion. 
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4.3. Activities of DacB, DacC and PbpG are not essential for recovery of rod shape 
in imipenem-induced spheroplasts in P. aeruginosa 
 
4.3.1. Summary 
A previous study reported that incubation of P. aeruginosa with 5x MIC of imipenem or 
meropenem with a static growth at 37°C caused the development of spherical shaped cells which 
were able to recover their shape after elimination of IMI or MER from the growth medium 
(Monahan et al, 2014). Taking advantage of the different mutant described in the previous section, 
the role of DacB, DacC and PbpG in the recovery of the rod shape can be studied. Then, we are 
about to pursue this analysis by producing that round cells by IMI induction and their recovered rod 
cells (in the wild type PAO1 and all the constructed Pae mutants) following the same procedure 
described previously (Monahan et al, 2014) and then to analyze their PG composition by HPLC 
(only for PAO1 and PAO∆dacB∆dacC∆pbpG∆ampC). Bocillin-FL test of round cells and rod 
shape recovered cells of the wild type PAO1 and the mutant PAO∆ampC was done to identify their 
changes in PBPs pattern. Also, phase contrast and fluorescence microscopy was used to pursue the 
change in cell shape and viability. Results of PG analysis showed that by comparing to non-induced 
cells, PG composition of IMI-induced round cells of both of the wild type and mutant had a 
decrease in monomers, D-D muropeptides, pentapeptides and length and an increase in dimers, 
trimers, anhydro-muropeptides and crosslinking degree; also they had a large increase in M3 and 
decrease in M4, D44 and D45 muropeptides. However, PG composition of rod shape recovered 
cells had muropeptides with relative abundance similar to that of non-induced cells. Fluorescence 
microscopy showed that the round cells were viable however there were some unviable cells 
observed. Bocillin-FL test shows that membranes of round cells of both of the wild type PAO1 and 
the mutant PAO∆ampC had a low amount of DacC and lost DacB while the rod shape recovered 
wild type PAO1 had a recovered DacB but DacC was still detected as a low amount; while at the 
opposite of that, the rod shape recovered PAO∆ampC mutant had a recovered DacC at high amount 
and DacB at low amount. Also both of overnight recovered and non-induced cells had no PbpG 
detected.  
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4.3.2. Microscopic examination of  imipenem-induced spheroplasts wild type 
and mutant PAO1 cells 
Round cells were produced after 4 hours incubation of the wild type PAO1 and the 
constructed Pae mutants in CAMHB media supplemented with 0.5 M sucrose and induced with 5x 
MICs of IMI for 4 hours at 37°C without agitation (section 3.10). MICs for IMI for the wild type 
PAO1 and constructed Pae mutants are mentioned in table 4.12. We found that round cells of both 
of PAO1 and all mutants recovered their rod shape after elimination of IMI from the medium with 
static overnight growth at 37°C. Non-induction conditions were also performed as a control for the 
change in the morphological pattern. Phase-contrast and fluorescence microscopy (using green 
CYTO 9 staining, section 3.11) showed that in both of PAO1, PAO∆ampC and the quadruple 
mutant (PAO∆dacB∆dacC∆pbpG∆ampC) the round cells were viable and alive. Some dead cells, 
indicated by white arrows in figure 4.15, were observed also in both strains, but in higher amount 
for the mutant. Under non-induction conditions cells from wild and quadruple mutant were all 
viable and alive. Moreover, published data of recovered cells, after removal of IMI in wild type 
strain, show they had normal morphology and were alive (Monahan et al, 2014); and also quadruple 
mutant in our assay seemed to have a normal rod shape and cells were all alive. All other 
constructed single and double Pae mutants displayed the same behavior (under microscope) for 
IMI-induced spheroplast formation and rod shape recovery after removal of IMI from the growth 
medium (not shown).   
 
4.3.3. PG composition of imipenem-induced spheroplasts wild type PAO1 and 
mutants  
Only PG of spheroplasts and recovered cells of PAO1wild type and 
PAO∆dacB∆dacC∆pbpG∆ampC mutant was analyzed by HPLC because we wanted to compare the 
effect of inactivation of all LMM-PBPs (dacB, dacC and pbpG) on PG composition with that of 
PAO1 wild type. It is just a way to reveal physiological role of these main Pae DD-CPases and 
EPases in PG composition during spheroplast formation and rod shape recovery.   
IMI-induced round PAO1 cells of wild type and the mutants  PAO∆dacB∆dacC∆pbpG 
∆ampC were grown in CAMHB media supplemented with 0.5 M sucrose and induced with 5x 
MICs of IMI at 37°C without agitation (section 3.10). After 4  incubation with IMI and 22 h 
incubation after removal of IMI, PG was collected from round-induced and non-induced cells, 
digested and analyzed by HPLC (section 3.12). Differences in main general structure of PG were 
found for both wild type and mutant under non induction conditions, compared with data of the 
same strains grown in exponential phase in LB and 180 rpm. These changes are expected due to 
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differences in media and growth conditions. However, major changes were found for round-induced 
and non-induced for both PAO1 and mutant strains. We found that PG of round cells in both strains 
had an increase in dimers, trimers, anhydro-muropeptides and crosslinking and a decrease in 
monomers, D-D muropeptides and length (table 4.15a). Respect to the individual muropeptides, 
round-shaped PAO1 wild type and the mutant PAO∆dacB∆dacC∆pbpG∆ampC had unusual 
increase in M3 and decrease in M4, D44 and D45 while M5 was not changed in the quadruple 
mutant (table 4.15b). After elimination of imipenem the round-shaped cells recovered the original 
rod shape and PG analysis after recovery showed normal levels of M3 and M4. The given data 
indicates that the activities DacB, DacC, PbpG and AmpC are not essential for rod shape recovery 
in P. aeruginosa.  
 
4.3.4. Bocillin-FL test of imipenem-induced spheroplasts wild type PAO1 and 
PAOΔampC   
As the pattern of changes in morphology and PG structure were equivalent in PAO and 
PAO∆dacB∆dacC∆pbpG∆ampC, indicating no role for the LMM-PBPs on the mechanism of 
production of round cell, then we decided to analyze the presence of these LMM-PBP on the wild 
type (complete set of PBPs) and the ampC mutant (no AmpC production). Round cells and 
recovered cells of the wild type PAO1 and the mutant PAOΔampC were produced as described 
before (section 3.10) with 5x MICs of imipenem. Bocillin-FL binding reaction involved incubation 
of a 100 µg of cell membrane proteins of PAO1 and PAO∆ampC with 10 µM Bocillin-FL in PBS 
(1x-pH 7.5) at 37°C for 30 min. The Bocillin-FL binding pattern of PBPs of membranes of 4 hours 
non-induced PAO1 and PAO∆ampC displayed a full pattern of PBPs: PBP1a, PBP1b, PBP2, PBP3, 
PBP4(DacB), PBP5(DacC) and PBP7(PbpG), with higher binding for PBP7 in PAO∆ampC, while 
overnight non-induced cells of both strains had lost PBP7 band. The Bocillin-FL binding pattern of 
PBPs of membranes of 4 hours IMI-induced round cells of PAO1 and PAO∆ampC displayed an 
equivalent pattern with the loss of all PBPs bands, except for small amount of their DacC band. On 
another hand, overnight recovered PAO1 and PAO∆ampC had regained all PBPs band with the 
exception of PBP7, but they have a different pattern of expression of PBP4 and PBP5. The given 
data show that overnight recovered PAO1 had very low PBP5 amount and considerable amount of 
PBP4, but in the contrary, overnight recovered PAO∆ampC had a low amount of PBP4 and large 
amount of PBP5 (fig. 4.16). 
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Table 4.15a. HPLC analysis of muropeptides prepared from PG of imipenem-induced Pae spheroplasts.  
 
Strain 
 
Conditions 
Time 
(h) 
Cell 
shapec 
Muropeptides (% Molar)a    
Mono Di Tri D-D Lpp Anhy Penta Crosslink D-D/T Length 
PAO1 No IMI 4 Normal 63.6 33.9 2.5 3.7 2.1 6.2 5.7 38.8 9.5 16.2 
+ IMI 4 >95% 
Round 
59.2 37.9 2.9 2.3 1.2 12.3 2.1 43.8 5.2 8.1 
No IMI 22 Normal 62.1 34.9 2.9 8 2.3 5.7 12.9 40.8 19.6 17.7 
Recovery 22 Normal 57.6 39.1 3.3 4.9 2.8 6.8 6.6 45.7 10.7 14.6 
PAO∆dacB ∆dacC 
ΔpbpG∆ampC 
No IMI 4 Normal 60.2 36.3 3.5 1.2 2.9 6 59.6 43.3 2.7 16.7 
+ IMI 4 >95% 
Round 
52 43.2 4.8 1.2 2.2 14.8 55.4 52.9 2.3 6.8 
No IMI 22 Normal 52.7 42.8 4.5 1.4 2.7 8.3 66.4 51.7 2.7 12 
Recovery 22 Normal 58.5 37.1 4.4 3.5 3.7 8.3 59.3 45.9 7.7 12.1 
 a As described previously within table 4.7. b No IMI: cells was not treated with imipenem; +IMI: cells were treated with 5x MIC of 
imipenem; Recovery: cells after removal of imipenem; PG was analyzed from induced and non-induced cells after 4 and 22 hours 
static growth at 37°C in CAMHB media supplemented with 0.5 M sucrose.  c The wild type PAO1 and the mutant  PAO∆dacB 
∆dacCΔpbpG∆ampC are rod shaped but after their incubation with imipenem by 4 hours, their shapes turned into spheres (Fig. 4.15) 
and recovered their rod shapes after elimination of IMI in overnight growth. Spheres PG of induced PAO1 cells displayed increase in 
monomers and decrease in M4, D43 and D44; while, Spheres PG of the quadruple mutant displayed a large increase in M3 and 
decrease in M4, D43, D44 and D45 and no change in M5. After recovery the PG composition had normal proportions of muropeptides 
as in non-induced cells.  
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 Table 4.15b. Selected muropeptides produced from PG of imipenem-induced Pae spheroplasts.   
 
Strain 
 
conditionsb 
Time 
(h) 
Cell 
Shapec 
Muropeptides (% Molar)a 
M3 M4 M5 D43 D44 D45 T444 T445 D44N D45N T444N T445N 
PAO1 No IMI 4 Normal 8.7 22.7 0.4 3.9 19.1 0.7 1.4 0.3 3.2 0.1 1 0 
+ IMI 4 > 95% 
Round 
14.3 14 0.2 2 10.8 0.3 0.6 0 4.4 0 0.8 0 
No IMI 22 Normal 6.27 14.5 2 3.1 15.1 0.3 1.3 0.3 2.7 0.2 1 0 
Recovery 22 Normal 7.7 21.8 0.6 3.9 23.1 0.8 2.1 0.4 3.9 0.2 1.4 0 
PAO∆dacB ∆dacC 
ΔpbpG∆ampC 
No IMI 4 Normal 4.2 7 13.1 1.5 11.8 17.3 0.9 2 1.3 2.1 0.6 1.3 
+ IMI 4 >95% 
Round 
6.7 5.9 13.1 0.9 6.2 11.3 0.4 0.9 2.2 3.7 0.3 1 
No IMI 22 Normal 3.1 5.1 16.1 1.5 12 22.4 1 2.8 1.9 2.9 0.7 1.9 
Recovery 22 Normal 2.7 5.1 12.5 1.9 8 14.5 1 2 1.7 2 0.5 1.1 
a As described previously within table 4.10b. b As described within table 4.15a. This table shows the molar abundance of common 
muropeptides in PG of imipenem-induced PAO1 cells which displayed large increase in M3 and decrease in M4, D43 and D44 in the 
wild type PAO1. While, PG of the quadruple mutant Spheroplasts displayed a large increase also in M3 and decrease in M4, D43, 
D44 and D45 and displayed no change in M5. After overnight recovery, the PG composition had normal proportions of muropeptides 
as in non-induced cells.  
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Figure 4.15. Microscopic examination of  spheroplasts of imipenem-induced PAO1 
wild type, PAOΔampC  and PAOΔdacBΔdacCΔpbpGΔampC mutants.  
A. Microscopic images of phase-contrast (ph) and fluorescence with CYTO 9 (F) of the 
wild type PAO1 (I) PAOΔampC (II) and PAOΔdacBΔdacCΔpbpGΔampC (III) showing 
spheroplasts which were obtained after incubation with 5x MICs of imipenem (+IMI) in 
CAMHB media supplemented with 0.5 M sucrose for 4 hours at 37°C without agitation; where 
the green colored spheres and their corresponding phase-contrast are supposed to be alive 
cells while the others pointed by white arrows are supposed to be dead cells. Scale bars are 
2 µm. 
Fig. is continued on the next page.  
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Figure 4.15 continued. Microscopic examination of spheroplasts of imipenem-induced 
PAO1 wild type, PAOΔampC and PAOΔdacBΔdacCΔpbpGΔampC mutants.  
B. Phase-contrast images of wild type wild type PAO1, PAOΔampC and 
PAOΔdacBΔdacCΔpbpGΔampC before addition of imipenem (IMI) to the growth medium (CAMHB 
media supplemented with 0.5 M sucrose at 37°C without agitation). C. Phase-contrast images of 
wild type wild type PAO1, PAOΔampC and PAOΔdacBΔdacCΔpbpGΔampC after elimination of 
IMI from the medium (CAMHB media supplemented with 0.5 M sucrose) and overnight incubation 
at 37°C without agitation. RE: recovery of rod shape from Pae spheroplasts (A) after elimination of 
IMI from the growth medium. Scale bars (white color) are 2 µm.  
B. 
C. 
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Figure 4.16. Bocillin-FL binding test of Pae spheroplasts membranes of IMI-induced 
PAO1 wild type and PAOΔampC mutant.  
The Pattern of PBPs (at left) of PAOΔampC mutant and the wild type PAO1are shown. 
Assay of Bocillin-FL with cell membranes of PAO1 and PAOΔampC which were grown in 
CAMHB media supplemented with 0.5 M sucrose at 37°C without agitation. PAO1/NI/4 h 
and PAOΔampC/NI/4 h: non-induced (NI) PAO1 and PAOΔampC after 4 hours of 
growth; PAO1/+IMI/4 h and PAOΔampC/+IMI/4 h: induced PAO1 and PAOΔampC after 
4 hours of growth with 5x IMI which produced round cells ; PAO1/NI/ON and 
PAOΔampC/NI/ON: non-induced (NI) PAO1 and PAOΔampC after 4 hours of overnight 
(ON) growth; PAO1/ΔIMI/ON and PAOΔampC/ΔIMI/ON: overnight recovery of rod 
shape after elimination of IMI (ΔIMI) from the growth medium of PAO1 and PAOΔampC. 
The reaction contained 100 µg membrane proteins which was incubated with 10 µM 
Bocillin-FL in 1x PBS (pH 7.5) at 37°C for 30 min.  
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5. Discussion  
 
5.1. Motivation and design of this study 
 
Functional characterization of Pae-AmpC from P. aeruginosa has a significant importance 
because AmpC overproduction and emergence of AmpC mutants (e.g. ESACs) are considered as 
one of the basic resistance tools used by this clinically problematic microorganism to overcome the 
inhibitory effect of most of β-lactam antibiotics (Bush & Jacoby, 2010; Jacoby, 2009; Lister et al, 
2009). AmpC enzymes are historically known as β-lactamases but they were thought to have a DD-
peptidase activity (CPase and/or EPase) due to structural similarities with LMM-PBPs (e.g. Eco-
AmpH) that have these activities (Bishop & Weiner, 1992; Gonzalez-Leiza et al, 2011; Hall & 
Barlow, 2004; Joris et al, 1988; Kong et al, 2010; Sauvage et al, 2008). So, this study (section 4.1) 
concerned especially with tracking DD-peptidase activity in vivo and in vitro for Pae-AmpC forms 
(wild type and mutants) in E. coli and in P. aeruginosa by HPLC analysis of their PG and 
muropeptides; that was beside characterization of β-lactamase activity, β-lactam resistance and the 
effect of Pae-AmpC overproduction in these bacterial strains.  
In addition to their structural similarities, LMM-PBPs play a role in ampC regulation and β-
lactam resistance, likewise it was reported that inhibition of LMM-PBPs by β-lactam antibiotics 
triggers AmpC overproduction and sometimes mutations that can lead to the emergence of ESACs  
(Bush & Jacoby, 2010; Kong et al, 2010; Lister et al, 2009). Also, it was found that deletion of 
dacB triggered AmpC overexpression and β-lactam resistance in P. aeruginosa (Moya et al, 2009). 
So that, we aimed also to unveil the physiological role and functional interaction of the main LMM-
PBPs (dacB, dacC and pbpG) in P. aeruginosa in ampC regulation, bacterial resistance and PG 
composition in P. aeruginosa which was achieved by the construction of single and combined 
mutants of these LMM-PBPs with and without Pae-ampC inactivation in PAO1 strain (section 4.2). 
Then, these Pae mutants were tested for their PG composition by HPLC analysis, their ampC 
expression by RT-PCR and their resistance to some β-lactam antibiotics. 
On the other hand it was found that imipenem supplemented growth of P. aeruginosa produced 
spherical shaped cells and elimination of imipenem from the medium helped these round cells to 
recover their rod shape (Monahan et al, 2014). So, we aimed to characterize LMM-PBPs (DacB, 
DacC and PbpG) in the round and the recovered cells of P. aeruginosa by Bocillin-FL test and to 
pursue the physiological role of these LMM-PBPs on the recovery of the rod shape from round cells 
after elimination of imipenem from the growth medium(section 4.3).     
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5.2. Functional characterization of Pae-AmpC β-lactamase 
 
5.2.1. Various forms of Pae-AmpC were produced 
 
The first main goal was to characterize the function of AmpC-F1 (the wild type Pae-AmpC 
precursor form), AmpC-F3 (the wild type mature AmpC, without signal peptide) and two 
uncharacterized AmpC mutants (AmpC-F1:C3 and AmpC-F1:C6) to compare their functional 
activities and to characterize the effect of the two mutations on AmpC activity in PG composition 
and bacterial resistance. Because all of AmpC-F1, AmpC-F1:C3 and AmpC-F1:C6 were not 
produced in large amount from their encoding pET28b vectors in Bl21(DE3) (fig. 4.2), we designed 
another AmpC forms (AmpC-F4, AmpC-F4:C3, AmpC-F4:C6 and AmpC-F4) in order to 
overproduce the precursor form of Pae-AmpC and these two mutants using pET28b vectors. Also, 
some AmpC forms were designed to have C-terminal TEV protease site (e.g. AmpC-F3-TEV, 
AmpC-F3:C3-TEV, AmpC-F3:C6-TEV and AmpC-F6-TEV) to remove the poly-His tag (by TEV 
protease) from the purified proteins to be crystallized. 
 
 
5.2.2. Interpretation of AmpC production using pET28b and pUCP24 vectors 
 
AmpC production from ampC-encoding pET28b recombinant vectors   
Detection of the different forms of AmpC proteins by SDS-PAGE and the corresponding 
western blot analysis is proportional to AmpC production by different recombinant plasmids. 
AmpC-F1 (the wild type) and the two mutants AmpC-F1:C3 and ampC-F1:C6 were not detected by 
SDS-PAGE or western blot because they were not actually produced. By returning to the forward 
primer (ampC-Fw1) of their PCR amplification, it has the sequence 
(5'…TTTCCATGGATGCGCGATACCAGATTCC…3') providing the transcription process with 
two ATG that could be a starting codon for the peptide sequence; the 1st ATG (underlined) is 
favored rather than at the 2nd one (underlined, bold, the actual AmpC initiation codon) because it is 
closer to the RBS, which means that the normal AmpC peptide sequence was not produced but 
rather another short and different amino acid sequence peptide. This explanation is highly supported 
by the expression profile (detection by SDS-PAGE and western blot) of the other AmpC forms that 
have the 1st ATG (closer to RBS) and can be used as a start codon for AmpC amino acid sequence 
(table 3.2; fig 3.1). So, there was protein overproduction in case of AmpC-F2, AmpC-F4, AmpC-
F4:C3, AmpC-F4:C6 and AmpC-F4-TEV (periplasmic forms), except for AmpC-F3, AmpC-F3:C3-
TEV and AmpC-F3:C6-TEV (cytoplasmic forms, without signal peptides) having a low expression 
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which may be due to the instability of this forms in the cytoplasm or its degradation by some 
cytoplasmic proteases (fig. 4.2→4.5). Also we found that all the purified AmpC forms were stable 
when stored at -20°C except AmpC-F3 which showed some degradation after 3 months or more 
which was observed during HPLC analysis with muropeptides (fig. 4.9).  
 
AmpC production from ampC-encoding pUCP24 recombinant vectors   
AmpC-F3 and AmpC-F4 were detected in a low amount by western blot after IPTG 
induction of pUCP-F3 and pUCP-F4, respectively, in PAO1 wild type and mutant strains. Also, 
there was no difference in western blot detection of AmpC-F3 and AmpC-F4 in cases of induction 
and no-induction with IPTG (fig. 4.6). Also, the β-lactamase activities in Pseudomonas 
transformants of pUCP-F3 under induction conditions were almost similar compared with the no-
induction cases (table 4.3). However, Pseudomonas transformants of pUCP-F4 showed lower β-
lactamase activities in induction conditions when compared with non-induction conditions. This can 
be explained by returning to the design of the cloned sequence of both of ampC-F3 and ampC-F4 in 
pUCP24 (fig. 3.2) where two pairs of RBS and starting codon (ATG) are present, the 1st pair (RBS-
ATG) is original in pUCP24 vector while the 2nd pair is external and was retrieved from the 
corresponding sequence of ampC in pET28b recombinant vectors. Expression from the 2nd pair will 
only produce the desired AmpC peptide, however the data indicates that IPTG induction, only 
affected the 1st RBS-ATG pair which produces a different peptide. Also, expression of ampC from 
the 2nd ATG by means of the 1st RBS is not favored because the 1st ATG is closer to 1st RBS and at 
the right distance for start of translation.  
 
5.2.3. Mutations, sub-cellular localization and solubility can largely affect 
AmpC β-lactamase activity 
In E. coli BL21(DE3)/pET-ampC, AmpC-F4 showed the highest β-lactamase activity in 
cellular fractions of E. coli Bl21(DE3)/pET-F4, (table 4.2) and remarkable increase in β-lactam 
resistance (table 4.5) because it had the majority of its mature form soluble (fig. 4.3). The purified 
mature form AmpC-F3 showed the highest activity on nitrocefin (table 4.4) however it showed a 
very low activity in vivo (table 4.2) which may be due to its low expression or degradation. Because 
AmpC-F3 was produced in the cytoplasm, it did not change the profile of bacterial resistance in 
Bl21(DE3). AmpC-F2 showed a moderate β-lactamase activity (table 4.2) and decreased the 
susceptibility to some β-lactams beside resistance to amoxicillin/clavulanic acid, AMC (table 4.5) 
which may be due to the very low production of the mature form (fig 4.2).  
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The two mutants AmpC-F4:C3 and AmpC-F4:C6 showed a very low β-lactamase activity 
in vivo and in vitro (tables 4.2, 4.4) and did not change the profile of bacterial resistance against the 
tested β-lactams except for amoxicillin/clavulanic acid, AMC (table 4.5); indicating that these two 
mutations affected largely the β-lactamase activity of Pae-AmpC.  
Although both of AmpC-F2 and AmpC-F4 have some modification in the signal peptide 
(fig. 4.1), both of them would be proficient to produce the wild type of the mature AmpC form by 
elimination of the signal peptide. By following the β-lactamase activity in cellular fractions of E. 
coli DV900(DE3)/pET-ampC, we found that AmpC-F3, AmpC-F4:C3 and AmpC-F4:C6 showed 
the same behavior as encountered in Bl21(DE3) while AmpC-F2 showed higher activity and 
AmpC-F4 produced lower activity which could be due to the low production of the soluble mature 
form (table 4.2; fig. 4.2-4.5). As described before (table 4.1; fig 4.1), AmpC-F2, AmpC-F4:C3 and 
AmpC-F4:C6 have single amino acid mutations; R2→G, P243→L and I51→T, respectively, which 
could affect the general protein folding and in turn AmpC activity as demonstrated by low β-
lactamase activity of AmpC-F4:C3 and AmpC-F4:C6 and the intermediate activity of AmpC-F2 
(tables 4.2, 4.4, 4.5). 
On line databases (Benson et al, 2009; Sayers et al, 2009; Winsor et al, 2011) showed that 
there are a total number of 179 SNPs, which include 80 silent SNPs and 99 missense SNPs, along 
the total length of Pae-ampC (PA4110) gene, representing about 14,99 SNPs, involving 8,29 silent 
SNPs and 6,70 missense SNPs, per gene length unit. These values are largely about the mean value 
for Pseudomonas SNPs. Also, it was found that SNPs changes did not take place within the active 
site residues and neither in amino acids (e.g. N70 and R76) responsible for interaction with C3 and 
C4 of β-lactam nucleus. It was reported in some P. aeruginosa isolates that some amino acid 
mutations (e.g. A97V and T105A) in the region close to the active site Ser64 in some clinical ampC 
variants (e.g. PDC-2 variant with G27D, A97V, T105A, and V205L substitutions) enhanced the 
hydrolytic activity of AmpC into an extended spectrum AmpC cephalosporinases activity, ESAC 
(Rodriguez-Martinez et al, 2009). On the other hand, mutations in active site residues results in 
decreased β-lactamase activity (Jacoby, 2009). Similarly, K67R mutant displayed lower β-
lactamase activity and minimal conformational changes compared to the wild type AmpC (Chen et 
al, 2009). Conversely, all these missense SNPs must indicate adaptations to change the global 
structure to adapt the active site to new substrates, without changes on the essential and well 
conserved catalytic residues. 
In Pseudomonas transformants of pUCP-F3 and pUCP-F4, the β-lactamase activity of 
AmpC-F4 was 10-times higher than that of AmpC-F3, which may be due to the low expression, 
instability or the misfolding of this second form (table 4.3; fig. 4.6). Although AmpC-F4 was 
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detected by SDS-PAGE and western blot at a very high level in E. coli Bl21(DE3) and very low 
level in all PAO1 strains , the bacterial resistance of Pae transformants was largely higher than 
those of BL21(DE3) as seen by resistance of all Pae/pUCP-F4 transformants (table 4.6) to FOX, 
AMC, CRO and TIC in comparison of resistance of Bl21(DE3)/pET-F4 transformants (table 4.5) to 
AMC and moderate resistance to FOX which may be explained by more active and higher AmpC 
folding in homologous PAO1 strains rather than in heterologous Bl21(DE3).  
 
5.2.4. The secondary DD-peptidase activity was clear with AmpC-F3 rather 
than the other studied AmpC forms  
Our data proved basically previous suggestions (Bishop & Weiner, 1992; Hall & Barlow, 2004; 
Joris et al, 1988; Kong et al, 2010; Sauvage et al, 2008) that AmpC can produce DD-peptidase 
activity (EPase and/or CPase) which can be inferred or clearly observed from the following 
observations on the HPLC analysis of PG composition and muropeptides: 1) The DD-EPase activity 
could be deduced from the increase in monomers, anhydromuropeptides and pentapeptides in 
parallel with the decrease in dimers upon AmpC expression in Bl21(DE3)/pET-ampC in vivo with 
most of AmpC forms (table 4.7), and also from in vitro analysis with whole PG of CS109 and 
DV900 with AmpC-F3 form only (table 4.10a). 2) The DD-CPase activity could be inferred from 
the increase in M4 and decrease in M5, D44, D45, T445, D45N and T445N beyond incubation of 
purified AmpC-F3 with the whole DV900-PG (table 4.10b) and the hydrolysis of individual dimeric 
muropeptides, D44 and D45, after incubation with AmpC-F3 (fig. 4.9, 4.10). Our data, also show 
that the produced mature form (AmpC-F3) has the highest β-lactamase activity in vitro (Vmax=100 
µM) which was very high (8-fold or more) compared to the other AmpC forms (table 4.4), also it 
was the only AmpC form having DD-peptidase activity (DD-EPase) in vitro and it had inferred DD-
CPase and DD-EPase in vitro higher than the other forms. These data indicate that the active site in 
AmpC-F3 has high accommodation, folding and flexibility permitting higher binding affinity and 
faster reaction with its β-lactam substrates and also with some PG muropeptides which are 
substrates for LMM-PBPs (DD-peptidases), the enzymes of the PG metabolism which have a close 
structural similarity with AmpC β-lactamases (Hall & Barlow, 2004; Sauvage et al, 2008). On the 
other hand, orthologous of Eco-PBP5 are known as been the main DD-CPases of the different 
bacteria, and it was reported that the mature form of Pae-PBP5 (PAO sPBP5) was produced and 
characterized having both a DD-CPase and wide spectrum β-lactamase activity (Smith et al, 2013). 
That result is in good accordance with our data, and allows highlighting two things; firstly, the 
production of the soluble mature form can display higher activity to its common substrates and can 
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increase the affinity to other secondary or low-affinity substrates. Furthermore, these findings may 
explain that both of class C serine β-lactamases and DD-peptidases have a common ancestor and 
how β-lactamases were evolved from the DD-peptidases (Hall & Barlow, 2004). Our data 
highlighted the other side of AmpC activity and physiological function concerning its ancestor DD-
peptidases (PBPs) which were clustered together in one grouped (COG1680) by phylogenetic 
classification of proteins encoded in complete genomes (Tatusov et al, 2003). 
 
5.2.5. AmpC-F3 crystallization & obstacles on the way! 
Recently, crystal structures of Pae-AmpC in native form and bound to avibactam (non-β-lactam 
inhibitor) and bound to aztreonam (β-lactam monobactam) were developed using vapor diffusion in 
hanging drop setting (Lahiri et al, 2014; Lahiri et al, 2013). These crystal structures showed that 
conserved domains and active site residues of Pae-AmpC comprise amino acids Ser64* (catalytic 
residue), Lys67, Gln120, Tyr150, Asn152, Lys315, Thr316 and Asn346 which are conserved in 
most of AmpC β-lactamases with a little exceptional changes in some amino acids among other 
species (e.g. Asn346, the most variable residue) (Lahiri et al, 2014). In that study, they used pET-9a 
vector for cloning, Bl21(DE3) as a host strain which was grown in auto-inducing medium ZYP-
5052 at 37 °C for 48 hours and for purification they used cationic chromatography and gel filtration 
which is somehow different from our procedure for purification of AmpC-F3. Although at the end 
we had a protein concentration of AmpC-F3 very close to what was used in the former study and 
crystallographers adopted the same techniques used in that work but, unfortunately we did not get 
crystals of AmpC-F3 by the time of submission of this thesis, which may be due to the instability 
and the degradation of this AmpC-F3 form (with poly-His tag). Also, the produced AmpC-F3-TEV 
(without poly-His tag) after TEV protease treatment was insoluble due to unclear reasons, may be 
misfolding, (Costa et al, 2014) and we had to use sarkosyl as ionic solvent for resuspension (Seddon 
et al, 2004), which added another difficulty to AmpC crystallization. His-tag terminal peptide stem 
may affect the protein structure and in turn the formation of protein crystals (Rosano & Ceccarelli, 
2014; Smyth et al, 2003; Terpe, 2003). So, cloning and purification of AmpC-F3 that could produce 
a stable protein form without His-tag would be required. Moreover, 3D structure for AmpC-F3 
would give us a clue for the peptidase activity of this form, and the required adaptation of the active 
site of a β-lactamase for accommodation a muropeptide substrate. 
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5.3. Role of Pseudomonas aeruginosa LMM-PBPs in PG composition, β-lactam 
resistance and ampC regulation in P. aeruginosa 
 
5.3.1. Role of P. aeruginosa LMM-PBPs in cell wall physiology  
 
Previous analyses of the P. aeruginosa cell membrane identified eight proteins able to bind 
H3-benzylpenicillin or I125-ampicillin, (PBP1a, PBP1b PBP2, PBP3, PBP3b PBP4, PBP5 and PBP7) 
and in silico analysis revealed the presence of eight open reading frames annotated as potential 
penicillin-binding proteins (Liao & Hancock, 1997; Song et al, 1998; Weigel et al, 1994). In this 
study we have used fluorescence-labeled antibiotic (Bocillin-FL) to identified PBPs of wild type 
and mutants strains of PAO1 (fig. 4.13, 4.14). PBPs patterns of single and multiple deletion mutants 
correlated perfectly with the loss of the expected PBP for each mutant PBP4 (DacB), PBP5 (DacC) 
and PBP7 (PbpG) with the exception of the two mutants PAO∆dacB and PAO∆dacB∆pbpG which 
had undetected DacC band although it was clearly detected in their corresponding mutants with 
ampC deletion (PAO∆dacB∆ampC and PAO∆dacB∆pbpG∆ampC), respectively. This apparently 
mysterious lost for DacC in these two mutants may be due to their high AmpC production, that 
cleaves the Bocillin-FL lowering the needed concentration for detection, mutations on the dacC 
gene, or low dacC expression. However, we have confirmed by DNA sequencing that there is no 
dacC mutations on these two mutants (PAO∆dacB and PAO∆dacB∆pbpG), and data of PG 
pentapeptide content of these strains, suggest a normal level of DacC (DD-CPase) produced. So, 
most plausible explanation is high production of β-lactamase activity on these mutant strains. 
Nevertheless, it will be interesting more future morphological and physiological studies to pursue 
and to compare the behavior of DacC in these two mutants with their corresponding ampC mutants 
(PAO∆dacB∆ampC and PAO∆dacB∆pbpG∆ampC). Presumably, these data would give information 
on the implication of the protein on important cellular process, as it has been obtained by the 
orthologous PBP in E. coli. These PBPs (DacB, DacC and PbpG) belong to the class C LMM-PBPs, 
type 4, type 5 and type 7, respectively. All PBPs in these subclasses have DD-endopeptidase and/or 
DD-carboxypeptidase. Largest changes in peptidoglycan structure (increase in pentapeptide 
content) were observed for the triple mutant, DacB-DacC-PbpG, with a structure similar to the nine-
PBPs deletion mutant of E. coli, where all DD-endopeptidase and DD-carboxypeptidase activities 
were depleted causing aberrant cellular morphology in E. coli (Vega & Ayala, 2006). So, these 
three PBPs must represent the major endolytic armory of P. aeruginosa. Crystal structure of 
PaePBP5 (DacC) reveals a protein fold that is highly similar to the related E. coli PBP5 and PBP6, 
and also more closely resemble features seen previously only in the class A β-lactamases (Smith et 
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al, 2013). Gram-negative bacteria most often have a major type-5 PBP which is the most abundant 
PBP they produce (Sauvage et al, 2008). The most highly expressed PBP in P. aeruginosa 
membranes is also PBP5 (Noguchi et al, 1979) and as it is also shown in this work. It has been 
recently shown that PBP5 is a DD-carboxypeptidase that preferentially degrades low-molecular-
weight substrates (Smith et al, 2013). In this work we confirm that PBP5 is the major DD-
carboxypeptidase in P. aeruginosa, as evidenced by the fact that of the three single LMM-PBP 
mutants only dacC led significantly increased pentapeptide levels. Moreover, our results indicate 
that DacB plays a significant role as DD-carboxypeptidase when DacC is absent and that the DD-
carboxypeptidase activity of PbpG is only apparent when both, DacC and DacB, are inactivated. On 
the other hand, the peptidoglycan structure of dacB and pbpG single and double mutants indicated 
that P. aeruginosa PBP4 and PBP7 have DD-endopeptidase activity as previously suggested for E. 
coli (Korat et al, 1991). 
No major effect on cell morphology of growth parameters was seen for any of single, double or 
triple mutants (fig. 4.12), suggesting that major changes observed in the peptidoglycan structure do 
not affect significantly the morphology of the cell under laboratory conditions. However in E. coli, 
it was reported that PBP5 inactivation was the only single mutation of LMM PBPs to produce 
aberrant cellular shape, but further inactivation of PBP6 or PBP4 and PBP7 caused more 
deformation in cell morphology (Meberg et al, 2004; Nelson & Young, 2000; Nelson & Young, 
2001). In parallel to our findings within P. aeruginosa (fig. 4.11), it was found in E. coli that 
multiple mutants of all possible LMM PBPs did not affect their growth curves in LB medium at 
37°C and the cells were viable (Denome et al, 1999; Vega & Ayala, 2006). However, the in vivo 
role, and particularly the impact on virulence, of P. aeruginosa LMW PBPs still needs to be 
explored.  
 
 
5.3.2. Role of P. aeruginosa LMM-PBPs in AmpC regulation and β-lactam 
resistance 
It was reported previously that inactivation of Pae-dacB stimulated AmpR-dependent 
AmpC overexpression and β-lactam resistance (Cavallari et al, 2013; Moya et al, 2009); in this 
study, we found that among LMM-PBPs, the only single gene inactivation that triggered AmpC 
overexpression and β-lactam resistance was dacB inactivation but further inactivation of Pae-dacC 
and Pae-pbpG, as combined double and multiple deletions with dacB, led to an enormous increase 
on AmpC expression and in turn higher β-lactam resistance in PAO1 (table 4.12). Also, we found 
that among the constructed double mutants, PAOΔdacBΔdacC was the only one produced AmpC 
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overexpression (about 10-fold higher) and β-lactam resistance higher than the single mutant 
PAOΔdacB, inferring a synergetic role of dacC in AmpC overexpression and β-lactam resistance. 
By the same way, pbpG inactivation in the double mutant PAOΔdacBΔdacC showed a maximal 
AmpC overexpression (about 3-fold higher), suggesting a secondary synergetic effect of pbpG in 
AmpC overexpression and β-lactam resistance. Our data showed that the synergetic behaviors of 
dacC and pbpG in AmpC expression were not helpful for AmpC overexpression without dacB 
inactivation. The increase of AmpC expression beyond FOX induction in the wild type and all 
PAO1 mutants was mainly due to the sensitivity of DacB to FOX as demonstrated in table 4.11. It 
was reported that the increase of anhydro-muropeptides and their binding to AmpR is the main 
effector of AmpC over-expression which also is regulated by the activities of the permeases AmpG 
and AmpP, the amidases AmpD, AmpDh2 and AmpDh3 and the hydrolase NagZ and generates β-
lactam resistance in P. aeruginosa (Balasubramanian et al, 2012; Boudreau et al, 2012; Fisher & 
Mobashery, 2014; Jacobs et al, 1997; Johnson et al, 2013; Lister et al, 2009). Moreover, we found 
that the increase in anhydro-muropeptides was mostly accompanied with DacB inactivation (as 
single and combined forms) during high AmpC expression. Also, our data shows that DacB activity 
(on/off) alone or in addition to the activities of DacC and PbpG are critical for ampC expression in 
PAO1. Also, our results show however that DacC is the major DD-CPase, and that the DacC mutant 
is the only single LMM-PBP mutant producing a significant increase in pentapeptide levels (up to 
4.4-fold higher than wild-type PAO1). Thus, increased PG pentapeptide levels, and neither 
apparently any other effect on peptidoglycan structure (table 4.13), do not explain, at least for P. 
aeruginosa, the major role of PBP4 in AmpC induction. Whether the PBP4 effect is driven by 
significantly increasing periplasmic soluble anhydromuropeptides levels needs still to be explored. 
Nevertheless, our results suggest that increased peptidoglycan pentapeptide levels, explain the 
major role of PBP5 in ampC expression when PBP4 is absent. Indeed, except for the specific effect 
of PBP4, a correlation between peptidoglycan pentapeptide levels and ampC expression was 
documented (Tayler et al, 2010).  
Our data showed that MICs for the antipseudomonal penicillins (piperacillin), 
cephalosporins (cefotaxime, ceftazidime, and cefepime) and monobactams (aztreonam) correlated 
well with ampC expression data (table 4.12); they were significantly increased in the DacB mutant 
and further increased in the DacB-DacC double mutant. On the other hand, unlike for ampC 
expression, β-lactam resistance was not further increased in the triple DacB-DacC-PbpG mutant. 
Besides the obvious effect on resistance driven by the impact on ampC expression, we asked 
whether P. aeruginosa LMM PBPs had a direct effect on β-lactam susceptibility. For this purpose, 
we analyzed the β-lactams MICs for all combinations of LMM PBPs and AmpC mutants. As 
Discussion 
 
138 | P a g e  
 
Alaa Ropy_Doctoral Thesis 
 
expected (Livermore, 1992; Zamorano et al, 2011), the inactivation of AmpC in wild-type PAO1 
produced a marked increase in the susceptibility of strong AmpC-inducer β-lactams, including the 
carbapenems, cefoxitin and ampicillin, whereas the MICs of weak AmpC-inducer β-lactams 
(antipseudomonal penicillins, cephalosporins and monobactams) were not significantly modified. 
Remarkably, the MICs for nearly all β-lactams were lower in the DacC-AmpC mutant compared to 
the single AmpC mutant, and this effect was further enhanced in the DacB-DacC-PbpG-AmpC 
mutant, indicating that LMM PBPs, particularly DacC, play a role in the intrinsic level of β-lactam 
resistance in P. aeruginosa. Our results are therefore in agreement with recent studies suggesting 
that E. coli LMM PBPs, particularly PBP5, play a role in intrinsic β-lactam resistance (Sarkar et al, 
2010; Sarkar et al, 2011). Purified E. coli PBP5 failed to show significant β-lactamase activity and 
therefore it was concluded that the role of this PBP in intrinsic β-resistance could be consequence of 
β-lactam trapping. However, interestingly, the recently crystalized P. aeruginosa PBP5 does show 
certain broad spectrum (including penicillins, cephalosporins and carbapenems) β-lactamase 
activity (Smith et al, 2013). Therefore, the observed effect of PBP5 in P. aeruginosa intrinsic 
resistance is expected to result from both, trapping and hydrolysis of β lactams. 
We found that the carbapenems IMI and MER were resistant to hydrolysis by the wild type 
AmpC as the observed MICs were 0.5 µg/ml for both of them in both of the wild type PAO1 and in 
the triple mutant PAOΔdacBΔdacCΔpbpG although their corresponding AmpC expression was 347 
and 5742, respectively, under induction conditions (table 4.12). Resistance to carbapenems by 
AmpC overproduction in P. aeruginosa requires additional resistance mechanisms efflux pump 
overproduction, decreased OprD, and/or production of a class A/class B carbapenemase (Lister et 
al, 2009; Rodriguez-Rojas et al, 2013). Also, it was reported that OprD inactivation alone is known 
to result in clinical imipenem resistance which supports the previous idea of the ability of combined 
resistance mechanisms to develop carbapenems resistance (Gutierrez et al, 2007).   
 
5.4. Activities of DacB, DacC and PbpG are not essential for recovery of rod shape 
in imipenem-induced spheroplasts in P. aeruginosa 
It was described that imipenem-supplemented media caused transition of the rod shaped 
wild type P. aeruginosa cells into cell wall-defective spherical shaped cell (Monahan et al, 2014).  
We achieved the same results with the wild type PAO1 and the mutant PAO∆dacB∆dacC∆pbpG 
∆ampC which were able to produce round cells (spheroplasts) after 4 hours incubation with IMI, 
and both of them were able to recover their normal rod shape after elimination of IMI, inferring that 
activities of DacB, DacC and PbpG are not necessary for recovery of rod shape as shown by 
microscopic examination (fig 4.15). Similarly, all other single and combined Pae mutants of dacB, 
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dacC, pbpG and ampC that were constructed in this study displayed the same behavior in the ability 
of IMI-induced spheroplasts formation and rod shape recovery upon growth in imipenem-free 
media (data not shown). By comparing the PG composition of round cells and the recovered rod 
shaped ones in the wild type and in the final quadruple mutant, we found that PG of round cells 
contained unusual high amount of M3, which may be related to the high amount of 
anhydromuropeptides and shorter PG length. Also we found that after recovery of rod shape, PG 
contained a normal ratio of M3 and other muropeptides with normal PG length (table 4.15a, 4.15b). 
Also, we found that analysis of PBPs pattern in round cells by Bocillin-FL of both the wild type 
PAO1 and PAO∆ampC displayed loss of bands of PBP1a, PBP1b, PBP2, DacB and PbpG with low 
intensity of DacC, although they were detected in their recovered rod cells (fig 4.16). We found that 
imipenem was able to block these PBPs in vitro which may explain that they were also blocked in 
the IMI-induced spheroplasts in vivo. Inhibition of PBPs by imipenem caused spherophast 
formation due to blocking of PG synthesizing machinery and degradation of their cell wall. PG of 
these Pae spheroplasts was less than one tenth when compared with normal untreated cells and had 
large increase in anhydromuropeptides (PG glycan chains ends, susceptible of degradation). 
Moreover, it has an increase in M3 which can be explained by the activity of increased LD-CPase 
which are produced when cell walls are degraded (Korza & Bochtler, 2005). Also the decrease in 
pentapeptides and the increase in PG crosslinking can be explained by blocking of DD-CPase 
activity (i.e. DacC) and the DD-EPase activity (i.e. DacB and PbpG), respectively. Also, the 
decrease in pentapeptides (PG donors for transpeptidation reaction) resulted in low values of PG 
length in spheroplasts. After elimination of imipenem from the growth medium Pae cells, PG 
synthesizing machinery was back to work normally and was able to re-build the rod shaped PG and 
so Pae cells were able to revert into shape again. Also, in PG of the recovered Pae cells, M3 
returned to its normal level because it was used for the construction of new PG subunits (Johnson et 
al, 2013). It was reported that inactivation of PBP2 in E. coli by amdinocillin (β-lactam antibiotic) 
led to inhibition of cell elongation and the formation of osmotically stable round cells with one half 
less in their murein content when compared with normal cells (de Pedro et al, 2001) which is in 
according to what is described for inhibition of PBP2 by mecillinam in stimulation of round cell 
formation in both of E. coli and P. aeruginosa (Noguchi et al, 1979). Similarly, it was reported that 
inactivation of PBP2 and PBP3 by mecillinam and aztreonam, respectively, produced enlarged 
spheres however inactivation of both of PBP1a and PB1b was lethal in E. coli (Denome et al, 1999). 
Likewise, it was reported that carbapenems (e.g. imipenem, meropenem) showed strong affinities to 
PBP2 of E. coli and P. aeruginosa, PBP1a of E. coli and PBP1b of P. aeruginosa (Yang et al, 
1995).  
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It was settled that PBP1a, PBP1Bb and PBP2 are responsible for PG elongation and 
insertion of newly formed PG units into the old PG network; PBP3 is responsible mainly for cell 
division, and LMM-PBPs (DacB, DacC and PbpG) participate in PG maturation and recycling 
(Sauvage et al, 2008). In E. coli, it was identified that PBP1b, PBP5 and PBP6 are among eight 
proteins identified for regeneration of normal rod shape from E. coli spheroplasts (formed by the 
effect of lysozyme) which failed in the recovery process by loss of these proteins (Ranjit & Young, 
2013; Weiss, 2013). In that study, it was demonstrated that E. coli spheroplasts of PBP1b mutant 
were unable to recover the rod shape but rather become enlarged and lysed; spheroplasts of mutants 
of PBP5 and PBP6 displayed recovery of defective shapes however spheroplasts of mutant PBP4 or 
PBP7 regenerated their normal rod shape  (Ranjit & Young, 2013). In our study, we described that 
combined deletions of dacB, dacC and pbpG did not remarkably affect morphology of P. 
aeruginosa and mutants still retain their rod shape. Consequently, we can conclude that the 
formation of cell wall-defective spheroplasts in Pseudomonas aeruginosa after imipenem induction 
was due to the inhibition of PBPs, especially HMM-PBPs (PBP1a, PBP1b, PBP2 and PBP3). Also, 
the ability of spheroplasts of the quadruple mutant PAO∆dacB∆dacC∆pbpG∆ampC to revert into 
rod shape confirms that DacB, DacC and PbpG are dispensable and unessential for this reversion 
process in Pseudomonas aeruginosa.   
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6. Conclusions  
 
 The single amino acid mutations P243→L and I51→T, in AmpC-F1:C3 and AmpC-
F1:C6, respectively, caused a large decrease β-lactamase activity. 
 AmpC-F4 (precursor form) produced higher β-lactamase activity in vivo, most 
probably due to correct localization, while AmpC-F3 (mature form) produced β-
lactamase activity of 8-fold higher than AmpC-F4 in vitro.  
 AmpC β-lactamase in Pseudomonas can comprise a secondary DD-EPase or DD-
CPase activity. 
 The LMM-PBPs DacB and PbpG are more sensitive to FOX (ampC inducer) than 
DacC. 
 DacC is the main DD-CPase in P. aeruginosa, and DacB and PbpG were suggested 
to elicit some DD-CPase in the mutant PAOΔdacC. 
 Fluctuations in DacB activity are critical for ampC regulation. 
 dacB inactivation was the only single mutation of LMM-PBPs found to trigger 
AmpC overproduction and β-lactam resistance. 
 Inactivation of both of dacC and pbpG can stimulate large AmpC overexpression 
only when dacB was inactivated (synergetic effect). 
 Activities of DacB, DacC and PbpG are not essential for recovery of rod shape in 
imipenem-induced P. aeruginosa spheroplasts. 
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Conclusiones 
 
 Las mutaciones individuales de aminoácido P243 → L y I51 → T, en AmpC-
F1: C3 y AmpC-F1: C6, respectivamente, causaron una gran disminución de la 
actividad β-lactamasa. 
 AmpC-F4 (forma precursora) produjo una mayor actividad de β-lactamasa en 
vivo, probablemente debido a su correcta locaclización, mientras que AmpC-
F3 (forma madura) produjo una actividad β-lactamasa 8 veces superior a 
AmpC-F4 in vitro. 
 AmpC en Pseudomonas puede tener una actividad DD-EPase/DD-CPase 
secundaria. 
 Las LMM-PBPs DacB y PbpG son más sensibles a FOX (inductor de ampC) 
que DacC.  
 DacC es la enzima DD-CPase principal en P. aeruginosa, mientras que DacB y 
PbpG pueden compensar la pérdida de actividad DD-CPase en el mutante 
PAOΔdacC  
 Las fluctuaciones en la actividad enzimática de DacB son críticas para la 
regulación de ampC. 
 La inactivación de dacB fue la única mutación individual de LMM-PBPs capaz 
de desencadenar la sobreproducción de AmpC y la resistencia a β-lactámicos. 
 La inactivación de los genes dacC y pbpG pueden estimular la sobreexpresión 
de AmpC sólo cuando dacB fue simultáneamente inactivado (efecto sinérgico). 
 Las actividades de DacB, DacC y PbpG no son esenciales para la recuperación 
de la forma bacilar a partir de esferoplastos de P. aeruginosa inducidos por 
imipenem. 
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Addendum 
                                  
 
 
Figure A.1. Colony-PCR amplifications of the different ampC forms displaying their 
DNA fragment sizes. 
 Agarose gel electrophoresis shows DNA sizes of ampC-F4, ampC-F4:C3, ampC-F4:C6, ampC-F2 
and ampC-F3which were amplified by colony-PCR of Bl21(DE3) harboring pET-F4, pET-F4:C3, 
pET-F4:C6, pET-F2 and pET-F3, respectively. For simplification, only colony-PCR confirmation of 
some ampC forms were shown while all other ampC were confirmed by the same way in 
transformants of Bl21(DE3), DV900(DE3) and PAO1 strains; where, ampC-F1 and ampC-F4-TEV 
displayed a very close size and migration as shown by ampC-F4; ampC-F1:C3 and ampC-F1:C6 
displayed a very close size and migration as shown by ampC-F4:C3 and ampC-F4:C6, respectively. 
All of ampC-F3:C3, ampC-F3:C6 and ampC-F3-TEV displayed a very close size and migration as 
shown by ampC-F3. Colony PCR of ampC-F1, ampC-F4-TEV, ampC-F1:C3, ampC-F1:C6, ampC-
F3:C3, ampC-F3:C6 and ampC-F3-TEV were amplified from the clones pET-F1, pET-F4-TEV, 
pET-F1:C3, pET-F1:C6, pET-F3:C3, pET-F3:C6 and pET-F3-TEV, respectively, in E. coli; while 
we cloned only the two forms ampC-F3 and ampC-F4 in PAO1 strains using the vectors pUCP-F3 
and pUCP-F4, respectively. All of these clones have been confirmed by DNA sequencing.    
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Figure A.2. Confirmation of the constructed pbpG and dacC gene-specific mutagenesis 
vectors.  
(A) Verification of the constructed pbpG gene-specific mutagenesis vector by colony PCR 
and agarose gel electrophoresis: lane 1: DNA Ladder (SmartLadder); lane 2: PCR 
negative control; lane 3: pbpG-PCR positive control; lane 4: colony PCR of E coli XL1 
havepEXTΔpbpG::Gm vector. (B) Confirmation of the constructed dacC gene-specific 
mutagenesis vector by treatment with restriction enzymes: lane 1: 100bp DNA Ladder; lane 
2: pEXTΔdacC::Gm circular vector; lane 3: pEXTΔdacC::Gm cleaved with Hind III; lane 
4: pEXTΔdacC::Gm cleaved with HindIII, EcoRI and BamHI.  All colony PCR and enzyme 
digestions were visualized by 1% agarose gel electrophoresis.  
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Figure  A.3. Verification of the constructed mutants PAOΔpbpG, PAOΔdacB ΔpbpG 
and  PAOΔpbpGΔampC by colony PCR and agarose gel electrophoresis.  
(A) Confirmation of recombination for PAOΔpbpG::Gm and PAOΔdacBΔpbpG::Gm constructs: 
lanes 1, 2 and 5: not PAOΔpbpG::Gm genotype; lanes 3 and 4: have PAOΔpbpG::Gm genotype; 
lane 6: PCR negative control; 7: PCR positive control for PAO1 pbpG; lane 8: DNA Smart Ladder; 
lanes 9, 10, 12, 13, and 14: not PAOΔdacBΔpbpG::Gm genotype; lanes 11 and 15: have 
PAOΔdacBΔpbpG::Gm genotype. (B) Confirmation of elimination of Gm resistance cassette; lanes 
1→6: have PAOΔpbpG genotype; lanes 7 and 8: pbpG-PCR negative and positive controls; lane 9: 
smart Ladder; lanes 10→15: have PAOΔdacBΔpbpG genotype. (C) Confirmation of recombination 
for PAOΔampC ΔpbpG::Gm construct; lane 1:  λ HindIII DNA ladder. Lane 2: pbpG-PCR positive 
control; lane 3: PCR positive control for recombination using   pEXTΔpbpG::Gm; lanes 6→13:  
have  PAOΔampCΔpbpG::Gm genotype; (D) Confirmation of elimination of Gm resistance cassette 
from PAOΔampCΔpbpG::Gm; lane 1: λ HindIII DNA ladder; lanes 2 and 3: pbpG-PCR negative 
and positive control, respectively; lane 4:  PCR positive control for recombination using   
pEXTΔpbpG::Gm; lanes 5 and 6: have PAOΔpbpG ΔampC genotype.   
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Figure  A.4. Verification of the constructed mutants PAOΔdacCΔampC, 
PAOΔdacCΔpbpG, PAOΔdacC, PAOΔdacBΔdacC and PAOΔdacBΔdacCΔpbpG.  
(A) Confirmation of recombination; lanes 1→7:  havePAOΔampC ΔdacC::Gm genotype; 
lanes 8, 23, 34 and 46: dacC-PCR positive control; lanes 9→15:  have PAOΔdacC::Gm 
genotype; lanes 16 and 22:  have PAOΔpbpGΔdacC::Gm genotype; lanes 17→21: not 
PAOΔpbpGΔdacC::Gm genotype; lanes 24 and 28: have PAOΔdacBΔdacC::Gm genotype; 
lanes 25→27 and 29→31: not PAOΔdacBΔdacC::Gm genotype; lane 32: 100 bp DNA 
ladder; lanes 33 and 45: PCR negative control; lanes 35 and 37→43: have 
PAOΔdacBΔpbpGΔdacC::Gm genotype. (B) Confirmation of removal of Gm resistance 
cassette; lanes 1 and 29: 100 bp DNA ladder; lanes 2→6: have PAOΔdacCΔampC 
genotype; lanes 7→11: have PAOΔdacC genotype; lanes 12→15: have PAOΔdacCΔpbpG 
genotype; lanes 16 and 17: dacC PCR positive control; lanes 18→24: have 
PAOΔdacBΔdacCΔpbpG genotype; lanes 25→28:  have PAOΔdacBΔdacC genotype.      
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Figure A.5. Verification of the constructed mutants PAOΔdacBΔampC and 
PAOΔdacBΔpbpGΔampC. 
(A) Confirmation of recombination of PAOΔdacBΔampC::Gm construct; lane 1: 100 bp 
DNA ladder; lane 2 and 18: recombination PCR control positive using   
pEXTΔampC::Gm; lane 3: ampC PCR positive control; lanes 4→16:  Not 
PAOΔdacBΔampC::Gm genotype; lane 17: has PAOΔdacBΔampC::Gm genotype; lanes 19 
and 22: have PAOΔdacBΔpbpGΔampC::Gm genotype. (B) Confirmation of removal of Gm 
resistance cassette; lane 1: 100 bp DNA ladder; lanes 3 and 4: have PAOΔdacBΔampC 
genotype; lanes 5 and 6: ampC PCR positive control; lanes 7, 8, 10, 11, and 13: have 
PAOΔdacBΔpbpGΔampC genotype.  
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Figure  A.6. Verification of the constructed mutants PAOΔdacBΔdacCΔampC, 
PAOΔdacCΔpbpGΔampC and PAOΔdacBΔdacCΔpbpGΔampC.  
(A) Confirmation of recombination in PAOΔdacCΔpbpGΔampC::Gm and 
PAOΔdacCΔpbpGΔ ampC::Gm constructs; lanes 1 and 27: ampC PCR positive control; 
lane 2: recombination PCR positive control using   pEXTΔampC::Gm; lanes 3→7: have 
PAOΔdacBΔ dacCΔ ampC::Gm genotype; lanes 11 and 18: λ HindIII DNA ladder; lanes 12 
and 16: have PAOΔdacCΔpbpGΔampC::Gm genotype; lanes 19→25: have 
PAOΔdacBΔdacCΔpbpGΔampC::Gm genotype. (B)  Confirmation of removal of Gm 
resistance cassette; lane 1: PCR negative control; lanes 2 and 20: recombination PCR 
positive control using   pEXTΔampC::Gm; lanes 3 and 19: ampC PCR positive control; 
lanes 4, 10, 18 and 26:  λ HindIII DNA ladder; lanes 5→9: have PAOΔdacBΔdacCΔampC 
genotype; lanes 13→15 and 17: have PAOΔdacCΔpbpGΔampC genotype; lanes 21 and 24: 
have PAOΔdacBΔdacCΔpbpGΔampC genotype. All colony PCR amplifications were 
visualized by agarose gel electrophoresis.                  
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Figure  A.7. Verification of the constructed mutant PAOΔdacBΔpbpGΔampC ΔdacC.   
(A) Confirmation of recombination in PAOΔdacBΔpbpGΔampCΔdacC::Gm construct; lane 
1: λ HindIII DNA ladder; lanes 2→11: have PAOΔdacB ΔpbpGΔampCΔdacC::Gm 
genotype. (B) Confirmation of removal of Gm resistance cassette; lanes 1 and 8: dacC-
PCR positive control; lane 2: λ HindIII DNA ladder; lanes 3→7: have 
PAOΔdacBΔpbpGΔampCΔdacC genotype.                           
 
 
 
